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ABSTRACT 
 
      Approximately 30% of dogs affected by immune-mediated hemolytic anemia 
(IMHA) die or are euthanized, often due to thrombosis. Neutrophils may contribute 
directly to thrombosis by releasing strands of DNA associated with nuclear and extra-
nuclear proteins. These structures, termed neutrophil extracellular traps (NETs), have 
pro-thrombotic properties in humans and mice. This thesis addresses three major 
questions: (1) do canine neutrophils produce NETs? (2) do NETs activate the canine 
coagulation system? and (3) is cell-free DNA, a marker correlated with NET formation, 
elevated in dogs with spontaneous IMHA? 
     Canine granulocytes were incubated with platelet activating factor or phorbol 12-
myristate 13-acetate. Both agonists increased fluorescence of Sytox green, a nucleic acid 
dye incapable of entering viable cells. Fluorescent imaging for DNA and elastase 
confirmed NET release. 
     A spectrophotometric assay was developed to measure canine clot formation and lysis. 
This did detect altered clot kinetics in dogs with various disorders, but was unsuitable for 
use in IMHA due to interferences from hemoglobin and bilirubin. The assay did however 
provide the basis for in vitro investigations of the effect of NETs on coagulation. When 
NETs were added to citrated plasma, maximum clot formation velocity was increased 
and time to 50% clot lysis delayed. The effect on clot lysis but not formation velocity was 
reduced by DNase digestion, suggesting the latter was mediated by NET proteins. 
However, at higher concentrations, DNA alone could also increase maximum clot 
xii 
 
 
formation velocity. By flow cytometry, NETs were shown to increase phosphatidylserine 
and P-selectin exposure on canine platelets. This persisted after DNase digestion. 
Therefore, intact NETs, NET proteins and DNA have pro-thrombotic properties. 
     Plasma was collected from 28 dogs with spontaneous IMHA and 20 healthy controls. 
Cell-free DNA was purified and measured by PicoGreen fluorescence. Cell-free DNA 
was increased and as DNase activity was not reduced in IMHA, this was attributed to 
increased release rather than impaired degradation of DNA. Potential sources of DNA 
include NETs, necrosis and apoptosis. 
     In conclusion, canine neutrophils release NETs and both NETs and DNA alone 
promote hypercoagulability. Cell-free DNA is increased in IMHA, suggesting NETs or 
other forms of cell death may contribute to thrombosis.  
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CHAPTER 1. INTRODUCTION 
General Introduction: Defining The Problem 
     Destruction of red blood cells after binding of self-reactive antibodies is a common 
cause of anemia in dogs (1). This process, termed immune-mediated or autoimmune 
hemolytic anemia (IMHA or AIHA), was first described in dogs in 1957 (2) and has been 
a focus of veterinary research since the 1970s (3). Numerous treatment strategies have 
been used, including immunosuppression (4,5), immunomodulation by intravenous 
immunoglobulin (6,7), blood transfusion (8) or hemoglobin-based oxygen carriers (9), 
removal of antibodies by plasmapheresis (10,11), splenectomy (12,13,14), anti-platelet 
drugs (15,16) and anti-coagulation (17,18,19).  
     Despite these efforts, there has been little improvement in mortality (Figure 1).  
Around 30% of affected dogs still die or are euthanized during, or shortly after, 
hospitalization often because of thrombosis (8,20,21). There is a lack of adequately 
powered clinical trials addressing optimal strategies to prevent thrombosis in IMHA, but 
there is some evidence that the anti-coagulant heparin can improve outcome when 
carefully monitored (17). Perhaps unsurprisingly given the limited availability and 
expense of the optimal monitoring assay, heparin is still not a particularly frequently 
delivered therapy. Only 15% of dogs in a recent large case series received unfractionated 
or low molecular weight heparin (8).  
     A better understanding of the mechanisms behind thrombosis in IMHA could improve 
treatment of the disease by leading to: 
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a) Discovery of biomarkers which differentiate dogs at high versus low risk of 
thrombosis: Such markers would benefit individual dogs by allowing aggressive 
treatment to be targeted at high risk individuals while sparing those at lower risk the 
associated financial costs and possible adverse effects. Markers could also be 
beneficial at the population level, by allowing targeted recruitment of high risk 
patients to clinical trials, thus potentially increasing their power while reducing their 
cost. 
b) Discovery of novel therapeutic targets. Drugs which target processes directly 
involved in thrombosis in IMHA may be safer and more efficacious than current 
strategies that rely on globally impairing platelet or coagulation cascade activation. 
     Basic science investigations and studies in humans suggest a direct link between 
inflammation and thrombosis in autoimmune disease (22,23,24). This connection is 
multi-factorial, but neutrophil extracellular traps (NETs) are one component that has 
attracted interest (25). These are webs of DNA associated with histones and extra-nuclear 
proteins that are released by neutrophils in response to inflammatory or infectious stimuli 
and are capable of activating both human platelets and coagulation factors (26,27). 
     The following literature review will examine the pathogenesis of IMHA and existing 
knowledge regarding thrombotic mechanisms to determine if NETs are likely to be a 
contributor to thrombosis in IMHA. Where there are gaps in our knowledge of the canine 
disease, it may be possible to infer from studies of the equivalent disease in humans, 
usually termed AIHA. Therefore, the extent to which the disease is equivalent in the two 
species will also be examined.  
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Literature Review 
Prevalence of IMHA/AIHA in humans versus dogs 
     In humans, AIHA is a rare disease with a prevalence of 1-9/100,000 (47). Studies 
conducted in veterinary referral hospitals report rates of 0.2-0.35% (34,48). While this is 
 
Figure 1. Short term survival for dogs with IMHA has changed little in the last 6 decades. Studies 
were identified by the PubMed search ((dog[Title/Abstract] OR canine[Title/Abstract]) AND 
(autoimmune hemolytic [Title/Abstract]OR immune-mediated [Title/Abstract]) AND (anemia 
[Title/Abstract]OR anaemia [Title/Abstract]) performed 4.10.16. Criteria for inclusion of studies were 
(i) a minimum of 5 cases meeting the authors’ definition of IMHA; (ii) proportion of dogs surviving to 
discharge or at 14 days from presentation reported. Studies were excluded if it was obvious that dogs 
had been previously reported. Mean and 95% confidence intervals are plotted. Confidence intervals 
were calculated using the equation (1.96*√[(proportion survived*proportion died)/total]). Mean 
survival is plotted as a red line. There was no significant relationship between year of publication and 
proportion of dogs surviving based on simple linear regression (R2 0.07, p=0.15).  
(Refs: 4,5,6,7,8,9,15,18,19,20,21,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46) 
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likely an overestimate of the prevalence in the general dog population, it does suggest 
IMHA is more common in dogs than AIHA in humans. As small patient numbers are a 
major barrier to research into treatment of rare diseases, dogs could provide a valuable 
spontaneous model of AIHA. 
Pathogenesis of erythrocyte destruction 
     The pathogenesis of erythrocyte destruction depends on antibody class and binding 
temperature preference as summarized in Figure 2, and discussed in more detail below.  
Loss of self-tolerance 
     The precise mechanism by which self-tolerance is lost remains incompletely 
understood and the processes involved likely vary between patients. As reviewed by 
Fagiolo and Toriani-Terenzi (2003) (49), proposed mechanisms include: 
 
 
Figure 2. Mechanisms of erythrocyte destruction in IMHA. C’: complement; green: C3b or its 
degradation products; purple: IgM; blue: IgG. MAC: membrane attack complex, the terminal 
component of the complement cascade. 
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• Modification of erythrocyte antigens, for example by binding of a drug (50), 
generating a novel antigen. 
• A pro-inflammatory cytokine milieu may alter peptide processing by antigen 
presenting cells resulting in display of cryptic (i.e. previously hidden or ignored) 
erythrocyte antigens capable of activating autoreactive T helper cells (51,52).  
• Molecular mimicry, in which exposure to a foreign antigen (e.g. during infection or 
drug treatment) that is structurally similar to a self-erythrocyte antigen results in 
activation of cross-reactive T helper cells (53).  
• Polyclonal activation of T and/or B cells as a mechanism for activation of self-
reactive anergic B or T cell clones is suggested by an association between AIHA and 
donor T-cells activation of recipient B cells in graft versus host disease (54).  
• Failure to maintain normal peripheral tolerance is also likely important since there is 
an imbalance in T cell subsets in humans with AIHA: T-regulatory cells are reduced 
(55) and Th17 cells increased (56). Preliminary evidence suggests the same may be 
true in dogs (57).  T-regulatory cells are important in maintaining peripheral 
tolerance, whereas Th17 cells contribute to a pro-inflammatory environment linked to 
autoimmunity (57). The importance of establishing and maintaining both central and 
peripheral tolerance is supported by the association between autoimmune 
lymphoproliferative syndrome and childhood Evan’s syndrome, a condition in which 
2 or more cytopenias (usually thrombocytopenia and anemia) are present (58). 
Autoimmune lymphoproliferative syndrome is the result of mutations in genes such 
as Fas, which prevent apoptosis of auto-reactive lymphocytes, resulting in high levels 
of autoimmune disease and accumulation of lymphocytes within the tissues (58).    
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Triggers for loss of self-tolerance: primary vs secondary IMHA 
     An underlying disease or environmental exposure can sometimes be identified as a 
trigger, in which case IMHA is classified as a secondary condition. However, in other 
dogs there is no obvious cause and IMHA is considered primary, or idiopathic. Based on 
a few reports that specifically address primary versus secondary IMHA and others which 
state the numbers of dogs excluded from studies of primary IMHA, 71-89% of canine 
IMHA cases are primary (14,45,59,60). This is in marked contrast to a large study of 
human cases, in which only 37% (191/511) of warm AIHA; 48% (131/275) of cold and 
45% (27/60) of mixed cases were primary (61). Other more recent, but smaller case 
series, have replicated this relatively low proportion of primary human cases (48% (62), 
22% (63); 35% (64)). 
     The lower proportion of primary cases in humans may reflect more extensive 
investigation for underlying disease. This is hinted at by studies demonstrating a reduced 
percentage of primary human cases when secondary disease is more aggressively 
pursued. For example, in a recent human study 38/110 patients with an initial diagnosis 
of primary AIHA were reclassified as secondary after complete diagnostics (65). 
Similarly, Roumier et al (2014) reported an 11% decrease in primary cases between 
1980- 2000 and 2001-2012 case series (64). This was attributed to harmonization of 
diagnostic work up and improved identification of lymphoproliferative disorders by 
immunophenotyping (64). Furthermore, human case series from lower income countries 
also typically report higher levels of primary AIHA than European studies (66,67). 
     However, the lower numbers of canine secondary IMHA cases likely also reflects 
different environmental exposures, for example dialysis (61) or hematopoietic stem cell 
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transplant (54) are rarely performed in veterinary patients. If adult dogs are genuinely 
more commonly affected by primary IMHA than adult humans, it may increase their 
value as a spontaneous model for warm AIHA in children, where the rates of primary 
disease approach those reported in dogs (59-63% (62,68)).  
Triggers for loss of self-tolerance: primary IMHA 
     Loss of self-tolerance in primary IMHA appears multifactorial with both genetic and 
environmental factors contributing to disease development. 
Genetics 
     There has long been a suspicion that IMHA has a genetic component, because certain 
breeds appear predisposed and there is evidence of a heritable susceptibility to 
autoimmune disease within bloodlines (69). Breeds identified as over-represented among 
general IMHA cases compared with controls include cocker spaniels (4,5,15,21,30,32,34, 
70,71), English springer spaniels (30,21,72,73), collie breeds (30,72), Maltese (73), 
Hungarian vizlas (73), Airedale terriers (73), miniature schnauzers (15), shih tzus (71), 
bichon frise (72), miniature pinschers (72), Finish spitz (72) and Welsh corgis (71). 
Labrador retrievers (74) were over-represented in a series of cases with non-regenerative 
anemia, and dobermans and Airedales among dogs with both IMHA and severe 
thrombocytopenia (36). 
     It should be emphasized that these breed associations are not particularly consistent. 
Not all studies find breed associations (14) and many of the high-risk breeds have been 
identified by only one or two studies. Even cocker spaniels, for whom the evidence of 
breed predilection is most repeatable, have not always been over-represented (73). This 
may reflect power effects, or geographical differences in breed genetics. However, most 
8 
 
 
studies identify sporadic occurrence of IMHA in many different pedigree breeds (e.g. 23 
different breeds in a study of 42 dogs (5)), and reports in non-pedigree, outbred dogs are 
not unusual (72). Although familial Evans syndrome has been reported in humans as an 
autosomal recessive inherited disease, it is extremely rare (75). In children with AIHA, 2 
out of 243 had a first degree relative with AIHA, and 27/243 a first degree relative with 
any autoimmune disease (68). This suggests that in both humans and dogs, genetics is 
only one of many contributing factors to the development of IMHA. 
     There have been a number of efforts to identify the specific genes contributing to 
susceptibility. Kennedy et al (2006) sequenced three loci within the dog leukocyte 
antigen class II region (DLA II, equivalent to the MHC II region in the human genome) 
in dogs with IMHA and healthy controls (76). Haplotypes associated with increased or 
reduced risk of IMHA were identified, but the haplotypes implicated in IMHA varied 
between breeds (76). This suggests that although many breeds may carry a genetic risk 
for IMHA, the basis of this risk may vary between breeds.  
     However, when cocker spaniels with IMHA or Evans syndrome were compared with 
aged cockers without a history of autoimmune disease, an association between disease 
and the DQB1*007:01 haplotype reported by Kennedy et al (2006) was not replicated 
(76,77). Similarly, there was no evidence of an association between IMHA and variation 
in the CTLA4 promoter gene (examined because human studies have linked genetic 
susceptibility to autoimmunity to CTLA4, a T cell inhibitory ligand) (77). However, all 
cocker spaniels, regardless of disease history, had high prevalence of DLA-
DQB1*007:01 and homozygosity for this and a single CTLA4 promoter haplotype was 
very common (77). This led the authors to suggest that cocker spaniels commonly carry 
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genes that increase their risk of IMHA, but other genetic and environmental factors 
influence development of disease (77). 
     Although genetics are clearly not the only factor influencing susceptibility, genes 
associated with increased risk may provide clues to pathogenesis. Identification of DLA 
II haplotypes associated with IMHA and other canine autoimmune diseases has led to 
speculation that susceptibility to canine immune-mediated disease is due to variations in 
the peptide cleft of MHC molecules displaying antigen to T helper cells (78). A recent 
study of 15 candidate genes identified an association between a variant of DLA-79 and 
IMHA (79).  Although the precise function of the protein encoded by DLA-79 remains 
unclear, it is an MHC Ib molecule. These proteins are relatively non-polymorphic; bind 
peptides and lipid and often act as a bridge between innate and adaptive immunity (79). 
     However, inferences about the pathogenesis of IMHA made from apparent genetic 
associations must be viewed with considerable caution (78). When SNPs were analyzed 
across a wider stretch of the canine DLA II region than in earlier studies, there were 
strong associations between necrotizing meningoencephalitis of pugs throughout the 
region (78). This suggests that some of the apparent associations between DLA II loci 
and canine autoimmune diseases may be spurious, with the true genes of interest located 
downstream of the sequenced DLA II region (78). 
Gender 
     In human adults, primary warm AIHA is more common in females than males (64% 
vs 36% n=308) (80). A similar gender bias has been reported in some 
(14,15,34,72,81,82), but not all veterinary studies (5,30). Failure to identify a gender 
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difference in some studies may represent genuine population differences, or reflect the 
low power and potential biases of often small and retrospective studies. When the results 
of studies in which gender is reported are combined, there are 1386 (62%) females and 
851 (38%) males (4,6,7,8,13,14,15,17,18,19,20,21,30,32,33,34,36,38,39,41,42,43,44,46, 
71,72,73,76, 77,79,81,82,83,84,85,86,87,88,89, 90,91,92,93,94,95,96, 97,98,99,100). 
     The increased risk of AIHA and a number of other autoimmune diseases in females 
has often been attributed to the pro-inflammatory effects of estrogen (101). This is 
unlikely to be relevant to IMHA, as neutering has been implicated as a risk factor for 
development of disease (15,34). When results of those studies reporting neutering status 
are combined, 951/1189 (80%) affected females and 545/760 (72%) males are neutered 
(6,8,13,15,17,18,19,20,30,32,33,34,36,38,39,41,42,43,44,46,71,72,73,76,77,81,82,83,84,
85,87,88,89,90,91,92,94,96,97,98,99,100). The hormonal environment of pet dogs is 
therefore more analogous to that of pre-pubescent children. 
     In humans, female infants are not at increased risk of AIHA (68), but a strong female 
bias is present for other autoimmune diseases such as juvenile idiopathic arthritis (101). 
As recently reviewed by Chiaroni-Clarke et al (2016), this increased risk may be the 
result of genetic variation on the X-chromosome; skewed X-chromosome inactivation in 
females (e.g. leading to biased presentation of maternal or paternal X-linked self-antigens 
within the thymus); reactivation of X-linked genes leading to overexpression; lack of Y-
chromosome mediated control of gene expression; female-specific epigenetic risks or 
gender differences in environmental exposure (101). 
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Age 
     IMHA has been reported in both juvenile and elderly dogs, with the youngest dog 
identified in this literature search only 13 weeks (20) and the oldest 15 years old (100). 
However, for studies where a mean and/or median ages was reported, it is consistently 
between 5 and 8 years (4,5,14,15,18,20,21,30,32,33,34,36,39,41,43,44,71,73,81,84,86, 
87,89,90,91,93,95,102,103,104). This tendency for IMHA to develop in middle aged 
rather than juvenile animals is suggestive that development of primary IMHA is 
influenced by environmental factors.  
Environment 
     Although specific environmental triggers for primary IMHA have yet to be identified, 
there are several lines of evidence that environmental factors contribute to development 
of IMHA. Pet dogs belonging to sufferers of the autoimmune disease, systemic lupus 
erythematosus (SLE), are at increased risk of developing SLE, suggesting the same 
environmental influences may be acting on both species (105). There is a report of three 
bitches living in the same breeding colony all developing a suspected immune-mediated 
pancytopenia within a short time period (106), and of recent stressful events in the history 
of dogs developing presenting for IMHA (14). Of 9 case series of primary IMHA 
reporting seasonal incidence, 4 did not identify a strong seasonal effect (5,32,73,98); 
warm seasons were associated with increased risk in 3 (15,30, 82) and fall or cooler 
months in 2 (14,107). Kidd et al (2014) found a seasonal increase in San Diego but not in 
Los Angeles (82). As the 2 cities have distinct climates, the possibility that environmental 
triggers vary between locations should be considered (82). Modification of disease 
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phenotype by environmental factors is suggested by lower survival for Japanese dogs 
presenting with IMHA during a warm season (71). 
Triggers for loss of self-tolerance: secondary IMHA 
     Disorders implicated as causes of secondary IMHA are summarized in Table 1. The 
general categories are similar to those proposed in humans, with evidence for IMHA 
secondary to neoplasia, infection, drug therapy, and as part of a generalized autoimmune 
disease in both species (129). One notable feature is that while IMHA has been reported 
in dogs with lymphoproliferative neoplasia, these reports are relatively infrequent. For 
example, of 491 dogs with B cell chronic lymphocytic leukemia, 1 dog was identified as 
possibly having IMHA (130). In contrast, approximately 11% of human chronic 
lymphocytic leukemia patients and annually 2-3% of those with lymphoma develop 
warm AIHA (61,129). Similarly, respiratory tract infections, particularly viral and 
mycoplasma infections, are an important cause of secondary cold AIHA in humans (61). 
Parvo virus may be associated with canine IMHA (14), but in general tick-borne disease 
appears to be a more common infectious trigger in dogs (60, 109,110). 
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Table 1. Suggested causes of secondary IMHA in dogs. (*) studies in which a causal link between 
exposure and IMHA was shown experimentally. (#) tumor in remission at time of diagnosis; (^) was 
concurrently receiving antibiotics, but these were not associated with a positive lymphocyte transformation 
test. ($) other investigators concluded that heartworm infection did not cause IMHA (128). A possible link 
with vaccination is discussed in the main text 
Potential 
Trigger  
Possible Examples References 
Infection 
Vector borne Anaplasma phagocytophilium; Anaplasma platys (108,109,110) 
Babesia canis; Babesia canis rossi; Babesia gibsoni (35,60,111,112,113,114, 
115) 
Borrelia turicatae (116) 
Dirofilaria immitis $ (34,103) 
Ehrlichia canis (45,60) 
Mycoplasma haematoparvum (38) 
Parasitic Ancylostoma caninum / Hookworm (30, 117) 
Whipworm (30) 
Bacterial Bacterial abscess (agent not specified) (96) 
Bacterial endocarditis (14,59) 
Septicemia (agent not specified) (45) 
Salmonellosis (29) 
Urinary tract infection/prostatitis (30,59) 
Viral Canine parvo virus (14) 
Neoplasia 
Unknown Unidentified type (34,44,45,59) 
Carcinoma Bronchoalvelolar carcinoma; Carcinoma (unspecified 
type); Pancreatic carcinoma 
(30,59,60) 
Hematopoietic/ 
Round cell 
Essential polycythemia; Hematopoietic tumors; 
Lymphoma; Mast cell tumor; Myelogenous leukemia; 
Myeloproliferative neoplasia 
(14, 38,59,60,100#,118) 
 
 
 
Neuroendocrine Phaeochromocytoma (14) 
Sarcoma Chondrosarcoma; Hemangiosarcoma; 
Leiomyosarcoma; Poorly differentiated sarcoma; 
Reticulum cell sarcoma 
 
(59,60, 119,120) 
 
Envenomation 
 Bee sting (121) 
Mainland Tiger snake (Notechis scutatus) (122) 
Inflammation 
 Dermatitis (60) 
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Table 1 continued. 
 Gastroenteritis (60) 
Generalized pyogranulomatous inflammation (cause 
not specified) 
(14) 
Mesenteric lymphadenitis (60) 
(Pancreatitis) (20, 30,45,59,103) 
Pneumonia/respiratory disease (59,60) 
Drug-induced 
 Amiodarone (123) 
Carprofen (36,124^) 
 Cephalexin, Cefazedone (36, 45, 125*,126*) 
Clavulanate-potentiated amoxicillin (36) 
 Fipronil (36) 
Griseofulvin (14) 
Phenobarbital (45) 
Pirimicarb (127*) 
Praziquantel (36) 
Sulphonamides (45,59) 
Drug not specified (43) 
Generalized autoimmune disorders 
 Hypothyroidism (29,43) 
Polyarthritis/Rheumatoid arthritis (29, 59) 
Systemic lupus erythematosus (43) 
Allergic dermatitis (43) 
Other Organ failure/dysfunction (30,43,59,103) 
 
     It is important to recognize the limitations of the data used to identify triggers of 
canine IMHA. There are rare experimental studies in which exposure to a particular drug 
triggered IMHA in previously healthy dogs (125,126). Even the triggers identified in 
these studies do not induce disease in all exposed individuals, suggesting interactions 
with other factors such as genetics are important in development of secondary IMHA 
(125). For other suggested triggers, a causal relationship has not been proven. Rather, 
these are based on reports of the concurrent presence of signs compatible with IMHA and 
an exposure or disease. 
     At best some of the suggested associations are debatable. For example, pancreatitis 
has been used as a criterion for excluding dogs from studies of primary IMHA (45). This 
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may be valid, as inflammation is a potential cause of loss of self-tolerance, but equally 
pancreatitis could be secondary to hypoxia or thrombosis (70). Similarly, 
phaeochromocytoma has been reported concurrently with IMHA (14), but is also 
common incidental findings at necropsy (131). This presents a dilemma when designing 
studies to investigate canine primary IMHA: excluding all dogs with a possible trigger 
could severely limit enrollment but including dogs with secondary disease complicates 
interpretation of survival data. Even when potential triggers of IMHA are used as 
exclusion criteria, there is the question of how hard should an investigator search before 
concluding these are absent in a particular patient? 
     One particularly controversial potential cause of secondary IMHA is vaccination. The 
link between vaccination and IMHA was proposed by Duval et al (1996), who reported 
15/58 (26%) of dogs with IMHA had been vaccinated within 1 month of presentation 
(107). This was significantly more than the number of control dogs admitted for 
conditions other than IMHA vaccinated in the same time period (p<0.001) and suggested 
that IMHA may be triggered by vaccination more frequently than the industry estimate of 
< 1 case per million (107). When other studies which have reported frequency without 
comparison to a control group are combined, 38/633 dogs (6%) had a recent history of 
vaccination (8,14,15,21,30,32,36, 38,82,90,100). Increased frequency of recent 
vaccination among cases versus controls was not replicated in a subsequent study (34) 
and there is no evidence for differences in survival associated with vaccination (32,107). 
Vaccination history will therefore not be used to exclude dogs from the research 
presented in this thesis. 
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Autoantibodies and erythrocyte destruction in IMHA 
     The class or classes of anti-erythrocyte antibodies produced against the host’s 
erythrocytes has important implications both for the clinical signs and treatment of 
IMHA. Jandl et al (1957) produced early evidence that different antibodies induce 
different forms of erythrocyte destruction (132). Radio-labelled erythrocytes were first 
pre-incubated with anti-dog erythrocyte immunoglobulins to produce antibody positive, 
but not spontaneously agglutinating, red cells. When re-infused, radioactivity rapidly 
accumulated principally in the spleen (132). Similar rapid removal of radiolabeled 
erythrocytes has been reported in dogs with spontaneous IMHA (35). Accumulation of 
incompatible erythrocytes within the spleen was replicated in humans with incomplete 
(i.e. non-spontaneously agglutinating, likely IgG) antibodies (132). In contrast, in humans 
with agglutinating antibodies (likely IgM), radioactivity predominantly accumulated in 
the liver (132). Those humans with high titers of antibodies capable of inducing 
hemolysis in the presence of complement ex vivo had very rapid increases in plasma 
hemoglobin and redistribution of radioactivity from the erythrocyte to the plasma fraction 
(132). 
     These observations provided the initial basis for dividing erythrocyte destruction into 
intravascular hemolysis, in which erythrocytes are lysed directly in circulation, and 
extravascular hemolysis, in which cells are trapped principally in the liver or spleen. 
Investigations into interactions between antibody classes, complement and phagocytes 
have provided insights into the mechanisms behind these different forms of erythrocyte 
destruction. Intravascular hemolysis requires the activation of complement leading to 
assembly of the membrane attack complex within the erythrocyte membrane and thus 
17 
 
 
osmotic lysis of erythrocytes (133). Consideration of the molecular structures involved in 
activation of the complement cascade explains the restriction of intravascular hemolysis 
to only a subset of IMHA cases, 
     As reviewed by Kojouharova et al (2010), activation of the complement cascade by 
antibodies requires first activation of C1q. C1q is formed from 18 chains (6A, 6B and 
6C), each of which has a collagen-like domain and a globular head (134). Disulfide 
bridges link two chains, and the collagen like domains of these dimers form a triple helix 
(134). Within the collagen like domains there is an interruption of the Gly-X-Y repeats, 
creating a flexible hinge region which allows the doublets to diverge into globular heads 
(134). Three of these doublets are linked by noncovalent interactions into a hexamer 
resembling a bunch of tulips (135). When at least two of these heads are engaged there is 
widening of the angle between them, transmitting a conformational change to the C1r 
subunit of the C1 complex, which in turn cleaves and activates C1s leading to activation 
of the complement cascade (134). 
     IgM is the most effective antibody class at activating complement, due in part to its 
multimeric structure (136). Most IgM circulates as a pentamer and although binding sites 
for C1q are accessible on all the heavy chains in circulation it is proposed that when free 
in circulation the spatial relationships between these sites are too fluid to readily allow 
recruitment of C1q (137). However, once multiple variable regions are engaged by 
antigen (as occurs on the erythrocyte surface), IgM becomes sufficiently rigid to 
simultaneously bind multiple heads of C1q (137). Some but not all IgG subclasses are 
also able to activate C1q, with IgG3 doing so most efficiently, IgG1 having moderate, 
IgG2 weak and IgG4 no complement fixing ability (138).  
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     Key residues responsible for differences in C1q affinity have been identified to 
explain differences in complement fixing ability (139), but it should be noted that there is 
also a concentration effect (140). Although individual IgG1 monomers have only low 
affinity for C1q, if antibodies are present at sufficient density on a single erythrocyte, 
non-covalent interactions between Fc regions result in hexamer assembly (141). 
Formation of these hexamers creates a stable structure for engagement of multiple heads 
of C1q, increasing the efficiency of complement activation (141). 
     Thus IgM, IgG1 and IgG3 can all potentially produce complement mediated 
intravascular hemolysis if antibody titers are sufficient (133,142). IgA has also rarely 
been reported as the sole antibody in cases of intravascular hemolysis (143). IgA does not 
activate complement, so the mechanism for intravascular hemolysis remains unclear 
(133). One possible explanation is that IgM was present in vivo but detached prior to in 
vitro testing (133).  
     Equally, not all patients with evidence of complement activation have overt 
intravascular hemolysis (144). In these individuals, the concentration of complement may 
be insufficient to induce membrane attack complex formation. However, deposition of 
C3 on erythrocyte surfaces will also contribute to extravascular hemolysis by engaging 
complement receptors (principally by C3b, iC3b and possibly C3dg binding CR3) 
triggering phagocytosis by macrophages (145). Hepatic, rather than splenic, macrophages 
express the highest levels of complement receptors explaining Jandl et al’s (1957) 
original observation that in a subset of individuals, antibody-coated erythrocytes are 
principally entrapped within the liver (132,146). 
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     Although complement can contribute to extravascular hemolysis, it is not required for 
extravascular destruction. This was demonstrated by Schreiber and Frank (1972) IgG or 
IgM coated erythrocytes were infused into guinea pigs (140). IgM mediated destruction 
was principally hepatic and was eliminated in C4 deficient guinea pigs, whereas IgG 
mediated destruction was largely splenic and persisted in complement deficient animals 
(140). A key difference between IgM and IgG is that Fcγ receptors are expressed on 
macrophages and mediate phagocytosis, whereas Fcμ receptors are principally expressed 
by T and B cells (147). Both hepatic (148) and splenic macrophages (149) express Fc 
receptors, but erythro-concentration and slow transit of erythrocytes through narrow 
splenic sinusoids likely favors interaction and thus phagocytosis in the spleen (150,151).   
     Variation in mechanisms of erythrocyte destruction are specifically relevant to the 
questions examined in this thesis regarding thrombosis in IMHA. As discussed 
subsequently, most research into thrombotic mechanisms has focused on the effects of 
free heme in intravascular hemolysis whereas possible links between extravascular 
hemolysis and hypercoagulability has received little attention. The antibodies present in 
dogs with IMHA, and information regarding mechanisms of destruction that can be 
inferred from these, will therefore be discussed in further detail. 
Properties of antibodies present in canine IMHA 
Methods for detecting erythrocyte antibodies 
     When considering the antibodies involved in canine IMHA it is important to recognize 
the strengths and weaknesses of the commonly used techniques for detection of auto-
antibodies. These assays, combined with diagnostic investigations to exclude an 
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underlying cause, are the basis for a diagnosis of IMHA and will be used as case 
inclusion criteria in this thesis.  
     Spontaneous auto-agglutination: If 
autoantibodies reach a sufficiently high 
concentration, they can simultaneously 
bind more than one erythrocyte. This 
links multiple cells into clumps that may 
be large enough to appreciate 
macroscopically (Figure 3) and have a “bunch of grapes’ appearance microscopically. 
Recognition of these structures on dried blood smears was used as evidence of IMHA in 
some early reports (81,84). However, this is problematic because interactions between 
plasma macromolecules and erythrocyte membranes can produce stacks of erythrocytes 
(rouleaux), which when superimposed one on top of each other mimic the “bunch of 
grapes” appearance of agglutination (152,153). The saline agglutination test was 
developed to distinguish true auto-agglutination (which will persist) from rouleaux 
(which disperse on addition of saline) (153).   
     Despite its widespread use in veterinary medicine, there is a lack of consensus as to 
how the saline agglutination test should be performed. Many investigators simply add 
blood to one or more drops of saline on a glass slide (17,96), but others consider the test 
positive only if agglutination persists after multiple (usually 3) saline centrifugation 
washes (4,37,97). When results are combined from 19 studies in which the saline 
agglutination test was performed without washing (or where technique is not described); 
sensitivity is 76% (676/873 dogs positive; 95% confidence interval: 74-80%) (5,6,8,13, 
 
Figure 3. Macroscopic agglutination. Whole 
blood anti-coagulated with EDTA was mixed in a 
1:4 ratio with saline. Grossly visible agglutination 
persisted, consistent with IMHA. 
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15,17,19,32,33,34,36,41,44,86,91,92,96,100,154). For studies in which saline washing 
was performed sensitivity is considerably lower at 23% (51/218 positive; 95% confidence 
interval 18-30%) (30,37,97,107).  
     Advocates of centrifugal washing consider it necessary to improve specificity. 
However, the specificity of the test with or without washing has received relatively little 
attention. Caviezel et al. (2014) reported 4/26 sick dogs with diseases other than IMHA 
had agglutination pre-washing (97), but one of these dogs had pure red cell aplasia which 
is an immune mediated form of erythrocyte destruction (155) and 2 had neoplasia, a 
potential cause of secondary IMHA (61). Case series of diseases other than IMHA 
occasionally also report spontaneous agglutination that does not persist with washing 
(e.g. Coombs’ negative dogs with chronic granulocytic anaplasmosis (156)). However, 
Paes et al (2013) and Blois et al (2013) report 100% specificity for pre-washed samples 
from sick dogs with diseases other than IMHA (n=66 and 44 respectively) (96,154). In 
this thesis, the method described by Paes et al (2013), which uses 1 drop of blood to 4 
drops of saline, is therefore considered adequate evidence for presence of erythrocyte 
autoantibodies (96). 
     Washing versus diluting blood is not the only methodological variation. One area 
which is likely important, but has received virtually no attention is the temperature at 
which the test is carried out. This is not usually stated, though use of room temperature 
saline has been described (96). This could lead to antibodies which preferentially bind at 
core temperature being missed and antibodies which bind at colder temperatures (which 
may be less clinically significant) being detected. 
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     Although a positive saline agglutination test can provide evidence for the presence of 
autoantibodies, a negative test does not rule out their presence at concentrations too low 
to induce agglutination. Neither can conclusions be drawn as to the antibody class 
involved. It might be assumed that, due to its pentameric structure, IgM is responsible for 
autoagglutination. However, Harkin et al (2012) reported agglutination in dogs with IgG, 
IgM or both bound to erythrocytes (157), and IgG eluted from the surface of erythrocytes 
from a dog with IMHA was capable of agglutinating both its own, and normal dog 
erythrocytes (158). Studies of IgM and IgA in a mouse model of AIHA demonstrated the 
ability of both classes to induce agglutination in that species, and suggested entrapment 
of agglutinated erythrocytes within the spleen, and to a lesser extent the liver, may 
directly cause anemia (159). There is some evidence that agglutination may act similarly 
in humans (160). 
     Direct Antiglobulin Test (DAT or Coombs’ test): The direct anti-globulin test (DAT) 
is also known as the Coombs’ test in honor of the veterinary surgeon responsible for its 
development (161). The assay was designed to detect incomplete antibodies i.e. those that 
do not produce spontaneous agglutination. Washed patient red cells are incubated with 
antibodies raised against immunoglobulin or complement from the same species (e.g. 
rabbit or goat anti-dog or anti-human antibodies). If sufficient antibody or complement 
coats patient cells, binding of anti-complement or anti-immunoglobulin antibodies cross-
links antibodies or complement attached to different erythrocytes (162). Gel, tube and 
microtiter methods have been used in veterinary medicine, all of which use visual 
detection of this anti-immunoglobulin/complement induced agglutination as evidence for 
anti-erythrocyte antibodies (97). Reported concordance between these different methods 
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is strong so they will be considered together (97). The indirect antiglobulin test, which 
assesses the ability of patient serum to agglutinate normal erythrocytes has been reported 
in IMHA but is rarely used and will not be discussed further (83). 
     The DAT can be performed using monovalent antibodies against IgG, M, complement 
(typically C3 or C3b) and less commonly IgA individually, which allows the components 
responsible for erythrocyte destruction to be determined (3,162). Alternatively, 
polyvalent reagents containing a mix of anti-IgG, IgM and C3 antibodies can be used to 
detect if there is evidence of antibody binding but not the specific antibody involved 
(162). The latter is often the only test performed in veterinary medicine whereas in 
human medicine, while polyvalent DAT may be used for screening, if positive it is 
followed by monovalent testing to better guide therapeutics (129).  
     Similarly, in human medicine there is considerable interest in determining preferred 
binding temperatures of autoantibodies as this has implications for underlying causes, 
therapeutics and prognosis (129). Antibodies with preferential binding at below body 
temperature are termed cold agglutinins, whereas those with preferential binding at 37oC 
are warm agglutinins (129). IMHA is described as warm, cold or mixed based on the 
preferred binding temperatures of autoantibodies and mechanisms of destruction vary 
with antibody type (Figure 2) (129). The DAT is therefore typically performed at both 37 
and 4oC to distinguish warm versus cold agglutinins (129). In dogs, cold agglutinins are 
often dismissed as clinically irrelevant (the validity of which will be discussed 
subsequently) and the assay is often performed only at 37oC (162). 
     The simplified version of the DAT commonly used in dogs partly reflects concerns 
regarding reliability in dogs (162). Although DAT negative AIHA does occur in humans, 
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it remains an important diagnostic criterion for AIHA (163). Many veterinary studies do 
not require a DAT to be performed, providing other evidence of hemolysis (e.g. saline 
agglutination test, spherocytes, icterus, and/or hemoglobinemia/uria) is present (5,8,17). 
When results from studies reporting DAT were combined, sensitivity for 815 IMHA dogs 
(including results generated using different methods, temperatures and reagents) was 
76% (95% confidence interval 73-79%) (3,4,5,6,8,13,14,15,17,21,30,33,34,36,37,41,43, 
59,81,83,84,86,87,90, 96,107,164) and for 858 dogs with other diseases specificity was 
86% (95% confidence interval 83-88%) (3,14,81,83,96,97,128,156,164). Of the studies 
reporting results for healthy animals, there were 11 dogs with positive results and 385 
dogs were negative (3,83,96,97,128).  
     False positive test results may represent more a misinterpretation of a positive direct 
antiglobulin test than a failure of the test itself. DAT documents the presence of 
antibodies or complement on erythrocytes, which occurs during erythrocyte aging (165); 
by passive adsorption (166) and in autoimmune diseases other than classical IMHA (e.g. 
pure red cell aplasia (74,167). Detectable passive adsorption is more likely to occur at 
higher serum antibody concentrations (168), so it is unsurprising that false-positive DAT 
have often been reported in inflammatory or infectious diseases such as Dirofilaria 
immitis infection (128), immune-mediated thrombocytopenia (14); SLE (3), chronic 
inflammation (84) and neoplasia (84). False positives due to antibodies other than 
destructive autoantibodies can be reduced by careful selection of the titer at which 
agglutination is considered a positive result (81).  
     False negative results can arise when antibody or complement is at too low a 
concentration on erythrocytes to induce agglutination (169). This could occur if antibody 
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has eluted from the erythrocyte, for example due to delay in testing (169); inappropriate 
wash buffers (170), or if the sample is stored or tested at a temperature which does not 
overlap with the optimal binding temperature for the autoantibody (59,169). Use of 
excessively concentrated anti-immunoglobulin and/or complement antibodies can also 
create false negatives because there is so much secondary antibody available that it does 
not crosslink erythrocytes (the pro-zone effect) (97). Effect of prior immunosuppression 
appears individually variable, as Caviezel et al (2014) reported 3/9 dogs were DAT 
negative by day 10 of treatment (97). There is also evidence of quite marked differences 
in performance between different canine DAT reagents. Overmann et al (2007) reported a 
difference in sensitivity of 21% between two reagents (171) and Caviezel et al (2014) 
titers twice as strong with one reagent compared to another (97).  
     Direct flow cytometry: Direct flow cytometry uses anti-dog antibodies to detect if IgG, 
IgM, IgA or complement are bound to erythrocytes. Initial studies in dogs reported high 
sensitivity for IMHA cases, ranging from 100% to 92% for studies using anti-IgG, M, 
complement plus or minus anti IgA (172,173) and 72% when IgG alone was labelled (6). 
These studies were all relatively small (n=12-18) (6,172,173). Sensitivity was only 66% 
in the only large scale report (n=54) using anti-IgG, M, A and complement (157) and 
77% when IgM and IgG alone were used (n=22 IMHA cases, n=292 total) (174).  
    The technique may therefore perform less well in a clinical rather than a research 
setting (e.g. due to false negatives after immunosuppressive therapy; storage instability). 
However, this could also reflect variation in the reagents used as Kucinskiene et al (2005) 
reported marked differences in the sensitivity of two anti-dog IgG reagents (175). 
Kucinskiene et al (2005) also report better sensitivity for flow cytometry than 
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conventional direct antiglobulin testing, similar to reported test performance in humans 
(175,176). The assay also appears relatively specific: Morley et al (2008) reported a 
specificity of 93% for anemic dogs with a diagnosis other than IMHA and 86% when 
both anemic and non-anemic dogs were considered (174).  
     Spherocytes: Spherocytes appear on blood smears as small, round erythrocytes lacking 
central pallor. Their apparently reduced size is largely an illusion: instead spherocytes in 
AIHA have reduced surface area with little or no change in volume (177). Spherocytes 
are not specific for autoantibodies as they can occur with mechanical fragmentation 
(178), non-immune mediated lysis (179) or as a hereditary cytoskeletal abnormality 
(177), but large numbers are strongly suggestive of extravascular hemolysis (179). This is 
because spherocytes can develop when part of the erythrocyte membrane is removed by 
phagocytosis and the remaining membrane seals the defect allowing the cell to continue 
in circulation with a reduced surface area: volume ratio (150). Spherocyte production 
contributes further to anemia, because their reduced flexibility increases entrapment and 
subsequent clearance by the spleen (180).  
     When case series containing at least 3 dogs are combined, sensitivity of spherocytes 
for IMHA is 73% (926/1269 IMHA cases positive; 95% confidence interval 70-75%) 
(4,5,6,7,8,13,15,17, 20,21,30,32,33,34,36,37,41,43,81,84,86,87,90,91,92,96,97) and for 2 
reports that included sick dogs with diseases other than IMHA, specificity is 87% (12/97 
false positives, 95% confidence interval 79-93%) (96,97). Paes et al (2013) reported that 
specificity was increased to 95% if a cut-off of >5 spherocytes per high power field rather 
than 1 per high power field was used (96). This later cut-off is therefore used as evidence 
of IMHA in the current study.  
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     Harkin et al (2012) did find spherocytosis was more marked in dogs with IgG rather 
than IgM autoantibodies, consistent with Fcγ-mediated partial phagocytosis by splenic 
macrophages (157). However, some dogs with only IgM did have moderate 
spherocytosis, suggesting that complement mediated phagocytosis in the liver and 
possibly phagocytosis in the spleen triggered by, for example, oxidative damage (86) 
contributes to spherocytosis in IMHA.  
Antibody classes in dogs with IMHA 
     Reports of canine direct antiglobulin tests and flow cytometry results are summarized 
in Table 2. The pattern of antibody detection is similar to that reported for humans with 
warm AIHA. In both species, IgG is the most common antibody class (61). The high 
frequency of detection of IgG alone suggests that (principally splenic) extravascular 
hemolysis is the most common mechanism of erythrocyte destruction in dogs with 
IMHA.  
     However, amalgamation of results from multiple studies hides the variation in results 
reported by different groups. This is particularly noticeable for detection of C3 or its 
degradation products, with some authors reporting 60-85% (20,173) positive and others 
no positive cases (157,172). This may reflect differences in case inclusion criteria as 
Slappendel et al (1979) reported an association between complement positivity and 
concurrent disorders (3), although this was not replicated by Warman et al (2008) (59). 
Given the variability in detection antibody performance described above, an alternative is 
that false negative results lead to underestimation of the number of dogs with 
complement activation, and thus of the number of dogs with a possible intravascular 
component to their erythrocyte destruction. 
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     This possibility is supported by the only study of IgG subclasses in IMHA, in which 
7/7 dogs were positive for IgG1, which is capable of activating complement (85). 
Reductions in serum C4 and C3 have also been reported in approximately 40% of IMHA 
dogs, consistent with consumption (84). Clinical presentation also supports a higher 
frequency of complement mediated intravascular hemolysis than suggested by testing for 
complement and antibody. Of 682 dogs with primary IMHA, 211 (31%) had signs 
consistent with intravascular hemolysis (i.e. visible hematuria/positive urine dipstick 
result for heme or hemolyzed plasma) (4, 5,6,13,20,21,30,32,36,45,60,84,86,90,107). 
However, it should be noted only one of these reports performed urine sediment exams to 
determine if hematuria was consistent with hemoglobin rather than frank blood (4). As 
bleeding diathesis has been reported in thrombocytopenic IMHA patients (36), this may 
have led to overestimation of the frequency of intravascular hemolysis. Similarly, 
although hemolyzed plasma is suggestive of IMHA it has also been reported in healthy 
control dogs, presumably due to traumatic sample collection or handling (86). 
 Anti-erythrocyte antibody reactivity in dogs with IMHA 
     For human warm agglutinins, the most common erythrocyte antigens are Rhesus 
polypeptides (182), although other antigens have been identified including glycophorins 
(183) and band 3 proteins (182). Human cold agglutinins are usually, though not always 
directed against carbohydrate antigens (184,185). The antigens against which anti-
erythrocyte antigens are directed are not well defined in dogs. An epidemiological study 
found no difference in the frequency of the dog erythrocyte antigens 1.1, 1.2, 3, 4, 5 and 
7 between cases and controls (72). 
 
29 
 
 
 
Table 2: Reported antibody and complement binding detected by direct antiglobulin test or by flow 
cytometry on erythrocytes from dogs with IMHA. This is a summary of data reported by 
(3,6,14,20,30,31,59,85,107,157,172,173,174,181). Two reports which were excluded as the numbers of 
dogs positive for each combination of antibodies and complement was unclear (4,171).  
Antibody or 
complement bound to 
erythrocytes 
Number of positive 
IMHA dogs/Total 
number tested 
% positive 
IgG 226/521 43 
IgM 43/503 9 
IgA 1/103 1 
C3 30/449 7 
IgG, M 52/503 10 
IgG, C3 52/449 12 
IgG, M, C3 64/449 14 
IgM, C3 9/449 2 
IgG, A 0/103 0 
IgG, A, C3 0/103 0 
IgG, M, A 2/103 2 
IgG, A, C3, M 0/103 0 
IgM, A 1/103 1 
IgM, A, C3 1/103 1 
IgA, C3 0/103 0 
None 40/521 8 
 
     An early approach to screening non-blood group antigens was reported by Tsuchida et 
al (1991) (158). Proteins from the membranes of erythrocytes of normal and IMHA dogs 
were separated by SDS PAGE. A protein in the region of protein 4.1 was more prominent 
in cases than controls, and became less evident during remission (158). While this could 
represent a target for antibody binding, subsequent studies suggest this may simply 
reflect alterations in the protein 4.1a: 4.1b ratio between immature and aged erythrocytes 
(186). Subsequent investigations have eluted antibodies from IMHA erythrocytes using 
xylene or ethanol followed by immunoblotting against erythrocyte membrane proteins 
and identification of antigens based on molecular weight and testing against a purified 
candidate protein (187,188) or by mass spectroscopy (95).  
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     Thus far only IgG antigens have been investigated and only using normal dog 
erythrocyte proteins, so modified antigens would not be identified. Barker et al. identified 
IgG binding to glycophorins (4/8 dogs) and band 3 (1/8) in IMHA dogs and to the 
cytoskeletal protein spectrin in both healthy dog and IMHA sera (187,188). In at least 1 
dog there were additional IgG protein binding bands of 100kDa, 37kDa, 35kDa and 
32kDa, the identity of which was not determined (187). Glycophorins and band 3 both 
induced proliferation of T cells from IMHA cases but not healthy dogs, and spectrin 
induced proliferation of T cells from IMHA cases and a single healthy dog (188). 
However, the significance of band 3 antibodies is debatable as Tan et al (2012) found 
these in both healthy dogs and IMHA cases and IgG/band 3 interactions are involved in 
clearance of senescent erythrocytes (95,189).  
     In IMHA cases but not controls, Tan et al (2012) found evidence of IgG binding to 
complement component 3 (8/12) and also to two cytosolic erythrocyte proteins capable of 
translocating to the membrane and thus potentially interacting with autoantibodies: 
calpain (8/12) and peroxiredoxin 2 (4/12) (95). The antioxidant peroxiredoxin 2 moves to 
the membrane during oxidative stress (190), which has been documented in primary 
IMHA (86) and is associated with triggers of secondary IMHA (191,192). Calpain 1 is 
involved in triggering eryptosis (the erythrocyte equivalent of apoptosis) (193), which is 
also associated with oxidative damage (194). 
     These observations are intriguing, not least because they strengthen the link between 
IMHA and inflammation, which will be discussed further subsequently. However, it is 
unlikely that these antigens which are usually hidden within the cell contain the principal 
epitopes involved in IMHA (95). 
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Preferred binding temperatures of canine auto-antibodies  
     Results of studies which have assessed antibody binding for IMHA dogs at both 4 and 
37oC using monovalent DAT reagents are summarized in Table 3. Additionally, Kennedy 
et al (2006) et al reported that of 96 dogs with IMHA, 69 had a dominant warm reactive 
IgG DAT and 27 had an additional or dominant cold reactive IgM DAT (76). It should be 
noted that some authors have reported improved sensitivity for DAT when performed at 
4oC (85,175). This may reflect not just binding preferences of autoantibodies, but also 
preferential binding of the detection antibodies to dog immunoglobulin and complement 
at lower temperatures. However, as discussed above, a high proportion of IMHA cases 
have spontaneous agglutination at room temperature, suggesting cold agglutinins are 
frequently present in IMHA. Warman et al’s (2008) data suggests they usually reflect 
mixed, rather than cold, type disease (59). 
Table 3. Patterns of direct antiglobulin test reported at 4oC and 37oC. Direct antiglobulin tests were 
performed using polyvalent reagents and/or monovalent antibodies reactive against specific antibody 
classes or C3.  
Reference 4oC 37oC 4oC and 37 oC 
(59) Polyvalent 3/46 
IgG 6/46 
IgM 11/46 
C’ 12/46 
Polyvalent 1/46 
IgG 1/46 
IgM 0/46 
C3 1/46 
Polyvalent 42/46 
IgG 37/46 
IgM 1/46 
C’ 4/46 
(31) 5/11 IgG 
2/11 IgM 
2/11 IgG, IgM 
0/11 2/11 IgG, 
1/11 C3 
 
 
     In humans, warm, cold and mixed AIHAs are well recognized and determine if therapy 
is based around anti-complement or anti-B cell strategies (133). In dogs, there are 
sporadic reports of cold agglutinin disease (195,196) and it has been anecdotally reported 
that cold-reactive IgM antibodies are associated with more acute and severe disease (76). 
However, as discussed performing DAT at only 37oC is often justified in the veterinary 
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literature based on the observation that erythrocytes from a high proportion of normal 
dogs spontaneously agglutinate at 4oC (3). This together with reports of dogs with cold 
agglutinins but no evidence of hemolysis (197) and increased frequency of cold 
agglutinins in secondary IMHA (59) could suggest these antibodies are clinically 
insignificant.  
     However, performing Coombs’ tests only at 37oC does seem somewhat illogical as 
spontaneous agglutination, or agglutination in saline at room temperature are common 
diagnostic criteria in veterinary studies (17,8). In humans, clinically significant cold 
agglutinins are distinguished by their high titer and thermal amplitude (i.e. ability to bind 
at temperatures around 30oC) (198). Mills et al (1985) reported spontaneous agglutination 
at 20oC for approximately 25% of IMHA dogs (84), suggesting re-examination of the 
importance of cold agglutinins in canine AIHA is warrented. 
Is IMHA a thrombotic disease? 
     A recent systematic review of human AIHA reported a pooled risk ratio for venous 
thrombosis of 2.63 (95% confidence interval: 1.37-5.05) (199). Only four studies met the 
inclusion criteria, and three of these included only hospitalized patients so may be biased 
toward more severe cases (200,201,202).  The remaining study relied on insurance claims 
data so also represents a selected population.  Interpreting increased thrombosis rates in 
human AIHA is also complicated by several factors (203). Firstly, a high proportion of 
cases are secondary either to neoplasia or to autoimmune diseases such as 
antiphospholipid antibody syndrome (204), rheumatoid arthritis (61) or SLE (61), all of 
which are associated with increased thrombotic risk (203,205,206). Secondly, prolonged 
follow up is needed both to accurately establish thrombosis rates and to classify AIHA as 
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primary or secondary. This is because thrombotic risk remains elevated for years after 
diagnosis (201) and AIHA can precede overt signs of neoplasia by months to years (207). 
Thirdly, the apparent increased thrombotic risk in AIHA may be associated with drugs 
and therapeutic interventions rather than the disease itself. For example, in a recent case 
series, four of the twelve patients with thrombosis developed abdominal thrombi post-
splenectomy (64).  
     In dogs, IMHA is widely accepted to carry a high risk of thrombosis. Thrombosis or 
lesions consistent with coagulation disturbance have been reported as the first or second 
most common necropsy finding in fatal cases (4,33,70). When studies which include 
reporting of thrombosis are combined, 164 of 756 (22%) dogs had suspected or 
confirmed thrombosis (4,6,7, 8,15,17, 18,19,29,30,31,33,34 35,37,38,39, 
42,44,45,60,87,90,94).1 
     This is likely an inaccurate estimate of the true rate of thrombosis. Necropsy is not 
always performed in veterinary cases. Even when performed, canine thrombi are rapidly 
dissolved compared with other species due to high urokinase activity (208), and 
microthrombi may be missed when cutting in tissues for histology. Ante-mortem 
diagnosis of thrombosis is also challenging, particularly for pulmonary thrombosis as 
radiographic signs are often absent or non-specific (209). Multi-slice spiral computed 
tomography pulmonary angiography is critical for ante-mortem diagnosis in humans, but 
is not yet frequently performed in veterinary medicine (210). Difficulty in diagnosis may 
lead to underestimates of thrombosis rate, but because diagnosis is often based on 
                                                           
1 This does not include studies where suspected or confirmed thrombosis was a requirement for inclusion 
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relatively non-specific signs, there is also the possibility of overestimation. For example, 
acute onset neurological signs have led to suspicion of thrombosis in IMHA cases (87), 
but can also occur due to bilirubin toxicity (211) or extrameduallary hematopoiesis in the 
choroid plexus (212). 
     Regardless of the imprecision of the estimate of incidence of thrombosis in IMHA, 
there are several observations suggesting dogs with spontaneous IMHA may provide 
valuable insights into the pathogenesis of thrombosis in human AIHA. Dogs do not have 
a high rate of spontaneous thrombosis (213) or atherosclerosis (214), so thrombi that arise 
in IMHA likely relate to the disease. Canine IMHA is commonly primary (14,45,59,60); 
admittedly limited evidence suggests IMHA is not associated with increased risk of 
subsequent neoplasia in dogs (48) and although reported in canine IMHA (215), 
antiphospholipid antibodies are not thought to contribute frequently to thrombosis in 
IMHA (94). Therefore, multiple sources of background “noise” are reduced in the canine 
model. Furthermore, although dogs do receive some pro-thrombotic interventions (e.g. 
corticosteroids, catheterization) (29) other potentially pro-thrombotic treatments are only 
infrequently delivered (e.g. splenectomy (13,64), intravenous immunoglobulin (9,216, 
217). Although thrombosis can occur sometime after discharge, most studies report 
thrombosis occurring principally during initial hospitalization and most deaths in the first 
2 weeks to 3 months (20,21). This reduces the need for prolonged follow up, simplifying 
study design. 
     Although modelling of human disease is clearly valuable, from a veterinary 
perspective understanding thrombotic mechanisms is only really valuable if thrombosis 
contributes significantly to mortality and morbidity in dogs. Dogs with IMHA are 4 times 
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more likely to die in hospital than the general referral population (21). However, thrombi 
are relatively frequent incidental findings in humans undergoing imaging for other 
reasons (218,219). Therefore, although thrombosis is a common post-mortem lesion, it 
does not necessarily mean it contributed directly to death or euthanasia of the dog.  
     Other important causes of mortality include failure to control erythrocyte destruction 
(45); organ damage which may be due to hypoxia rather than thrombosis (e.g. hepatic 
necrosis, pancreatitis) (70) and adverse events related to treatment (summarized in Table 
4). Whelan et al’s 2009 report of treatment costs between $1652 and $8753 is also a 
reminder that financially driven euthanasia is a common cause of death (7). However, 
there are also clear examples in the literature of thrombosis as the principal cause of 
death or euthanasia (17).  A causal role for thrombosis in mortality is supported by 
evidence that the anti-thrombotic therapies heparin and aspirin may improve outcome in 
IMHA (15,17). 
     One surprising limitation when trying to understand the pathogenesis of thrombosis is 
the lack of information regarding location of thrombi in IMHA patients. There are 
distinct differences in the mechanisms of arterial, venous and pulmonary vasculature 
thrombi, but thrombus type is often not clearly reported in canine studies (235). Of the 
reports summarized above, 9 thrombi were specified as venous, 4 arterial, 1 in the hepatic 
sinusoids and 57 in the pulmonary vasculature (4,6,7,15,17,18,19,29,30,31,33,34,38,44,   
45,60,94).  
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Table 4. Adverse events related to treatment reported in dogs with IMHA. PUPD: polydipsia/polyuria. 
IVIg: intravenous immunoglobulin. 
Complication Treatment Non-fatal/Outcome not 
reported 
Fatal 
Infection Corticosteroids  Fusarium sporotrichioides 
(220) Neospora caninum 
(221); Phialosimplex 
caninus (222) 
Corticosteroids, 
Azathioprine 
Erysipelothrix rhusiopathiae 
(223) 
Blastomycosis (224)  
Disseminated Citrobacter 
freundii (225); Bacterial 
endocarditis (226); 
Scedosporium prolificans 
(227)  
Corticosteroids, 
Cyclophosphamide 
Mycoplasma haemocanis (228) Pneumonia (10) 
Corticosteroids, 
Cyclosporine 
Curvularia lunata (229); 
Alternaria infectoria (230) 
Disseminated Toxoplasma 
gondii (231); Unspecified 
systemic mycosis (45)  
Corticosteroids, 
multiple other 
immunosuppressants 
 Pericarditis Candida 
albicans/Acinetobacter spp. 
(232) 
 
Corticosteroids, 
Mycophenalate 
mofetil 
Unspecified skin infection (45); 
pneumonia (45); esophagostomy 
tube infection (45)  
Diarrhea with crypt necrosis 
(46) 
Not specified  Clostridium piliforme 
hepatitis (33) 
Transfusion Babesia gibsoni (115)  
Drug side-
effects 
Corticosteroids Calcinosis cutis (224) PUPD 
(5); Gastric ulceration (45) 
Unspecified side-effects 
(19) 
Corticosteroids, 
cyclosporin A 
Insulin resistance (233)  
Cyclosporine Hyperplastic gingivitis (234) 
vomiting/diarrhea (45); 
Hepatopathy (45); Hirsutism 
(45) 
 
Mycophenalate 
mofetil 
Diarrhea/anorexia (19) diarrhea 
(45,46) 
 
Unfractionated or 
low molecular 
weight heparins 
Minor bleeding (18)  
Azathioprine Vomiting/diarrhea (20,45); 
Leukopenia (20); 
Hepatopathy(45); 
Thrombocytopenia (20) 
 
IVIg Injection site reaction; volume 
overload  (7) 
 
      
The high proportion of pulmonary thrombi is repeatable when reports that give thrombus 
location without specifying vessel type are included: lung n=57; spleen n=21; renal n=15; 
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specified vessel n=13; liver n=9; mesentery/gastrointestinal: n=4; heart n=4; central 
nervous system n=5; other n=3 (4,6,7,15,17,18,19, 29,30,31,33,34,38,41,44,45, 60,94).3  
Pulmonary thrombi may have arisen spontaneously in the lungs or have embolized from 
the venous circulation (235). Therefore, IMHA does appear to more commonly, but not 
exclusively, result in venous thromboembolism. 
Contributors to hypercoagulability in IMHA 
     Most basic research into the pro-coagulant effects of erythrocyte destruction has 
focused on the effects of intra-vascular hemolysis releasing erythrocyte contents directly 
into circulation, and it is unclear to what extent these mechanisms apply to extravascular 
hemolysis (236). Erythrocytes contain ADP, which directly activates platelets (237), and 
arginase (238). Arginase degrades L-arginine, the substrate for nitric oxide synthase 
(238). Reduced nitric oxide favors vasoconstriction and contributes to activation of 
platelets and factor XIII (239). Levels of nitric oxide are further reduced by reaction with 
hemoglobin, generating nitrate and methemoglobin (240). Methemoglobin decays to free 
heme, which acts partly via TLR-4 to activate endothelial cells, monocytes and 
neutrophils (240,241,242,243). Pro-thrombotic properties of activated endothelial cells 
include display of tissue factor (243,244) and adhesion molecules (e.g. P-selectin, von 
Willebrand’s factor) which recruit leukocytes (241) and platelets (245). Contributions of 
leukocytes to thrombosis will be discussed subsequently. Evidence for activation of these 
various components of the coagulation system in IMHA are discussed below. 
 
                                                           
3 In some cases, multiple thrombi locations were present in the same patient. 
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Evidence for global hypercoagulability 
     Thromboelastography is a global coagulation test, meaning it is carried out using 
whole blood and reflects the balance of contributions from multiple components of the 
coagulation system (246). The assay measures the rate and magnitude of changes in 
blood viscosity as it clots, generating parameters which reflect the speed of clot formation 
and breakdown and clot strength (246). Maximum amplitude (MA) and G (a calculated 
value derived from MA) indicate clot strength and are commonly elevated in IMHA 
(44,91,99). K and α (both measures of the rate of fibrin formation and cross-linking) are 
frequently also altered consistent with hypercoagulability (44,91,99). However, survival 
is worse for dogs classified as normocoagulable by thromboelastography (39).  
     Indicators of hypercoagulability are correlated with fibrinogen concentration. 
Therefore, a normocoagulable trace could suggest hypercoagulability so severe that 
fibrinogen has become depleted (39). This is a limitation of thromboelastography. 
Although hyperfibrinogenemia (as is commonly present in IMHA (32)) may contribute to 
thrombotic risk (247), it does not appear to be a major determinant clinically (248) and 
may be over-emphasized by thromboelastography. Similarly, because 
thromboelastography reflects blood viscosity, MA is artefactually increased by anemia 
(249). It is therefore important to also consider evidence for contributions of individual 
components to coagulation. 
 
 
 
39 
 
 
Platelet activation 
     One of the earliest indications that platelet activation contributes to hypercoagulability 
was provided by Weiss and Brazzell (2006) (87). Using flow cytometry, they 
demonstrated that P-selectin, a marker of platelet granule release, was increased on the 
surface of platelets from IMHA dogs (87,250). Evidence of platelet activation, as 
measured by markers of degranulation, has not been consistently replicated. Smith et al 
(2014) found no difference in mean platelet component (an indirect measure of platelet 
density and therefore degranulation) between IMHA dogs and those with orthopedic 
disease (251). This may reflect limited sensitivity of the parameter, or confounding 
effects related to their finding that platelet volume was increased in IMHA (251). Ridyard 
et al (2010) found P-selectin was increased only in certain platelet sub-populations or in 
IMHA dogs that were also severely thrombocytopenic (42).  
     However, there are other lines of evidence for platelet activation during IMHA. 
Ridyard et al (2010) reported increased platelet microparticle release in IMHA cases (42). 
Microparticles are small vesicles released by platelets (amongst other cell types) upon 
activation. The pro-coagulant properties of microparticles are 50-100 times that of 
platelets (252). This is in part because the negatively charged phospholipid 
phosphatidylserine is present at high levels in their outer membrane, providing ideal 
conditions for recruitment of factors VIII and Va and thus assembly of the tenase 
complex (252). While Kidd et al (2015) did not find an increased number of 
phosphatidylserine positive microparticles, there was an increase in their pro-coagulant 
activity (103). 
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     Hamzianpour et al (2016) used the thromboelastography parameter delta (Δ) to 
identify IMHA dogs in which platelet activation contributed to hypercoagulability (99). Δ 
is a measure of the time lapse between the initiation of fibrin formation and the split point 
at which the two arms of the TEG trace diverge (99). In humans, it provides a measure of 
thrombin generation, and therefore of activation of the enzymatic coagulation cascade 
(99). Of 27 IMHA cases studied, hypercoagulability was present in 18 (based on 
increased G, a general indicator of clot strength). Of these, 10 had a normal or prolonged 
Δ, suggesting platelets were the major contributor to hypercoagulability (99). The 
reliability of Δ has not been assessed in dogs, and G is derived from MA which as 
previously discussed is not reliable in the face of anemia (249).  
     A direct link between platelet activation and thrombosis is suggested by increased 
phosphatidylserine exposure on platelets in IMHA cases that developed thrombosis (87). 
The importance of platelets in the pathogenesis of thrombosis is also supported by a 
retrospective study reporting improved survival in dogs treated with aspirin (15), which 
reduces platelet activation by inhibiting the conversion of arachidonic acid to precursors 
of thromboxane A2 (253).. 
Enzymatic factor activation 
     Prolonged prothrombin and activated partial thromboplastin times have been 
repeatedly reported in IMHA (30,33,36,224), with one or both tests prolonged in close to 
or over 50% of cases in some reports (20,32,34). These assays assess activity of 
enzymatic factors of the tissue factor and common pathways and contact and common 
pathways respectively (254). Based on assays for activity of individual factors, mixing 
studies using normal dog plasma, kaolin activated clotting times and Russell’s viper 
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venom times, prolongation is typically due to factor deficiencies rather than antibody 
inhibition (33,43,94). Reduced activity of multiple coagulation factors is suggestive of 
accelerated consumption.  
     A generalized hypercoagulable state is supported by reports of reduced antithrombin 
in IMHA (33,44,91,255). Antithrombin is the principal inhibitor of thrombin, and has 
additional activity against other coagulation factors. Hypofibrinogenemia is also reported 
occasionally in IMHA, consistent with large scale conversion of fibrinogen to fibrin 
(20,32). Elevated D-dimers provides evidence of increased fibrin generation, crosslinking 
and subsequent breakdown (7,42,103,224).  
     IMHA cases may develop multi-organ thrombosis consistent with decompensated 
disseminated intravascular coagulopathy (DIC) (33). Even when coagulation factor 
consumption does not progress to overt DIC, reduced antithrombin (255) and prolonged 
clotting times are associated with reduced survival (5,7,15,32,43,71). The contribution of 
activation of the enzymatic coagulation cascade to thrombosis is supported by evidence 
that unfractionated heparin improves survival in IMHA (17). Heparin is a polysaccharide 
which principally acts to inhibit factor Xa, and when bound to antithrombin, thrombin 
(256). Reduced activation of thrombin not only impairs its cleavage of fibrinogen to 
fibrin but also dampens the amplification loop in which thrombin enhances its own 
generation by activation of factors V and VIII (256). For clarity, platelets and enzymatic 
coagulation factors have been discussed separately, but in reality the two systems are 
intimately linked (256). Therefore, heparin may also improve survival in part by reducing 
thrombin’s activation of platelets. 
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     It should however be noted that although a prospective randomized trial design was 
used to test the effects of heparin on survival, it was severely underpowered (17). The 
authors’ power calculation suggested 40 cases were required, but the trial was stopped 
after enrollment of 15 dogs, one of which was lost to follow up (17). The trial was 
stopped early partly due to difficulty in obtaining the drug and partly because the authors 
considered that the effect was sufficiently large that it would be unethical to deny the 
control group the drug (17). Stopping trials early carries a risk of overestimating the 
effect of treatment, as random fluctuations in survival in the treatment and control groups 
are overemphasized (257).  
The fibrinolytic system 
     Impaired fibrinolysis can contribute to thrombosis (258). Fibrinolysis has not been 
specifically examined in dogs with IMHA. Reduced plasminogen, the precursor of 
plasmin, has been reported (33). When combined with evidence of activation of the 
enzymatic coagulation cascade, this is suggestive of accelerated fibrinolysis driven by 
increased fibrin generation.  
Other cells contributing to hypercoagulability 
     Contributions of other cell types to hypercoagulability in IMHA have also received 
limited attention, but there are hints that they may be important. Monocyte-
chemoattractant protein-1 (MCP-1) is increased in IMHA (40,102) and levels are higher 
in non-survivors (102). MCP-1 is secreted by multiple cell types including the 
endothelium, and promotes mobilization of monocytes from the bone marrow and 
recruitment to sites of production (40,102).  
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     The importance of monocytes in thrombosis is suggested by increased tissue factor 
mRNA expression in IMHA (43). This study was shown using RNA extracted from 
whole blood, so the cellular fraction responsible remains unknown but the authors 
speculate that monocytes or platelets are likely sources (43). Similarly, Kidd et al (2015) 
demonstrated increased pro-coagulant activity of both phosphatidylserine and tissue 
factor containing microparticles (103). Erythrocytes may be contributing to the 
phosphatidylserine rich microparticles, and monocytes and endothelial cells are the likely 
source of the tissue factor rich microparticles (103). Endothelial antibodies are not 
increased in IMHA (259), suggesting activation or damage is secondary to erythrocyte 
destruction rather than a primarily immune-mediated process.  
NETs: a novel potential contributor to hypercoagulability in IMHA 
     Neutrophil extracellular traps (NETs) are a relatively recently recognized component 
of the innate immune system. The term was first used by Brinkmann et al. (2004) (26) to 
describe strands of DNA released by human neutrophils stimulated with IL-8, the protein 
kinase C activator phorbol 12-myristate 13-acetate or lipopolysaccharide. This DNA is 
associated with proteins normally located in the nucleus (e.g. histones); primary, 
secondary and tertiary neutrophil granules (e.g. cathepsin G, myeloperoxidase, elastase) 
or the cytoplasm (e.g. calprotectin) (26,260,261).  
     Based on evidence of viability in NET-releasing cells (e.g. vital dye exclusion, 
motility) and lack of leakage of the cytoplasmic protein lactate dehydrogenase, NETs are 
not simply the result of DNA and protein leaking out of dying cells (26). Instead, NETs 
are formed through an active process which is morphologically distinct from apoptosis or 
necrosis (26,262,263). Several morphologic features distinguished PMA-induced 
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NETosis from anti-Fas ligand induced apoptosis or necrosis induced by a pore forming 
toxin from Staph. aureus (263). Unlike apoptotic cells, there is no phosphatidylserine 
exposure before membrane rupture, nor chromatin fragmentation (263). The nuclear 
envelope disintegrates early in NETosis compared with apoptosis, in which the nucleus 
fragments but the nuclear envelope remains intact, sequestering chromatin from 
cytoplasmic contents (263). During necrosis, there is a swelling of the nucleus but Fuchs 
et al (2007) found the nuclear envelope remains intact even after prolonged culture (263). 
Similarly, cytoplasmic organelles are lost during NETosis, but remain distinct over the 
same time period in apoptotic and necrotic cells (263).  
     The changes induced by PMA represent only one of several routes to release of NET-
like structures. Staphylococcus aureus induces substantial release of DNA by human 
neutrophils within 60 minutes, considerably faster than the three-hour delay seen with 
PMA (263,264). The sequence of events induced by S. aureus is markedly different from 
PMA-induced NETosis (264). The space between the inner and outer nuclear envelope 
dilates and histone-associated DNA accumulates within it (264). Ultimately the nuclear 
envelope breaks down, but it remains intact during much or all of the first 60 minutes of 
stimulation (264). During this time, DNA-filled vesicles bud off from the nuclear 
envelope and fuse with the plasma membrane, releasing DNA into the extracellular 
environment (264). Unlike PMA induced NETosis, it is only once DNA is outside the 
cell that it comes into contact with granular proteins, which were released by dense 
granule fusion with the plasma membrane (263,264). NETs can also be derived from 
mitochondrial rather than nuclear DNA, for example when cells primed with GM-CSF 
are stimulated with complement factor C5a (265).   
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     Although there are clearly multiple mechanisms for NET release, the extent to which 
these processes are exclusive is unclear. For example, Keshari et al (2012) found both 
mitochondrial and nuclear DNA in NETs released by PMA or a nitric oxide donor (266). 
The molecular pathways underlying the different forms of NETosis are also incompletely 
understood. Activation of both NADPH oxidase and myeloperoxidase have been 
suggested as essential steps in NETosis, but Parker et al (2012) showed that requirements 
vary with agonist (267). NADPH oxidase activation was not required for ionomycin 
induced NETosis and myeloperoxidase, while required for PMA, was not essential for 
bacterial-induction of NETosis (267). Similarly, elastase translocation to the nucleus has 
been suggested as an essential step in NETosis (268), but it has been recently reported 
that elastase knockout mice show similar levels of NET formation to wildtype (269).  
Citrullination of histones by peptidylarginine deiminase 4 (PAD4) opens up chromatin 
and the inability of PAD4 knockout mice to form NETs suggests this is an important step 
in NETosis (270). However, while PMA stimulation has been reported to induced histone 
citrullination (270,271) others found that PMA does not induce, or even inhibits 
citrullination (272,273). The physiologic relevance of the different pathways leading to 
NETosis, and the extent to which results of studies using a specific agonist and set of 
culture conditions can be generalized require further investigation. 
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What is the evidence NETs may be involved in thrombosis during IMHA? 
     The hypothesis that NETs contribute to thrombosis in IMHA is built on four lines of 
evidence: 
1. NETs have pro-thrombotic components 
     NETs are found within human thrombi (274,275,276,277) and those induced in 
experimental animals (278,279). Using a flow restriction model of venous thrombosis, 
intra-vital microscopy elegantly demonstrated that DNA is released by neutrophils at 
sites of thrombosis, rather than passive trapped within a developing thrombus (279). 
Digestion of NETs by supplementing DNase 1 reduces thrombus formation (278,279) 
and anti-histone antibodies also reduce the severity of thrombosis in animal models 
(280). Similarly, PAD4 (-/-) mice incapable of citrullinating histones and thus undergoing 
conventional NETosis were less likely to form thrombi in a model of venous thrombosis 
but thrombosis is restored by infusion of wild type neutrophils (281). NETs therefore 
appear to play a direct role in thrombosis. 
     In humans, elevated cell free DNA, histones or nucleosomes (i.e. DNA/histone 
complexes) have been reported in hypercoagulable disorders including deep vein 
thrombosis (282), cancer (283) and thrombotic microangiopathies (284). These markers 
could be consistent with circulating NETs or with release of chromatin during other 
forms of cell death, such as necrosis (285). Other groups have used ELISAs capable of 
concurrently detecting DNA and myeloperoxidase to provide evidence of NETs in pro-
thrombotic states such as neoplasia (286) or immune-mediated disease (287,288). Histone 
citrullination also provides evidence for NETosis in hypercoagulable human patients 
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(289). Citrullination is not specific for NETosis as PAD4 expression is upregulated in 
neoplastic cells (290), and citrullination may occur in the extracellular environment 
(291). Even bearing these limitations in mind, elevated markers of cell death and 
potentially NETosis in human patients at risk of thrombosis strengthens the hypothesis 
that NETs could be involved in canine thrombosis. 
     Multiple pro-coagulant effects of NETs have been demonstrated for human cells and 
in murine and primate models. The DNA backbone provides a negatively charged surface 
for activation of the contact pathway (292). Tissue factor is concentrated within NETs 
along with its potential activator, protein disulfide isomerase (279). DNA also impairs 
clot lysis, both by providing a scaffold which supports the clot (293) and by forming an 
inhibitory complex with fibrin and plasmin (294). Histones are highly cytotoxic, causing 
endothelial damage and thus promoting thrombus initiation (295). Platelet activation, 
partly mediated by toll-like receptor 4, is also induced by histones (27). In addition, 
histones bind and impair activation of the endogenous anticoagulant anti-protein C thus 
reducing its inhibition of Factor Va, VIIIa and plasminogen activator inhibitor-1 (PAI-1) 
(296). Although the evidence that histones directly impair fibrinolysis is less clear cut 
than for DNA, they may also participate in inhibition of clot lysis (297). 
     The role of neutrophil granular NET proteins in hypercoagulability is less well 
demonstrated than for DNA and histones. Massberg et al (2010) found that elastase (-/-) 
mice had marked reductions in thrombus weight after ferric chloride injury of the carotid 
artery, linked to degradation of tissue factor pathway inhibitor (TFPI) by elastase (298). 
However, a recent study by Martinoid et al (2016) found no difference in outcome 
between elastase (-/-) and wild type mice in a murine model of deep vein thrombosis 
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(269). Therefore, the influence of neutrophil serine proteases on thrombosis may vary 
with vessel type. 
     NETs have not been previously demonstrated in dogs, but given that chromatin and 
possibly non-nuclear components of NETs have pro-coagulant properties in other 
species, investigation of NETs as a mediator of thrombosis in IMHA is warranted. 
2. IMHA is a highly inflammatory disease 
     IMHA creates severe systemic inflammation, as demonstrated by elevations in acute 
phase proteins including c-reactive protein (37,38, 44, 299), fibrinogen (44), ferritin (88), 
ceruloplasmin (299), α1 acid glycoprotein (38) and von Willebrand’s factor (33). It is 
therefore unsurprising that the majority of dogs with IMHA have a leukocytosis 
(4,21,33,73). This is principally due to a neutrophilia (33,70) which can be very severe, 
sometimes to the point of a leukemoid response (>70 x 103/μl) (21). There is often 
evidence of left shifts to immaturity (4,33,36,43) consistent with markedly increased 
mobilization from the bone marrow.  
     There are therefore large numbers of cells available to generate NETs. Furthermore, 
the degree of leukocytosis has been linked to more severe post-mortem lesions, including 
thrombi (70). Although the available evidence does not support elevated IL-8, a cytokine 
involved in NET production, in IMHA there are higher levels of GM-CSF in non-
survivors (43,102). GM-CSF promotes neutrophil production and activation and prime 
cells for NET release by complement (which is also activated in IMHA (59)) so 
elevations provide additional evidence that NETs may be involved (254, 265). Dogs with 
IMHA also relatively frequently have positive titers for antinuclear antibodies, which can 
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be directed against histones (15,30,83,84,107). NETs may be a source of exposure to 
histone antigens in IMHA.  
3. Triggers of NET formation are present in IMHA 
     In a mouse model of sickle cell anemia, free heme induced NET formation (242). 
Circulating hemoglobin reaches high levels in IMHA (300), and can decay to free heme 
(239). The severity of anemia in IMHA also generates significant hypoxia, as 
demonstrated by elevations in lactate (89) and tissue necrosis (70,92,104). Higher lactate 
is associated with worse survival, suggesting hypoxia may contribute to mortality (89). 
Hypoxia-inducible factor 1α induces NET release so tissue hypoxia could promote NET 
release (301). Even if NETs are not involved in IMHA, DNA and histones are present in 
all nucleated cells and are released during hypoxic cell death (280). Therefore, evaluation 
of the ability of chromatin to activate the canine coagulation system will be of value even 
if studies do not support a role for NETs. 
4. Reduced ability to degrade NETs may be present in IMHA 
     As discussed, the DNA backbone of NETs can be broken down by the enzyme DNase 
1 (279). Reduced ability to degrade DNA has been detected in a subset of human patients 
with systemic lupus erythematosus (SLE) (302). Dogs with IMHA as a component of 
SLE have been reported (60, 83,226,303). There are though two complicating factors in 
interpreting these cases. Firstly, positive direct antiglobulin tests have been reported in 
non-anemic dogs with SLE (81,304). Therefore, concurrent positive DAT and anemia 
does not necessarily prove the anemia in SLE is autoimmune. Secondly, antinuclear 
antibody (ANA) titers are often used to support a diagnosis of SLE. ANA is not a very 
50 
 
 
specific test (83), and as mentioned above, elevated titers are frequently reported in dogs 
with IMHA and other inflammatory diseases. 
     While these limitations cannot be dismissed, there are numerous reports of dogs with 
IMHA being concurrently, or subsequently affected by other autoimmune disorders 
including immune-mediated thrombocytopenia/pancytopenia (31,41,36,84,305), 
lymphocytic thyroiditits (31), potentially autoimmune skin lesions (29, 59, 215,306,307), 
polyarthritis (59,215), distal renal tubular acidosis (308) and immune mediated pancreatic 
beta cell destruction (309). In fact, the high frequency of autoimmune disease, including 
IMHA, in Italian greyhounds has led to a suggestion they may have a multiple 
autoimmune diseases syndrome (310). 
     It is therefore reasonable to hypothesize that in a subset of dogs with IMHA, there 
may be compromised ability to degrade NETs or chromatin derived from cells dying by 
other mechanisms. This could enhance the pro-coagulant properties of cell death products 
including NETs in IMHA. 
Thesis Organization 
This is a thesis by manuscript, with published or prepared manuscripts addressing three 
major questions organized as follows.   
1. Do canine neutrophils form NETs? Results of these investigations are reported in 
Chapter 2. 
2. Do NETs activate components of the canine coagulation system? Chapter 3 
describes development of a method for measuring clot formation and lysis in 
canine citrated plasma. This was not suitable for use in IMHA patients due to 
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interference from hemoglobin and bilirubin but an adapted version of this method 
was used in Chapter 4 to investigate effects of NETs on the enzymatic coagulation 
cascade in vitro. Chapter 5 describes interactions between canine NETs and 
platelets. 
3. Are markers correlated with NET formation increased in dogs with IMHA, and if 
so, is this due to impaired DNA degradation? Results of this investigation are 
presented in Chapter 6. A review article critically evaluating the ability of NETs 
and other markers to predict thrombosis in dogs concludes this thesis as Chapter 
7. 
 
 
References 
1. Rodriguez-Piñeiro, B. L. Deputte and L. Chabanne. 2012. "Causes of anaemia other than 
acute blood loss and their clinical significance in dogs." J Small Anim Pract. 53: 223-7. 
2. Miller GFW, Firth SN, Swisher SN, Yound LE. 1957. "Studies on the destruction of red 
blood cells by canine autoantibodies in normal dogs and in a dog with naturally occurring 
autoimmune hemolytic disease." Am J Dis Child. 93: 35. 
3. Slappendel, RJ. 1979. "The diagnostic significance of the direct antiglobulin test (DAT) 
in anemic dogs." Vet Immunol Immunopathol. 1: 49-59. 
4. Mason N, Duval D, Shofer FS, Giger U. 2003. "Cyclophosphamide exerts no beneficial 
effect over prednisone alone in the initial treatment of acute immune-mediated hemolytic anemia 
in dogs: a randomized controlled clinical trial." J Vet Intern Med. 17: 206-12. 
5. Swann JW, Skelly BJ. 2011. "Evaluation of immunosuppressive regimens for immune-
mediated haemolytic anaemia: a retrospective study of 42 dogs." J Small Anim Pract. 52: 353-8.  
6. Kellerman DL, Bruyette DS. 1997. "Intravenous human immunoglobulin for the 
treatment of immune-mediated hemolytic anemia in 13 dogs." J Vet Intern Med. 11: 327-32. 
7. Whelan MF, O'Toole TE, Chan DL, Rozanski EA, DeLaforcade AM, Crawford SL, 
Cotter SM. 2009. "Use of human immunoglobulin in addition to glucocorticoids for the initial 
treatment of dogs with immune-mediated hemolytic anemia." J Vet Emerg Crit Care (San 
Antonio). 19: 158-64. 
52 
 
 
8. Goggs R, Dennis SG, Di Bella A, Humm KR, McLauchlan G, Mooney C, Ridyard A, 
Tappin S, Walker D, Warman S, Whitley NT, Brodbelt DC, Chan DL. 2015. "Predicting 
Outcome in dogs with Primary Immune-Mediated Hemolytic Anemia: Results of a Multicenter 
Case Registry." J Vet Intern Med. 29: 1603-10. 
9. Grundy SA, Barton C. 2001. "Influence of drug treatment on survival of dogs with 
immune-mediated hemolytic anemia: 88 cases (1989-1999)." J Am Vet Med Assoc. 218: 543-6. 
10. Matus RE, Schrader LA, Leifer CE, Gordon BR, Hurvitz AI. 1985. "Plasmapheresis as 
adjuvant therapy for autoimmune hemolytic anemia in two dogs." J Am Vet Med Assoc. 186: 
691-3. 
11. Crump KL, Seshadri R. 2009. "Use of therapeutic plasmapheresis in a case of canine 
immune-mediated hemolytic anemia." J Vet Emerg Crit Care (San Antonio). 19: 375-80. 
12. Feldman BF, Handagama P, Lubberink AA. 1985. "Splenectomy as adjunctive therapy 
for immune-mediated thrombocytopenia and hemolytic anemia in the dog." J Am Vet Med 
Assoc. 187: 617-9. 
13. Horgan JE, Roberts BK, Schermerhorn T. 2009. "Splenectomy as an adjunctive treatment 
for dogs with immune-mediated hemolytic anemia: ten cases (2003-6)." J Vet Emerg Crit Care 
(San Antonio). 19: 254-61. 
14. Jackson ML, Kruth SA. 1985. "Immune-mediated Hemolytic Anemia and 
Thrombocytopenia in the Dog: A retrospective study of 55 cases diagnosed from 1979 through 
1983 at the Western College of Veterinary Medicine." Can Vet J. 26: 245-50. 
15. Weinkle TK, Center SA, Randolph JF, Warner KL, Barr SC, Erb HN. 2005. "Evaluation 
of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic 
anemia in dogs: 151 cases (1993–2002)." J Am Vet Med Assoc. 226: 1870-9. 
16. Mellett AM, Nakamura RK, Bianco D. 2011. "A prospective study of Clopidogrel 
therapy in dogs with primary immune-mediated hemolytic anemia." J Vet Intern Med. 25: 71-5. 
17. Helmond SE, Polzin DJ, Armstrong PJ, Finke M, Smith SA. 2010. "Treatment of 
immune-mediated hemolytic anemia with individually adjusted heparin dosing in dogs." J Vet 
Intern Med. 24: 597-605.  
18. Panek CM, Nakamura RK, Bianco D. 2015. "Use of enoxaparin in dogs with primary 
immune-mediated hemolytic anemia: 21 cases." J Vet Emerg Crit Care (San Antonio). 25: 273-7. 
19. Morassi A, Bianco D, Park E, Nakamura RK, White GA. 2016 . "Evaluation of the safety 
and tolerability of rivaroxaban in dogs with presumed primary immune-mediated hemolytic 
anemia." J Vet Emerg Crit Care (San Antonio). EPub ahead of print.  
20. Piek CJ, Junius G, Dekker A, Schrauwen E, Slappendel RJ, Teske E. 2008. "Idiopathic 
immune-mediated hemolytic anemia: treatment outcome and prognostic factors in 149 dogs." J 
Vet Intern Med. 22: 366-73. 
21. Reimer ME, Troy GC, Warnick LD. 1999. "Immune-mediated hemolytic anemia: 70 
cases (1988-1996)." J Am Anim Hosp Assoc. 35: 384-91. 
53 
 
 
22. Wojcik BM, Wrobleski SK, Hawley AE, Wakefield TW, Myers DD Jr, Diaz JA. 2011. 
"Interleukin-6: a potential target for post-thrombotic syndrome." Ann Vasc Surg. 25: 229-39. 
23. Rubio-Jurado B, Iñiguez-Franco P, Reyes PA, Robles G, Salazar-Páramo M, Zavala-
Cerna G, Riebeling C, Nava A. 2012. "The clinical significance of coagulation and the 
inflammatory response in autoimmunity." Clin Rev Allergy Immunol. 42: 172-80. 
24. Tichelaar YI, Kluin-Nelemans HJ, Meijer K. 2012. "Infections and inflammatory 
diseases as risk factors for venous thrombosis. A systematic review." Thromb Haemost. 107: 827-
37. 
25. Martinod K, Wagner DD. 2014. "Thrombosis: tangled up in NETs." Blood. 123: 2768-
76. 
26. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch 
Y, Zychlinsky A. 2004. "Neutrophil extracellular traps kill bacteria." Science. 303: 1532-5. 
27. Gould TJ, Vu TT, Swystun LL, Dwivedi DJ, Mai SH, Weitz JI, Liaw PC. 2014. 
"Neutrophil extracellular traps promote thrombin generation through platelet-dependent and 
platelet-independent mechanisms." Arterioscler Thromb Vasc Biol. 34: 1977-84. 
28. Lewis RM, Henry Jr WB, Thornton GW, Gilmore CE. 1963. "A syndrome of 
autoimmune hemolytic anemia and thrombocytopenia in dogs." Sci. Proc. Am. J. Vet. Med. 
Assoc. 1: 140-63. 
29. Klein MK, Dow SW, Rosychuk RA. 1989. "Pulmonary thromboembolism associated 
with immune-mediated hemolytic anemia in dogs: ten cases (1982-1987)." J Am Vet Med Assoc. 
195: 246-50. 
30. Klag AR, Giger U, Shofer FS. 1993. "Idiopathic immune-mediated hemolytic anemia in 
dogs: 42 cases (1986-1990)." J Am Vet Med Assoc. 202: 783-8. 
31. Day, MJ. 1996. "Serial monitoring of clinical, haematological and immunological 
parameters in canine autoimmune haemolytic anaemia." J Small Anim Pract. 37: 523-34. 
32. Burgess K, Moore A, Rand W, Cotter SM. 2000. "Treatment of immune-mediated 
hemolytic anemia in dogs with cyclophosphamide." J Vet Intern Med. 14: 456-62.  
33. Scott-Moncrieff JC, Treadwell NG, McCullough SM, Brooks MB. 2001. "Hemostatic 
abnormalities in dogs with primary immune-mediated hemolytic anemia." J Am Anim Hosp 
Assoc. 37: 220-7. 
34. Carr AP, Panciera DL, Kidd L. 2002. "Prognostic factors for mortality and 
thromboembolism in canine immune-mediated hemolytic anemia: a retrospective study of 72 
dogs." J Vet Intern Med. 16: 504-9. 
35. Mathes M, Jordan M, Dow S. 2006. "Evaluation of liposomal clodronate in experimental 
spontaneous autoimmune hemolytic anemia in dogs." Exp Hematol. 34: 1393-402. 
36. Goggs R, Boag AK, Chan DL. 2008. "Concurrent immune-mediated haemolytic anaemia 
and severe thrombocytopenia in 21 dogs." Vet Rec. 163: 323-7. 
54 
 
 
37. Griebsch C, Arndt G, Raila J, Schweigert FJ, Kohn B. 2009. "C-reactive protein 
concentration in dogs with primary immune-mediated hemolytic anemia." Vet Clin Pathol. 38: 
421-5.  
38. Mitchell KD, Kruth SA, Wood RD, Jefferson B. 2009. "Serum acute phase protein 
concentrations in dogs with autoimmune hemolytic anemia." J Vet Intern Med. 23: 585-91. 
39. Sinnott VB, Otto CM. 2009. "Use of thromboelastography in dogs with immune-
mediated hemolytic anemia: 39 cases (2000-2008)." J Vet Emerg Crit Care (San Antonio). 19: 
484-8. 
40. Duffy AL, Olea-Popelka FJ, Eucher J, Rice DM, Dow SW. 2010. "Serum concentrations 
of monocyte chemoattractant protein-1 in healthy and critically ill dogs." Vet Clin Pathol. 39: 
302-5. 
41. Orcutt ES, Lee JA, Bianco D. 2010. "Immune-mediated hemolytic anemia and severe 
thrombocytopenia in dogs: 12 cases (2001-2008)." J Vet Emerg Crit Care (San Antonio). 20: 338-
45. 
42. Ridyard AE, Shaw DJ, Milne EM. 2010. "Evaluation of platelet activation in canine 
immune-mediated haemolytic anaemia." J Small Anim Pract. 81: 296-304. 
43. Piek CJ, Brinkhof B, Teske E, Rothuizen J, Dekker A, Penning LC. 2011. "High 
intravascular tissue factor expression in dogs with idiopathic immune-mediated haemolytic 
anaemia." Vet Immunol Immunopathol. 144: 346-54. 
44. Goggs R, Wiinberg B, Kjelgaard-Hansen M, Chan DL. 2012. "Serial assessment of the 
coagulation status of dogs with immune-mediated haemolytic anaemia using 
thromboelastography." Vet J. 191: 347-53. 
45. Wang A., Smith J.R., Creevy K.E. 2013. "Treatment of canine idiopathic immune-
mediated haemolytic anaemia with mycophenolate mofetil and glucocorticoids: 30 cases (2007 to 
2011)." J Small Anim Pract. 54: 399-404. 
46. West LD, Hart JR. 2014. "Treatment of idiopathic immune-mediated hemolytic anemia 
with mycophenolate mofetil in five dogs." J Vet Emerg Crit Care (San Antonio). 24: 226-31. 
47. The Orphannet Consortium, Autoimmune hemolytic anemia. Accessed 5.11.16. 
http://www.orpha.net/consor4.01/www/cgi-bin/OC_Exp.php?lng=EN&Expert=98375.  
48. Keller, ET. 1992. "Immune-mediated disease as a risk factor for canine lymphoma." 
Cancer. 70: 2334-7. 
49. Fagiolo E, Toriani-Terenzi C. 2003. "Mechanisms of Immunological Tolerance Loss 
Versus Erythrocyte Self-antigens and Autoimmune Hemolytic Anemia." Autoimmunity. 36: 199-
204. 
50. Garratty, G. 2010. "Immune hemolytic anemia associated with drug therapy." Blood 
Reviews. 24: 143-50. 
55 
 
 
51. Lanzavecchia A. 1995. "How can cryptic epitopes trigger autoimmunity?" J Exp Med. 
181: 1945-8. 
52. Barker RN, Hall AM, Standen GR, Jones J, Elson CJ. 1997. "Identification of T-cell 
epitopes on the Rhesus polypeptides in autoimmune hemolytic anemia." Blood 90: 2701-15. 
53. Felder KM, Hoelzle K, Heinritzi K, Ritzmann M, Hoelzle LE. 2010. "Antibodies to actin 
in autoimmune haemolytic anaemia." BMC Vet Res. 6: 18. 
54. Sanz J, Arriaga F, Montesinos P, Ortí G, Lorenzo I, Cantero S, Puig N, Moscardó F, de la 
Rubia J, Sanz G, Sanz MA. 2007. "Autoimmune hemolytic anemia following allogeneic 
hematopoietic stem cell transplantation in adult patients." Bone Marrow Transplant. 39: 555-61.  
55. Ahmad E, Elgohary T, Ibrahim H. 2011. "Naturally occurring regulatory T cells and 
interleukins 10 and 12 in the pathogenesis of idiopathic warm autoimmune hemolytic anemia." J 
Investig Allergol Clin Immunol. 21: 297-304.  
56. Xu L, Zhang T, Liu Z, Li Q, Xu Z, Ren T. 2012. "Critical role of Th17 cells in 
development of autoimmune hemolytic anemia." Exp Hematol. 40: 994-1004.  
57. Swann JW, Garden OA. 2016. "Novel immunotherapies for immune-mediated 
haemolytic anaemia in dogs and people." Vet J. 207: 13-9. 
58. Seif AE, Manno CS, Sheen C, Grupp SA, Teachey DT. 2010. "Identifying autoimmune 
lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study." 
Blood. 115: 2142-5. 
59. Warman SM, Murray JK, Ridyard A, Eastwood J, Silva S, Day MJ. 2008. "Pattern of 
Coombs' test reactivity has diagnostic significance in dogs with immune-mediated haemolytic 
anaemia." J Small Anim Pract. 49: 525–30. 
60. Piek CJ, van Spil WE, Junius G, Dekker A. 2011. "Lack of evidence of a beneficial effect 
of azathioprine in dogs treated with prednisolone for idiopathic immune-mediated hemolytic 
anemia: a retrospective cohort study." BMC Vet Res. 7: 15. 
61. Sokol RJ, Hewitt S, Stamps BK. 1981. "Autoimmune haemolysis: an 18-year study of 
865 cases referred to a regional transfusion centre." Br Med J (Clin Res Ed). 282: 2023-7. 
62. Vaglio S, Arista MC, Perrone MP, Tomei G, Testi AM, Coluzzi S, Girelli G. 2007. 
"Autoimmune hemolytic anemia in childhood: serologic features in 100 cases." Transfusion. 47: 
50-4. 
63. Alwar V, Shanthala DA, Sitalakshmi S, Karuna RK. 2010. "Clinical patterns and 
hematological spectrum in autoimmune hemolytic anemia." J Lab Physicians. 2: 17-20. 
64. Roumier M, Loustau V, Guillaud C, Languille L, Mahevas M, Khellaf M, Limal N, 
Noizat-Pirenne F, Godeau B, Michel M. 2014. "Characteristics and outcome of warm 
autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 
60 patients." Am J Hematol. 89: E150-5. 
56 
 
 
65. Mauro FR, Coluzzi S, Paoloni F, Trastulli F, Armiento D, Ferretti A, Giovannetti G, 
Colafigli G, Molica M, La Rocca U, De Propris MS, Caronna R, Morano G, Guarini A, Girelli G, 
Foà R. 2016. “Clinical characteristics and outcome of patients with autoimmune hemolytic 
anemia (AIHA) uniformly defined as primary by a diagnostic work-up". Am J Hematol. Epub 
ahead of print.  
66. Naithani R, Agrawal N, Mahapatra M, Pati H, Kumar R, Choudhary VP. 2006. 
"Autoimmune hemolytic anemia in India: clinico-hematological spectrum of 79 cases." 
Hematology. 11: 73-6. 
67. Rattarittamrong E, Eiamprapai P, Tantiworawit A, Rattanathammethee T, Hantrakool S, 
Chai-Adisaksopha C, Norasetthada L. 2016. "Clinical characteristics and long-term outcomes of 
warm-type autoimmune hemolytic anemia." Hematology. 21: 1-7. 
68. Aladjidi N, Leverger G, Leblanc T, Picat MQ, Michel G, Bertrand Y, Bader-Meunier B, 
Robert A, Nelken B, Gandemer V, Savel H, Stephan JL, Fouyssac F, Jeanpetit J, Thomas C, 
Rohrlich P, Baruchel A, Fischer A, Chêne G, Perel Y; Centre de Référence National des 
Cytopénies Auto-immunes de l'Enfant (CEREVANCE). 2011. "New insights into childhood 
autoimmune hemolytic anemia: a French national observational study of 265 children." 
Haematologica. 96: 655-63. 
69. Day, MJ. 1996. "Inheritance of serum autoantibody, reduced serum IgA and autoimmune 
disease in a canine breeding colony." Vet Immunol Immunopathol. 53: 207-19. 
70. McManus PM, Craig LE. 2001. "Correlation between leukocytosis and necropsy findings 
in dogs with immune-mediated hemolytic anemia: 34 cases (1994-1999)." J Am Vet Med Assoc. 
218: 1308-13. 
71. Ishihara M, Fujino Y, Setoguchi A, Takahashi M, Nakashima K, Ohno K, Tsujimoto H. 
2010. "Evaluation of Prognostic Factors and Establishment of a Prognostic Scoring System for 
Canine Primary Immune-Mediated Hemolytic Anemia." J. Vet. Med. Sci. 72: 465–70. 
72. Miller SA, Hohenhaus AE, Hale AS. 2004. "Case-control study of blood type, breed, sex, 
and bacteremia in dogs with immune-mediated hemolytic anemia." J Am Vet Med Assoc. 224: 
232-5. 
73. McAlees, TJ. 2010. "Immune-mediated haemolytic anaemia in 110 dogs in Victoria, 
Australia." Aust Vet J. 88: 25-8. 
74. Stokol T, Blue JT, French TW. 2000. "Idiopathic pure red cell aplasia and 
nonregenerative immune-mediated anemia in dogs: 43 cases (1988-1999)." J Am Vet Med Assoc. 
216: 1429-36. 
75. Ahmed FE, Albakrah MS. 2009. "Neonatal familial Evans syndrome associated with 
joint hypermobility and mitral valve regurgitation in three siblings in a Saudi Arab family." Ann 
Saudi Med. 29: 227-30. 
76. Kennedy LJ, Barnes A, Ollier WE, Day MJ. 2006. "Association of a common dog 
leucocyte antigen class II haplotype with canine primary immune-mediated haemolytic anaemia." 
Tissue Antigens. 68: 502-8. 
57 
 
 
77. Therlfall AJ, Boag AM, Soutter F, Glanemann B, Syme HM, Catchpole B. 2015. 
"Analysis of DLA-DQB1 and polymorphisms in CTLA4 in Cocker spaniels affected with 
immune-mediated hemolytic anemia." Canine Genet Epidemiol. 2: 8. 
78. Safra N, Pedersen NC, Wolf Z, Johnson EG, Liu HW, Hughes AM, Young A, Bannasch 
DL. 2011. "Expanded dog leukocyte antigen (DLA) single nucleotide polymorphism (SNP) 
genotyping reveals spurious class II associations." Vet J. 189: 220-6. 
79. Friedenberg SG, Buhrman G, Chdid L, Olby NJ, Olivry T, Guillaumin J, O'Toole T, 
Goggs R, Kennedy LJ, Rose RB, Meurs KM. 2015. "Evaluation of a DLA-79 allele associated 
with multiple immune-mediated diseases in dogs." Immunogenetics Epub ahead of print.  
80. Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, Lunghi M, 
Tassinari C, Alfinito F, Ferrari A, Leporace AP, Niscola P, Carpenedo M, Boschetti C, Revelli N, 
Villa MA, Consonni D, Scaramucci L, De Fabritiis P, Tagariello G, Gaidano G, Rodeghiero F, 
Cortelezzi A, Zanella A. 2014. "Clinical heterogeneity and predictors of outcome in primary 
autoimmune hemolytic anemia: a GIMEMA study of 308 patients." Blood. 124: 2930-6. 
81. Jacobs RM, Murtaugh RJ, Crocker DB. 1984. "Use of a microtiter Coombs' test for study 
of age, gender, and breed distributions in immunohemolytic anemia of the dog." J Am Vet Med 
Assoc. 185: 66-9.  
82. Kidd L, Rasmussen R, Chaplow E, Richter K, Hill S, Slusser PG. 2014. "Seasonality of 
immune-mediated hemolytic anemia in dogs from southern California." J Vet Emerg Crit Care 
(San Antonio). 24: 311-5. 
83. Quimby FW, Smith C, Brushwein M, Lewis RW. 1980. "Efficacy of 
immunoserodiagnostic procedures in the recognition of canine immunologic diseases." Am J Vet 
Res. 41: 1662-6. 
84. Mills JN, Day MJ, Shaw SE, Penhale WJ. 1985. "Autoimmune haemolytic anaemia in 
dogs." Aust Vet J. 62: 121-3. 
85. Day, MJ. 1996. "IgG subclasses of canine anti-erythrocyte, antinuclear and anti-
thyroglobulin autoantibodies." Res Vet Sci. 61: 129-35.  
86. Pesillo SA, Freeman LM, Rush JE. 2004. "Assessment of lipid peroxidation and serum 
vitamin E concentration in dogs with immune-mediated hemolytic anemia." Am J Vet Res. 65: 
1621-4. 
87. Weiss DJ, Brazzell JL. 2006. "Detection of activated platelets in dogs with primary 
immune-mediated hemolytic anemia." J Vet Inter Med 20: 682–6.  
88. Friedrichs KR, Thomas C, Plier M, Andrews GA, Chavey PS, Young KM. 2010. 
"Evaluation of Serum Ferritin as a Tumor Marker for Canine Histiocytic Sarcoma." J Vet Intern 
Med 24: 904–11. 
89. Holahan ML, Brown AJ, Drobatz KJ. 2010. "The association of blood lactate 
concentration with outcome in dogs with idiopathic immune-mediated hemolytic anemia: 173 
cases (2003-2006)." J Vet Emerg Crit Care (San Antonio). 20: 413-20. 
58 
 
 
90. Warman SM, Helps CR, Barker EN, Day S, Sturgess K, Day MJ, Tasker S. 2010. 
"Haemoplasma infection is not a common cause of canine immune-mediated haemolytic anaemia 
in the UK." J Small Anim Pract. 51: 534–9.  
91. Fenty RK, Delaforcade AM, Shaw SE, O'Toole TE. 2011. "Identification of 
hypercoagulability in dogs with primary immune-mediated hemolytic anemia by means of 
thromboelastography." J Am Vet Med Assoc. 238: 463-7. 
92. Gow DJ, Gow AG, Bell R, Spratt D, Cash R, Ricketts S, Archer J, Mellanby RJ. 2011. 
"Serum cardiac troponin I in dogs with primary immune mediated hemlytic anemia." J Small 
Anim Pract. 52: 259–64. 
93. Karagianni AE, Solano-Gallego L, Breitschwerdt EB, Gaschen FP, Day MJ, Trotta M, 
Wieland B, Allenspach K. 2009. "Perinuclear antineutrophil cytoplasmic autoantibodies in dogs 
infected with various vector-borne pathogens and in dogs with immune-mediated hemolytic 
anemia." Am J Vet Res. 73: 1403-9.  
94. Miller AG, Dow S, Long L, Olver CS. 2012. "Antiphospholipid antibodies in dogs with 
immune mediated hemolytic anemia, spontaneous thrombosis, and hyperadrenocorticism." J Vet 
Intern Med. 26: 614-23. 
95. Tan E, Bienzle D, Shewen P, Kruth S, Wood D. 2012. "Potentially antigenic RBC 
membrane proteins in dogs with primary immune-mediated hemolytic anemia." Vet Clin Pathol. 
41: 45-55. 
96. Paes G, Paepe D, Meyer E, Kristensen AT, Duchateau L, Campos M, Daminet S. 2013. 
"The use of the rapid osmotic fragility test as an additional test to diagnose canine immune 
mediated haemolytic anaemia." Acta Vet Scand. 55: 74. 
97. Caviezel LL, Raj K, Giger U. 2014. "Comparison of 4 direct Coombs' test methods with 
Polyclonal Antiglobulins in Anemic and Nonanemic Dogs for In-Clinic or Laboratory Use." J Vet 
Intern Med. 28: 583–91. 
98. Ke SS, Anderson GA, Connolly SL. 2015. "Evaluation of prognostic indicators for 
canine primary immune-mediated haemolytic anaemia and application of a scoring system for the 
determination of prognosis." Aust Vet J. 93: 93-8. 
99. Hamzianpour N, Chan DL. 2016. "Thromboelastographic assessment of the contribution 
of platelets and clotting proteases to the hypercoagulable state of dogs with immune-mediated 
hemolytic anemia." J Vet Emerg Crit Care (San Antonio). 26: 295-9. 
100. Schaefer DM, Stokol T. 2016. "Retrospective study of reticulocyte indices as indicators 
of iron-restricted erythropoiesis in dogs with immune-mediated hemolytic anemia." J Vet Diagn 
Invest. 28: 304-8. 
101. Chiaroni-Clarke RC, Munro JE, Ellis JA. 2016. "Sex bias in paediatric autoimmune 
disease - Not just about sex hormones?" J Autoimmun. 69: 12-23. 
102. Kjelgaard-Hansen M, Goggs R, Wiinberg B, Chan DL. 2011. "Use of serum 
concentrations of interleukin-18 and monocyte chemoattractant protein-1 as prognostic indicators 
in primary immune-mediated hemolytic anemia in dogs." J Vet Intern Med. 25: 76-82. 
59 
 
 
103. Kidd L, Geddings J, Hisada Y, Sueda M, Concannon T, Nichols T, Merricks E, 
Mackman N. 2015. “Procoagulant microparticles in dogs with immune-mediated hemolytic 
anemia.” J Vet Intern Med. 29: 908-16.  
104. Cartwright JA, Gow DJ, Gow AG, Handel I, Reed N, Brown AJ, Cash R, Foote A, 
Mackenzie D, Bell R, Mellanby RJ. 2015. "Serum cardiac troponin I concentrations decrease 
following treatment of primary immune-mediated haemolytic anaemia." J Small Anim Pract. 56: 
516-20. 
105. Chiou SH, Lan JL, Lin SL, Chen DY, Tsai NY, Kuan CY, Lin TY, Lin FJ, Lee WM, 
Chang TJ. 2004. "Pet dogs owned by lupus patients are at a higher risk of developing lupus." 
Lupus. 13: 442-49. 
106. Scott-Moncrieff JC, Reagan WJ, Glickman LT, DeNicola DB, Harrington D. 1995. 
"Treatment of nonregenerative anemia with human gamma-globulin in dogs." J Am Vet Med 
Assoc. 206: 1895-900. 
107. Duval D, Giger U. 1996. "Vaccine-associated immune-mediated hemolytic anemia in the 
dog." J Vet Intern Med. 10: 290-5. 
108. Bexfield NH, Villiers EJ, Herrtage ME. 2005. "Immune-mediated haemolytic anaemia 
and thrombocytopenia associated with Anaplasma phagocytophilum." J Small Anim Pract. 48: 
543-8. 
109. Mazepa AW, Kidd LB, Young KM, Trepanier LA. 2010. "Clinical Presentation of 26 
Anaplasma phagocytophilum-Seropositive Dogs residing in an Endemic Area." J Am Anim Hosp 
Assoc. 46: 405-12. 
110. Antognoni MT, Veronesi F, Morganti G, Mangili V, Fruganti G, Miglio A. 2014. 
"Natural infection of Anaplasma platys in dogs from Umbria region (Central Italy)." Vet Ital. 50: 
49-56. 
111. Reyers F, Leisewitz AL, Lobetti RG, Milner RJ, Jacobson LS, van Zyl M. 1998. "Canine 
babesiosis in South Africa: more than one disease. Does this serve as a model for falciparum 
malaria?" Ann Trop Med Parasitol. 92: 503-11. 
112. Lobetti R, Dvir E, Pearson J. 2002. "Cardiac troponins in canine babesiosis." J Vet Intern 
Med. 16: 63-8.  
113. Möhr AJ, Lobetti RG, van der Lugt JJ. 2000. "Acute pancreatitis: a newly recognised 
potential complication of canine babesiosis." J S Afr Vet Assoc. 71: 232-9.  
114. Goddard A, Leisewitz AL, Kristensen AT, Schoeman JP. 2015. "Platelet activation and 
platelet-leukocyte interaction in dogs naturally infected with Babesia rossi." Vet J. 205: 387-92. 
115. Birkenheuer AJ, Correa MT, Levy MG, Breitschwerdt EB. 2005. "Geographic 
distribution of babesiosis among dogs in the United States and association with dog bites: 150 
cases (2000–2003)." J Am Vet Med Assoc. 227: 942-7. 
60 
 
 
116. Whitney MS, Schwan TG, Sultemeier KB, McDonald PS, Brillhart MN. 2007. 
"Spirochetemia caused by Borrelia turicatae infection in 3 dogs in Texas." Vet Clin Pathol. 36: 
212-6. 
117. Lobetti RG, Schoeman T. 2001. "Immune-mediated haemolytic anaemia: possible 
association with Ancylostoma caninum infection in three dogs." J S Afr Vet Assoc. 72: 52-4.  
118. Bass MC, Schultze AE. 1998. "Essential thrombocythemia in a dog: case report and 
literature review." J Am Anim Hosp Assoc. 34: 197-203. 
119. Jain NC, Switzer JW. 1981. "Autoimmune thrombocytopenia in dogs and cats." Vet Clin 
North Am Small Anim Pract. 11: 421-34. 
120. Mellanby RJ, Holloway A, Chantrey J, Herrtage ME, Dobson JM. 2004. "Immune-
mediated haemolytic anaemia associated with a sarcoma in a flat-coated retriever." J Small Anim 
Pract. 45: 21-4. 
121. Noble SJ, Armstrong PJ. 1999. "Bee sting envenomation resulting in secondary immune-
mediated hemolytic anemia in two dogs." J Am Vet Med Assoc. 214: 1026-7. 
122. Ong HM, Witham A, Kelers K, Boller M. 2015. "Presumed secondary immune-mediated 
haemolytic anaemia following elapid snake envenomation and its treatment in four dogs." Aust 
Vet J. 93: 319-26. 
123. Calvert CA, Sammarco C, Pickus C. 2000. "Positive Coombs' test results in two dogs 
treated with amiodarone." J Am Vet Med Assoc. 216: 1933-6. 
124. Mellor PJ, Roulois AJ, Day MJ, Blacklaws BA, Knivett SJ, Herrtage ME. 2005. 
"Neutrophilic dermatitis and immune-mediated haematological disorders in a dog: suspected 
adverse reaction to carprofen." Journal of Small Animal Practice 46: 237–42. 
125. Deldar A, Lewis H, Bloom J, Weiss L. 1988. "Cephalosporin-induced alterations in 
erythroid (CFU-E) and granulocyte-macrophage (CFU-GM) colony-forming capacity in canine 
bone marrow." Fundam Appl Toxicol. 11: 450-63.  
126. Bloom JC, Thiem PA, Sellers TS, Deldar A, Lewis HB. 1988. "Cephalosporin-induced 
immune cytopenia in the dog: demonstration of erythrocyte-, neutrophil-, and platelet-associated 
IgG following treatment with cefazedone." Am J Hematol. 28: 71-8. 
127. Jackson JA, Chart IS, Sanderson JH, Garner R. 1977. "Pirimicarb induced immune 
haemolytic anaemia in dogs." Scand J Haematol. 19: 360-6.  
128. Werner LL, Halliwell RE, Jackson RF, Needham TC, Limpach M. 1984. "An 
investigation of the role of immunologic factors in anemia associated with canine heartworm 
disease." Vet Immunol Immunopathol. 7: 285-92. 
129. Bass GF, Tuscano ET, Tuscano JM. 2014. "Diagnosis and classification of autoimmune 
hemolytic anemia." Autoimmun Rev. 13: 560-4. 
61 
 
 
130. Bromberek JL, Rout ED, Agnew MR, Yoshimoto J, Morley PS, Avery AC. 2016. "Breed 
Distribution and Clinical Characteristics of B Cell Chronic Lymphocytic Leukemia in Dogs." J 
Vet Intern Med. 30: 215-22. 
131. Gilson SD, Withrow SJ, Wheeler SL, Twedt DC. 1994. "Pheochromocytoma in 50 dogs." 
J Vet Intern Med. 8: 228-32. 
132. Jandl JH, Jones AR, Castle WB. 1957. "The destruction of red cells by antibodies in man. 
I. Observations of the sequestration and lysis of red cells altered by immune mechanisms." J Clin 
Invest. 36: 1428-59. 
133. Berentsen, S. 2015. "Role of Complement in Autoimmunity." Transfus Med and 
Hemother. 42: 303-10.  
134. Kojouharova M, Reid K, Gadjeva M. 2010. "New insights into the molecular 
mechanisms of classical complement activation." Mol Immunol. 47: 2154-60.  
135. Bally I, Ancelet S, Moriscot C, Gonnet F, Mantovani A, Daniel R, Schoehn G, Arlaud 
GJ, Thielens NM. 2013. "Expression of recombinant human complement C1q allows 
identification of the C1r/C1s-binding sites." Proc Natl Acad Sci U S A. 110: 8650-5. 
136. Smith RI, Coloma MJ, Morrison SL. 1995. "Addition of a mu-tailpiece to IgG results in 
polymeric antibodies with enhanced effector functions including complement-mediated cytolysis 
by IgG4." J Immunol. 154: 2226-36.  
137. Czajkowsky DM, Shao Z. 2009. "The human IgM pentamer is a mushroom-shaped 
molecule with a flexural bias." Proc Natl Acad Sci U S A. 106: 14960-5. 
138. Beurskens FJ, van Schaarenburg RA, Trouw LA. 2015. "C1q, antibodies and anti-C1q 
autoantibodies." Mol Immunol. 68: 6-13. 
139. Tao MH, Smith RI, Morrison SL. 1993. "Structural features of human immunoglobulin G 
that determine isotype-specific differences in complement activation." J Exp Med. 178: 661-7. 
140. Schreiber AD, Frank MM. 1972. "Role of antibody and complement in the immune 
clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing 
sites." J Clin Invest. 51: 575-82. 
141. Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, 
Voorhorst M, Ugurlar D, Rosati S, Heck AJ, van de Winkel JG, Wilson IA, Koster AJ, Taylor 
RP, Saphire EO, Burton DR, Schuurman J, Gros P, Parren PW. 2014. "Complement is activated 
by Ig activated by IgG hexamers assembled at the cell surface." Science. 343: 1260-3. 
142. Ma K, Caplan S. 2016. "Refractory IgG Warm Autoimmune Hemolytic Anemia Treated 
with Eculizumab: A Novel Application of Anticomplement Therapy." Case Rep Hematol. 2016: 
9181698. 
143. Beckers EA, van Guldener C, Overbeeke MA, van Rhenen DJ. 2001. "Intravascular 
hemolysis by IgA red cell autoantibodies." Neth J Med. 58: 204-7. 
62 
 
 
144. Fischer JT, Petz LD, Garratty G, Cooper NR. 1974. "Correlations between quantitative 
assay of red cell-bound C3, serologic reactions, and hemolytic anemia." Blood. 44: 359-73. 
145. Lin Z, Schmidt CQ, Koutsogiannaki S, Ricci P, Risitano AM, Lambris JD, Ricklin D. 
2015. "Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal 
hemoglobinuria." Blood. 126: 891-4. 
146. Yan J, Vetvicka V, Xia Y, Hanikýrová M, Mayadas TN, Ross GD. 2000. "Critical role of 
Kupffer cell CR3 (CD11bf/CD18) in the clearance of IgM-opsonized erythrocytes or soluble 
beta-glucan." Immunopharmacol. 46: 39-54. 
147. Kubagawa H, Oka S, Kubagawa Y, Torii I, Takayama E, Kang DW, Gartland GL, 
Bertoli LF, Mori H, Takatsu H, Kitamura T, Ohno H, Wang JY. 2779-93. "Identity of the elusive 
IgM Fc receptor (FcmuR) in humans." J Exp Med. 206: 2009. 
148. Tuijnman WB, Van Wichen DF, Schuurman HJ. 1993. "Tissue distribution of human IgG 
Fc receptors CD16, CD32 and CD64: an immunohistochemical study." APMIS. 101: 319-29. 
149. Nusrat AR, Wright SD, Aderem AA, Steinman RM, Cohn ZA. 1988. "Properties of 
isolated red pulp macrophages from mouse spleen." J Exp Med. 168: 1505-10. 
150. Lobuglio AF, Cotran RS, Jandl JH. 1967. "Red cells coated with immunoglobulin G: 
binding and sphering by mononuclear cells in man." Science 158: 1582-4.  
151. Ferrant A, Leners N, Michaux JL, Verwilghen RL, Sokal G. 1987. "The spleen and 
haemolysis: evaluation of the intrasplenic transit time." Br J Haematol. 65: 31-4. 
152. Chien S, Jan KM. 1973. "Ultrastructural basis of the mechanism of rouleaux formation." 
Microvasc Res. 5: 155-66. 
153. Stockham SL, Scott MA. 2008. "Erythrocytes." Chap. 3 in Fundamentals of Veterinary 
Clinical Pathology, p. 136. Blackwell publishing, Ames, IA. 
154. Blois SL, Richardson DM, Abrams-Ogg AC. 2013. "Comparison of a gel column blood 
typing method and a point-of-care cartridge for Dog Erythrocyte antigen DEA 1.1." J Vet Emerg 
Crit Care (San Antonio). 23: 340–3.  
155. Weiss, DJ. 2008. "Bone marrow pathology in dogs and cats with non-regenerative 
immune-mediated haemolytic anaemia and pure red cell aplasia." J Comp Pathol. 138: 46-53.  
156. Kohn B, Galke D, Beelitz P, Pfister K. 2008. "Clinical Features of Canine Granulocytic 
Anaplasmosis in 18 Naturally Infected Dogs." J Vet Int Med. 22: 1289-95. 
157. Harkin KR, Hicks JA, Wilkerson MJ. 2012. "Erythrocyte-bound immunoglobulin 
isotypes in dogs with immune-mediated hemolytic anemia: 54 cases (2001-2010)." J Am Vet 
Med Assoc. 241: 227-32. 
158. Tsuchida S, Usui R, Usui R, Muramatsu U, Ejima H, Ikemoto S. 1991. "Autoantibodies 
and red blood cell membrane proteins in a case of canine autoimmune hemolytic anemia." J Vet 
Med Sci. 53: 19-21. 
63 
 
 
159. Baudino L, Fossati-Jimack L, Chevalley C, Martinez-Soria E, Shulman MJ, Izui S. 2007. 
"IgM and IgA anti-erythrocyte autoantibodies induce anemia in a mouse model through 
multivalency-dependent hemagglutination but not through complement activation." Blood. 109: 
5355-62. 
160. Chadebech P, Michel M, Janvier D, Yamada K, Copie-Bergman C, Bodivit G, Bensussan 
A, Fournie JJ, Godeau B, Bierling P, Izui S, Noizat-Pirenne F. 2010. "IgA-mediated human 
autoimmune hemolytic anemia as a result of hemagglutination in the spleen, but independent of 
complement activation and FcαRI." Blood. 116: 4141-7. 
161. Young, K. M. 2005. "Laboratory Medicine." Vet Clin Pathol, 34: 324.  
162. Wardrop, K J. 2012. "Coombs' Testing and Its Diagnostic Significance in Dogs and 
Cats." Vet Clin North Am: Small Anim Pract. 42: 43-51. 
163. Miano, M. 2016. "How I manage Evans syndrome and AIHA in children." B J Haematol. 
172: 524–34. 
164. Sriwichai C, Jiraudommongkol M, Wutti-In Y, Vongchan P. 2011. "Production of an 
anticanine globulin (polyspecific) reagent for laboratory investigation." J Small Anim Pract. 52: 
476-83. 
165. Lutz HU, Bogdanova A. 2013. "Mechanisms tagging senescent red blood cells for 
clearance in healthy humans." Front Physiol. 4: 387. 
166. Dalal BI, Collins SY, Burnie K, Barr RM. 1991. "Positive direct antiglobulin tests in 
myeloma patients. Occurrence, characterization, and significance." Am J Clin Pathol. 96: 496-9. 
167. Weiss, DJ. 2006. "A retrospective study of the incidence and the classification of Bone 
Marrow Disorders in the Dog at a Veterinary Teaching Hospital (1996–2004)." J Vet Intern Med 
20: 955-61. 
168. Huh YO, Liu FJ, Rogge K, Chakrabarty L, Lichtiger B. 1988. "Positive direct 
antiglobulin test and high serum immunoglobulin G values." Am J Clin Pathol. 90: 197-200. 
169. Wardrop, KJ. 2005. "The Coombs' test in veterinary medicine: past, present, future." Vet 
Clin Pathol. 34: 325-34. 
170. Rolih S, Thomas R, Fisher F, Talbot J. 1993. "Antibody detection errors due to acidic or 
unbuffered saline." Immunohematology. 9: 15-8. 
171. Overmann JA, Sharkey LC, Weiss DJ, Borjesson DL. 2007. "Performance of 2 microtiter 
canine Coombs' tests." Vet Clin Pathol 36: 179-83. 
172. Wilkerson, M. J., Davis, E., Shuman, W., Harkin, K., Cox, J. and Rush, B. 2000. 
"Isotype-Specific Antibodies in Horses and Dogs with Immune-Mediated Hemolytic Anemia." J 
Vet Intern Med. 14: 190-6. 
173. Quigley KA, Chelack BJ, Haines DM, Jackson ML. 2001. "Application of a direct flow 
cytometric erythrocyte immunofluorescence assay in dogs with immune-mediated hemolytic 
anemia and comparison to the direct antiglobulin test." J Vet Diagn Invest. 13: 297-300. 
64 
 
 
174. Morley P, Mathes M, Guth A, Dow S. 2008. "Anti-erythrocyte antibodies and disease 
associations in anemic and nonanemic dogs." Journal of Veterinary Internal Medicine 22: 886-92. 
175. Kucinskiene G, Schuberth HJ, Leibold W, Pieskus J. 2005. "Flow cytometric evaluation 
of bound IgG on erythrocytes of anaemic dogs." Vet J. 169: 303-7. 
176. Thedsawad A, Taka O, Wanachiwanawin W. 2016. "Significances of red cell bound 
immunoglobulin G as detected by flow cytometry in patients with Coombs-negative immune 
hemolysis." Transfus Med. 26: 130-7. 
177. Da Costa L, Mohandas N, Sorette M, Grange MJ, Tchernia G, Cynober T. 2001. 
"Temporal differences in membrane loss lead to distinct reticulocyte features in hereditary 
spherocytosis and in immune hemolytic anemia." Blood. 98: 2894-9. 
178. Zini G, d'Onofrio G, Briggs C, Erber W, Jou JM, Lee SH, McFadden S, Vives-Corrons 
JL, Yutaka N, Lesesve JF, and International Council for Standardization in Haematology (ICSH). 
2012. "CSH recommendations for identification, diagnostic value, and quantitation of 
schistocytes." Int J Lab Hematol. 34: 107-16. 
179. Gurnee CM, Drobatz KJ. 2007. "Zinc intoxication in dogs: 19 cases (1991-2003)." J Am 
Vet Med Assoc. 230: 1174-9. 
180. Safeukui I, Buffet PA, Deplaine G, Perrot S, Brousse V, Ndour A, Nguyen M, 
Mercereau-Puijalon O, David PH, Milon G, Mohandas N. 2012. "Quantitative assessment of 
sensing and sequestration of spherocytic erythrocytes by the human spleen." Blood. 120: 424-30. 
181. Piek CJ, Teske E, van Leeuwen MW, Day MJ. 2012. "Good agreement of conventional 
and gel-based direct agglutination test in immune-mediated haemolytic anaemia." Acta Vet 
Scand. 54: 10. 
182. Iwamoto, S., Kamesaki, T., Oyamada, T., Okuda, H., Kumada, M., Omi, T., Takahashi, 
J., Tani, Y., Omine, M. and Kajii, E. 2001. "Reactivity of autoantibodies of autoimmune 
hemolytic anemia with recombinant rhesus blood group antigens or anion transporter band 3." 
Am. J. Hematol. 68: 106–14. 
183. Garratty G, Arndt P, Domen R, Clarke A, Sutphen-Shaw D, Clear J, Groncy P. 1997. 
"Severe autoimmune hemolytic anemia associated with IgM warm autoantibodies directed 
against determinants on or associated with glycophorin A." Vox Sang. 72: 124-30. 
184. Roelcke D, Hack H, Kreft H, MacDonald B, Pereira A, Habibi B. 1993. "IgA cold 
agglutinins recognize Pr and Sa antigens expressed on glycophorins." Transfusion. 33: 472-5. 
185. Janvier D, Lam Y, Galicier L, Bierling P. 2010. "A new cold autoagglutinin specificity: 
the third external loop of band 3." Transfusion. 50: 47-52. 
186. Rettig MP, Low PS, Gimm JA, Mohandas N, Wang J, Christian JA. 1999. "Evaluation of 
biochemical changes during in vivo erythrocyte senescence in the dog." Blood. 93: 376-84. 
187. Barker R.N., Gruffydd-Jones T.J., Stokes, C.R., Elson C.J. 1991. "Identification of 
autoantigens in canine autoimmune haemolytic anaemia." Clin Exp Immunol 85: 33-40. 
65 
 
 
188. Barker R.N., Elson C.J. 1995. "Red blood cell glycophorins as B and T-cell antigens in 
canine autoimmune haemolytic anaemia." Vet Immunol Immunopathol. 47: 225-38.  
189. Low PS, Waugh SM, Zinke K, Drenckhahn D. 1985. "The role of hemoglobin 
denaturation and band 3 clustering in red blood cell aging." Science. 227: 531-3. 
190. Rocha S, Costa E, Coimbra S, Nascimento H, Catarino C, Rocha-Pereira P, Quintanilha 
A, Belo L, Santos-Silva A. 2009. "Linkage of cytosolic peroxiredoxin 2 to erythrocyte membrane 
imposed by hydrogen peroxide-induced oxidative stress. Blood Cells Molec Dis. 43: 68–73. 
191. Chaudhuri S, Varshney JP, Patra RC. 2008. "Erythrocytic antioxidant defense, lipid 
peroxides level and blood iron, zinc and copper concentrations in dogs naturally infected with 
Babesia gibsoni." Res Vet Sci. 85: 120-4.  
192. Bottari NB, Munhoz TD, Torbitz VD, Tonin AA, Anai LA, Semolin LM, Jark PC, 
Bollick YS, Moresco RN, França RT, Lopes ST, Stefani LM, Tinucci-Costa M, Da Silva AS. 
2015. "Oxidative stress in dogs with multicentric lymphoma: Effect of chemotherapy on 
oxidative and antioxidant biomarkers." Redox Rep. 20: 267-74. 
193. Maćczak A, Cyrkler M, Bukowska B, Michałowicz J. 2016. "Eryptosis-inducing activity 
of bisphenol A and its analogs in human red blood cells (in vitro study)." J Hazard Mater. 307: 
328-35. 
194. Calderón-Salinas JV, Muñoz-Reyes EG, Guerrero-Romero JF, Rodríguez-Morán M, 
Bracho-Riquelme RL, Carrera-Gracia MA, Quintanar-Escorza MA. 2011. "Eryptosis and 
oxidative damage in type 2 diabetic mellitus patients with chronic kidney disease." Mol Cell 
Biochem. 357: 171-9. 
195. Slappendel RJ, van Erp CL, Goudswaard J, Bethlehem M. 1975. "Cold hemagglutinin 
disease in a toy Pinscher dog." Tijdschr Diergeneeskd. 100: 445-60. 
196. Greene CE, Kristensen F, Hoff EJ, Wiggins MD. 1977. "Cold hemagglutinin disease in a 
dog." J Am Vet Med Assoc. 170: 505-10. 
197. Rojas-Temahuay G, Crain S, Benson C, Sharkey L, Nothnagel G. 2014. "Cold agglutinin 
activity in 2 dogs." Vet Clin Pathol. 43: 330-36. 
198. Lambert, JF, Nydegger, UE. 2010. "Geoepidemiology of autoimmune hemolytic 
anemia." Autoimmun Rev. 9: A350-4. 
199. Ungprasert P, Tanratana P, Srivali N. 2015. "Autoimmune hemolytic anemia and venous 
thromboembolism: A systematic review and meta-analysis." Thromb Res. 136: 1013-7. 
200. Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. 2011. "Risk of 
venous thromboembolism in people admitted to hospital with selected immune-mediated 
diseases: record-linkage study." BMC Med. 9: 1. 
201. Zöller B, Li X, Sundquist J, Sundquist K. 2012. "Risk of pulmonary embolism in patients 
with autoimmune disorders: a nationwide follow-up study from Sweden." Lancet. 379: 244-9. 
66 
 
 
202. Yusuf HR, Hooper WC, Backman MG, Zhang QC, Tsai J, Ortel TL. 2014. "Risk of 
venous thromboembolism among hospitalizations of adults with selected autoimmune diseases." 
J. Thromb. Thrombolysis 38: 306–13. 
203. Yusuf HR, Hooper WC, Grosse SD, Parker CS, Boulet SL, Ortel TL. 2015. "Risk of 
venous thromboembolism occurrence among adults with selected autoimmune diseases: a study 
among a U.S. cohort of commercial insurance enrollees." Thromb Res. 135: 50-7. 
204. Rottem M, Krause I, Fraser A, Stojanovich L, Rovensky J, Shoenfeld Y. 2006. 
"Autoimmune hemolytic anaemia in the antiphospholipid syndrome." Lupus. 15: 473-7. 
205. Louzada ML, Majeed H, Dao V, Wells PS. 2011. "Risk of recurrent venous 
thromboembolism according to malignancy characteristics in patients with cancer-associated 
thrombosis: a systematic review of observational and intervention studies." Blood Coagul 
Fibrinolysis. 22: 86-91. 
206. Mustonen P, Lehtonen KV, Javela K, Puurunen M. 2014. "Persistent antiphospholipid 
antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a 
nationwide prospective study." Lupus. 23: 1468-76. 
207. Landgren O, Gridley G, Check D, Caporaso NE, Morris Brown L. 2007. "Acquired 
immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia." 
Br J Haematol. 139: 791-8. 
208. Lang IM, Marsh JJ, Konopka RG, Olman MA, Binder BR, Moser KM, Schleef RR. 
1993. "Factors contributing to increased vascular fibrinolytic activity in mongrel dogs." 
Circulation. 87: 1990-2000. 
209. Johnson LR, Lappin MR, Baker DC. 1999. "Pulmonary thromboembolism in 29 dogs: 
1985-1995." J Vet Intern Med. 13: 338-45. 
210. Goggs R, Chan DL, Benigni L, Hirst C, Kellett-Gregory L, Fuentes VL. 2014. 
"Comparison of computed tomography pulmonary angiography and point-of-care tests for 
pulmonary thromboembolism diagnosis in dogs." J Small Anim Pract. 55: 190-7. 
211. Belz KM, Specht AJ, Johnson VS, Conway JA. 2013. "MRI findings in a dog with 
kernicterus." J Am Anim Hosp Assoc. 49: 286-92. 
212. Brenner K, Pohlman L, Muldowney I, Petersen D, Schermerhorn T. 2013. "Peritoneal 
EMH in a Dog with Immune-Mediated Hemolytic Anemia." J Am Anim Hosp Assoc. 49: 319-22. 
213. Laurenson MP, Hopper K, Herrera MA, Johnson EG. 2010. "Concurrent diseases and 
conditions in dogs with splenic vein thrombosis." J Vet Intern Med. 24: 1298-1304. 
214. Hess RS, Kass PH, Van Winkle TJ. 2003. "Association between diabetes mellitus, 
hypothyroidism or hyperadrenocorticism, and atherosclerosis in dogs." J Vet Intern Med. 17: 489-
94. 
215. Stone MS, Johnstone IB, Brooks M, Bollinger TK, Cotter SM. 1994. "Lupus-type 
"anticoagulant" in a dog with hemolysis and thrombosis." J Vet Intern Med. 8: 57-61. 
67 
 
 
216. Benadiba J, Robitaille N, Lambert G, Itaj NK, Pastore Y. 2015. "Intravenous 
immunoglobulin-associated thrombosis: is it such a rare event? Report of a pediatric case and of 
the Quebec Hemovigilance System." Transfusion. 55: 571-5. 
217. Marie I, Maurey G, Hervé F, Hellot MF, Levesque H. 2006. "Intravenous 
immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the 
literature." Br J Dermatol. 155: 714-21. 
218. García-Fuster MJ, Fabia MJ, Furió E, Pichler G, Redon J, Forner MJ, Martínez F. 2014. 
"Should we look for silent pulmonary embolism in patients with deep venous thrombosis?" BMC 
Cardiovasc Disord. 14: 178. 
219. Schramm D, Bach AG, Meyer HJ, Surov A. 2016. "Thrombotic events as incidental 
finding on computed tomography in intensive care unit patients." Thromb Res. 141: 171-4. 
220. Kano R, Maruyama H, Kubota M, Hasegawa A, Kamata H. 2011. "Chronic ulcerative 
dermatitis caused by Fusarium sporotrichioides." Med Mycol. 49: 303–5. 
221. Magaña A, Sánchez F, Villa K, Rivera L, Morales E. 2015. "Systemic neosporosis in a 
dog treated for immune-mediated thrombocytopenia and hemolytic anemia." Vet Clin Pathol. 44: 
592-6. 
222. Armstrong PF, Sigler L, Sutton DA, Grooters AM, Hitt M. 2012. "Fungal myelitis caused 
by Phialosimplex caninus in an immunosuppressed dog." Med Mycol. 50: 509–12. 
223. Foster JD, Hartmann FA, Moriello KA. 2012. "A case of apparent canine erysipeloid 
associated with Erysipelothrix rhusiopathiae bacteraemia." Vet Dermatol. 23: 528–e108. 
224. Breuhl EL, Moore G, Brooks MB, Scott-Moncrieff JC. 2009. "A prospective study of 
unfractionated heparin therapy in dogs with primary immune-mediated hemolytic anemia." J Am 
Anim Hosp Assoc. 45: 125-33. 
225. Galarneau JR, Fortin M, Lapointe JM, Girard C. 2003. "Citrobacter freundii septicemia in 
two dogs." J Vet Diagn Invest. 15: 297-9. 
226. Malik R, Zunino P, Hunt GB. 2003. "Complete heart block associated with lupus in a 
dog." Aust Vet J. 81: 398-401. 
227. Taylor A, Talbot J, Bennett P, Martin P, Makara M, Barrs VR. 2014. "Disseminated 
Scedosporium prolificans infection in a Labrador retriever with immune mediated haemolytic 
anaemia." Med Mycol Case Rep. 6: 66-9. 
228. Bunch SE, Metcalf MR, Crane SW, Cullen JM. 1989. "Idiopathic pleural effusion and 
pulmonary thromboembolism in a dog with autoimmune hemolytic anemia." J Am Vet Med 
Assoc. 195: 1748-53. 
229. Swift IM, Griffin A, Shipstone MA. 2006. "Successful treatment of disseminated 
cutaneous phaeohyphomycosis in a dog." Aust Vet J. 84: 431-5. 
230. Dedola C, Stuart AP, Ridyard AE, Else RW, van den Broek AH, Choi JS, de Hoog GS, 
Thoday KL. 2010. "Cutaneous Alternaria infectoria infection in a dog in association with 
68 
 
 
therapeutic immunosuppression for the management of immune-mediated haemolytic anaemia." 
Veterinary Dermatology 21: 626-34. 
231. Webb JA, Keller SL, Southorn EP, Armstrong J, Allen DG, Peregrine AS, Dubey JP. 
2005. "Cutaneous manifestations of disseminated toxoplasmosis in an immunosuppressed dog." J 
Am Anim Hosp Assoc. 41: 198-202. 
232. Mohri T, Takashima K, Yamane T, Sato H, Yamane Y. 2009. "Purulent pericarditis in a 
dog administered immune-suppressing drugs." J Vet Med Sci. 71: 669-72. 
233. Murray SC, Gasser A, Hess RS. 2009. "Transient hyperglycaemia in a prediabetic dog 
treated with prednisone and cyclosporin A." Aust Vet J. 87: 352-355. 
234. Namikawa K, Maruo T, Honda M, Hirata H, Lynch J, Madarame H. 2012. "Gingival 
overgrowth in a dog that received long-term cyclosporine for immune-mediated hemolytic 
anemia." Can Vet J. 53: 67-70. 
235. Brakenridge SC, Henley SS, Kashner TM, Golden RM, Paik DH, Phelan HA, Cohen MJ, 
Sperry JL, Moore EE, Minei JP, Maier RV, Cuschieri J, and Inflammation and the Host Response 
to Injury Investigators. 2013. "Comparing clinical predictors of deep venous thrombosis versus 
pulmonary embolus after severe injury: a new paradigm for posttraumatic venous 
thromboembolism?" J Trauma Acute Care Surg. 74: 1231-7. 
236. Wouters D, Zeerleder S. 2015. "Complement inhibitors to treat IgM-mediated 
autoimmune hemolysis." Haematologica 100: 1388-95. 
237. Helms CC, Marvel M, Zhao W, Stahle M, Vest R, Kato GJ, Lee JS, Christ G, Gladwin 
MT, Hantgan RR, Kim-Shapiro DB. 2013. "Mechanisms of hemolysis-associated platelet 
activation." J Thromb Haemost. 11: 2148-54. 
238. Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, Diwan BA, 
Schimel DM, Cochard AE, Wang X, Schechter AN, Noguchi CT, Gladwin MT. 2007. 
"Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric 
oxide bioavailability." Blood. 109: 3088-98. 
239. L'Acqua C, Hod E. 2015. "New perspectives on the thrombotic complications of 
haemolysis." Br J Haematol. 168: 175-85. 
240. Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercellotti GM. 2013. "Hemolysis and 
free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of 
therapeutic proteins." Blood. 121: 1276-84. 
241. Belcher JD, Chen C, Nguyen J, Milbauer L, Abdulla F, Alayash AI, Smith A, Nath KA, 
Hebbel RP, Vercellotti GM. 2014. "Heme triggers TLR4 signaling leading to endothelial cell 
activation and vaso-occlusion in murine sickle cell disease." Blood. 123: 377-90. 
242. Chen G, Zhang D, Fuchs TA, Manwani D, Wagner DD, Frenette PS. 2014. "Heme-
induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease." 
Blood. 123: 3818-27. 
69 
 
 
243. Sparkenbaugh EM, Chantrathammachart P, Wang S, Jonas W, Kirchhofer D, Gailani D, 
Gruber A, Kasthuri R, Key NS, Mackman N, Pawlinski R. 2015. "Excess of heme induces tissue 
factor-dependent activation of coagulation in mice." Haematologica. 100: 308-14. 
244. Setty BN, Betal SG, Zhang J, Stuart MJ. 2008. "Heme induces endothelial tissue factor 
expression: potential role in hemostatic activation in patients with hemolytic anemia." J Thromb 
Haemost. 6: 2202-9. 
245. André P, Denis CV, Ware J, Saffaripour S, Hynes RO, Ruggeri ZM, Wagner DD. 2000. 
"Platelets adhere to and translocate on von Willebrand factor presented by endothelium in 
stimulated veins." Blood. 96: 3322-8. 
246. McMichael MA, Smith SA. 2011. "Viscoelastic coagulation testing: technology, 
applications, and limitations." Vet Clin Pathol. 40: 140-53. 
247. Machlus KR, Cardenas JC, Church FC, Wolberg AS. 2011. "Causal relationship between 
hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice." Blood. 117: 4953-63. 
248. Klovaite J, Nordestgaard BG, Tybjærg-Hansen A, Benn M. 2013. "Elevated fibrinogen 
levels are associated with risk of pulmonary embolism, but not with deep venous thrombosis." 
Am J Respir Crit Care Med. 187: 286-93. 
249. Brooks AC, Guillaumin J, Cooper ES, Couto CG. 2014. "Effects of hematocrit and red 
blood cell-independent viscosity on canine thromboelastographic tracings." Transfusion. 54: 727-
34. 
250. Mumford AD, Frelinger AL 3rd, Gachet C, Gresele P, Noris P, Harrison P, Mezzano D. 
2015. "A review of platelet secretion assays for the diagnosis of inherited platelet secretion 
disorders." Thromb Haemost. 114: 14-25. 
251. Smith JR, Smith KF, Brainard BM. 2014. "Platelet parameters from an automated 
hematology analyzer in dogs." Vet J. 201: 406-11. 
252. Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV, 
Ataullakhanov FI. 2007. "Platelet microparticle membranes have 50- to 100-fold higher specific 
procoagulant activity than activated platelets." Thromb Haemost. 97: 425-34. 
253. Harvey, JW. 2012. "Chapter 7: Evaluation of Hemostasis: Coagulation and Platelet 
Disorders." in Veterinary Hematology: A Diagnostic Guide and Color Atlas, pp. 191-225. 
Elsevier Health Sciences, Atlanta, GA. 
254. Harvey, JW. 2012. "Chapter 3. Hematopoesis." in Veterinary Hematology: A Diagnostic 
Guide and Color Atlas, pp. 33-48. Elsevier Health Sciences, Atlanta, GA. 
255. Kuzi S, Segev G, Haruvi E, Aroch I. 2010. "Plasma antithrombin activity as a diagnostic 
and prognostic indicator in dogs: a retrospective study of 149 dogs." J Vet Intern Med. 24: 587-
96. 
256. Hirsh J, Anand SS, Halperin JL, Fuster V. 2001. "Mechanism of action and 
pharmacology of unfractionated heparin." Arterioscler Thromb Vasc Biol. 21: 1094-6. 
70 
 
 
257. Briel M, Bassler D, Wang AT, Guyatt GH, Montori VM. 2012. "The dangers of stopping 
a trial too early." J Bone Joint Surg Am. 94: 56-60. 
258. Hoekstra J, Guimarães AH, Leebeek FW, Darwish Murad S, Malfliet JJ, Plessier A, 
Hernandez-Guerra M, Langlet P, Elias E, Trebicka J, Primignani M, Garcia-Pagan JC, Valla DC, 
Rijken DC, Janssen HL, and European Network for Vascular Disorders of the Liver (EN-V). 
2010. "Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome." Blood. 115: 388-95. 
259. Wells R, Guth A, Lappin M, Dow S. 2009. "Anti-endothelial cell antibodies in dogs with 
immune-mediated hemolytic anemia and other diseases associated with high risk of 
thromboembolism." J Vet Intern Med. 23: 295-300. 
260. Barrientos L, Marin-Esteban V, de Chisemartin L, Le-Moal VL, Sandre C, Bianchini E, 
Nicolas V, Pallardy M, Chollet-Martin S. 2013. “An improved strategy to recover large fragments 
of functional neutrophil extracellular traps.” Front Immunol. 4: 166. 
261.  Urban CF, Ermert D, Schmid M, Abu-Abed U, Goosmann C, Nacken W, Brinkmann V, 
Jungblut PR, Zychlinsky A. 2009. "Neutrophil extracellular traps contain calprotectin, a cytosolic 
protein complex involved in host defense against Candida albicans." PLoS Pathog. 5: e1000639. 
262. Takei H, Araki A, Watanabe H, Ichinose A, Sendo F. 1996. "Rapid killing of human 
neutrophils by the potent activator phorbol 12-myristate 13-acetate (PMA) accompanied by 
changes different from typical apoptosis or necrosis." J Leukoc Biol 59: 229-40. 
263. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, Weinrauch Y, 
Brinkmann V, Zychlinsky A. 2007. "Novel cell death program leads to neutrophil extracellular 
traps." J Cell Biol. 176: 231-41. 
264. Pilsczek FH, Salina D, Poon KK, Fahey C, Yipp BG, Sibley CD, Robbins SM, Green 
FH, Surette MG, Sugai M, Bowden MG, Hussain M, Zhang K, Kubes P. 2010. "A novel 
mechanism of rapid nuclear neutrophil extracellular trap formation in response to Staphylococcus 
aureus." J Immunol. 185: 7413-25. 
265. Yousefi S, Mihalache C, Kozlowski E, Schmid I, Simon HU. 2009. "Viable neutrophils 
release mitochondrial DNA to form neutrophil extracellular traps." Cell Death Differ. 16: 1438-
44. 
266. Keshari RS, Jyoti A, Kumar S, Dubey M, Verma A, Srinag BS, Krishnamurthy H, 
Barthwal MK, Dikshit M. 2012. "Neutrophil extracellular traps contain mitochondrial as well as 
nuclear DNA and exhibit inflammatory potential." Cytometry A. 81: 238-47. 
267. Parker H, Dragunow M, Hampton MB, Kettle AJ, Winterbourn CC. 2012. "Requirements 
for NADPH oxidase and myeloperoxidase in neutrophil extracellular trap formation differ 
depending on the stimulus." J Leukoc Biol. 92: 841-9. 
268. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. 2010. "Neutrophil elastase 
and myeloperoxidase regulate the formation of neutrophil extracellular traps." J Cell Biol. 191: 
677-91. 
71 
 
 
269. Martinod K, Witsch T, Farley K, Gallant M, Remold-O'Donnell E, Wagner DD. 2016. 
"Neutrophil elastase-deficient mice form neutrophil extracellular traps in an experimental model 
of deep vein thrombosis." J Thromb Haemost. 14: 551-8. 
270. Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y. 2010. "PAD4 is essential for 
antibacterial innate immunity mediated by neutrophil extracellular traps." J Exp Med. 207: 1853-
62. 
271. Liu CL, Tangsombatvisit S, Rosenberg JM, Mandelbaum G, Gillespie EC, Gozani OP, 
Alizadeh AA, Utz PJ. 2012. "Specific post-translational histone modifications of neutrophil 
extracellular traps as immunogens and potential targets of lupus autoantibodies." Arthritis Res 
Ther. 14: R25. 
272. Neeli I, Radic M. 2013. "Opposition between PKC isoforms regulates histone 
deimination and neutrophil extracellular chromatin release." Front Immunol. 4: 38. 
273. Douda DN, Khan MA, Grasemann H, Palaniyar N. 2015. "SK3 channel and 
mitochondrial ROS mediate NADPH oxidase-independent NETosis induced by calcium influx." 
Proc Natl Acad Sci U S A. 112: 2817-22. 
274. Nakazawa D, Tomaru U, Yamamoto C, Jodo S, Ishizu A. 2012. "Abundant neutrophil 
extracellular traps in thrombus of patient with microscopic polyangiitis." Front Immunol. 12: 333. 
275. Savchenko AS, Martinod K, Seidman MA, Wong SL, Borissoff JI, Piazza G, Libby P, 
Goldhaber SZ, Mitchell RN, Wagner DD. 2014. "Neutrophil extracellular traps form 
predominantly during the organizing stage of human venous thromboembolism development." J 
Thromb Haemost. 12: 860-70. 
276. de Boer OJ, Li X, Goebel H, van der Wal AC. 2016. "Nuclear smears observed in H&E-
stained thrombus sections are neutrophil extracellular traps." J Clin Pathol. 69: 181-2. 
277. Riegger J, Byrne RA, Joner M, Chandraratne S, Gershlick AH, Ten Berg JM, 
Adriaenssens T, Guagliumi G, Godschalk TC, Neumann FJ, Trenk D, Feldman LJ, Steg PG, 
Desmet W, Alfonso F, Goodall AH, Wojdyla R, Dudek D, Philippi V, Opinaldo S, Titova A, 
Malik N, Cotton J, Jhagroe DA, Heestermanns AA, Sinnaeve P, Vermeersch P, Valina C, Schulz 
C, Kastrati A, Massberg S; Prevention of Late Stent Thrombosis by an Interdisciplinary Global 
European Effort (PRESTIGE). 2016. "Histopathological evaluation of thrombus in patients 
presenting with stent thrombosis. A multicenter European study: a report of the prevention of late 
stent thrombosis by an interdisciplinary global European effort consortium." Eur Heart J. 37: 
1538-49. 
278. Brill A, Fuchs TA, Savchenko AS, Thomas GM, Martinod K, De Meyer SF, Bhandari 
AA, Wagner DD. 2012. "Neutrophil extracellular traps promote deep vein thrombosis in mice." J 
Thromb Haemost. 10: 136-44. 
279. von Brühl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, Khandoga A, 
Tirniceriu A, Coletti R, Köllnberger M, Byrne RA, Laitinen I, Walch A, Brill A, Pfeiler S, 
Manukyan D, Braun S, Lange P, Riegger J, Ware J, Eckart A, Haidari S, Rudelius M, Schulz C, 
Echtler K, Brinkmann V, Schwaiger M, Pressner KT, Wagner DD, Mackman N, Engelmann B, 
Massberg S. 2012. "Monocytes, neutrophils, and platelets cooperate to initiate and propagate 
venous thrombosis in mice in vivo." J Exp Med. 209: 819-35. 
72 
 
 
280. De Meyer SF, Suidan GL, Fuchs TA, Monestier M, Wagner DD. 2012. "Extracellular 
chromatin is an important mediator of ischemic stroke in mice." Arterioscler Thromb Vasc Biol. 
32: 1884-91. 
281. Martinod K, Demers M, Fuchs TA, Wong SL, Brill A, Gallant M, Hu J, Wang Y, 
Wagner DD. 2013. "Neutrophil histone modification by peptidylarginine deiminase 4 is critical 
for deep vein thrombosis in mice." Proc Natl Acad Sci U S A. 110: 8674-9. 
282. van Montfoort ML, Stephan F, Lauw MN, Hutten BA, Van Mierlo GJ, Solati S, 
Middeldorp S, Meijers JC, Zeerleder S. 2013. "Circulating nucleosomes and neutrophil activation 
as risk factors for deep vein thrombosis." Arterioscler Thromb Vasc Biol. 33: 147-51. 
283. Holdenrieder S, Stieber P, Bodenmuller H, Busch M, Fertig G, Furst H, Schalhorn A, 
Schmeller N, Untch M, Seidel D. 2001. "Nucleosomes in serum of patients with benign and 
malignant diseases." Int J Cancer. 95: 114–20. 
284. Fuchs TA, Kremer Hovinga JA, Schatzberg D, Wagner DD, Lämmle B. 2012. 
"Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic 
microangiopathies." Blood. 120: 1157-64. 
285. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. 2001. 
"DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their 
origin from apoptotic and necrotic cells." Cancer Res. 61: 1659-65. 
286. Yang C, Sun W, Cui W, Li X, Yao J, Jia X, Li C, Wu H, Hu Z, Zou X. 2015. 
"Procoagulant role of neutrophil extracellular traps in patients with gastric cancer." Int J Clin Exp 
Pathol. 8: 14075-86. 
287. Sur Chowdhury C, Giaglis S, Walker UA, Buser A, Hahn S, Hasler P. 2014. "Enhanced 
neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal 
transduction pathways and potential diagnostic utility." Arthritis Res Ther. 16: R122. 
288. Yalavarthi S, Gould TJ, Rao AN, Mazza LF, Morris AE, Núñez-Álvarez C, Hernández-
Ramírez D, Bockenstedt PL, Liaw PC, Cabral AR, Knight JS. 2015. "Release of neutrophil 
extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified 
mechanism of thrombosis in the antiphospholipid syndrome." Arthritis Rheumatol. 67: 2990-
3003. 
289. Thålin C, Demers M, Blomgren B, Wong SL, von Arbin M, von Heijne A, Laska AC, 
Wallén H, Wagner DD, Aspberg S. 2016. "NETosis promotes cancer-associated arterial 
microthrombosis presenting as ischemic stroke with troponin elevation." Thromb Res. 139: 56-
64. 
290. Chang X, Han J, Pang L, Zhao Y, Yang Y, Shen Z. 2009. "Increased PADI4 expression 
in blood and tissues of patients with malignant tumors." BMC Cancer. 9: 40. 
291. Chang X, Yamada R, Suzuki A, Sawada T, Yoshino S, Tokuhiro S, Yamamoto K. 2005. 
"Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue 
of rheumatoid arthritis." Rheumatology (Oxford). 44: 40-50. 
73 
 
 
292. Oehmcke S, Mörgelin M, Herwald H. 2009. "Activation of the human contact system on 
neutrophil extracellular traps." J Innate Immun. 1: 225-30. 
293. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, 
Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD. 2010. "Extracellular DNA traps 
promote thrombosis." Proc Natl Acad Sci U S A. 107: 15880-5. 
294. Gould TJ, Vu TT, Stafford AR, Dwivedi DJ, Kim PY, Fox-Robichaud AE, Weitz JI, 
Liaw PC. 2015. "Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis." 
Arterioscler Thromb Vasc Biol. 35: 2544-53. 
295. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, Taylor FB, Esmon 
NL, Lupu F, Esmon CT. 2009. "Extracellular histones are major mediators of death in sepsis." 
Nat Med. 15: 1318-21. 
296. Ammollo CT, Semeraro F, Xu J, Esmon NL, Esmon CT. 2011. "Extracellular histones 
increase plasma thrombin generation by impairing thrombomodulin-dependent protein C 
activation." J Thromb Haemost. 9: 1795-1803. 
297. Varjú I, Longstaff C, Szabó L, Farkas ÁZ, Varga-Szabó VJ, Tanka-Salamon A, 
Machovich R, Kolev K. 2015. "DNA, histones and neutrophil extracellular traps exert anti-
fibrinolytic effects in a plasma environment." Thromb Haemost. 113: 1289-98. 
298. Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, Brinkmann 
V, Lorenz M, Bidzhekov K, Khandagale AB, Konrad I, Kennerknecht E, Reges K, Holdenrieder 
S, Braun S, Reinhardt C, Spannagl M, Preissner KT, Engelmann B. 2010. "Reciprocal coupling 
of coagulation and innate immunity via neutrophil serine proteases." Nat Med. 16: 887-96. 
299. Tecles F, Spiranelli E, Bonfanti U, Cerón JJ, Paltrinieri S. 2005. "Preliminary Studies of 
serum Acute-Phase Protein Concentrations in Hematologic and Neoplastic Diseases of the Dog." 
J Vet Intern Med 19: 865-70. 
300. Lobetti, R. 2012. "Changes in the serum urea: creatinine ratio in dogs with babesiosis, 
haemolytic anaemia, and experimental haemoglobinaemia." Vet J. 191: 253-6. 
301. McInturff AM, Cody MJ, Elliott EA, Glen JW, Rowley JW. 2012. "Mammalian target of 
rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible 
factor 1 α." Blood. 120: 3118-3125. 
302. Leffler J, Ciacma K, Gullstrand B, Bengtsson AA, Martin M, Blom AM. 2015. "A subset 
of patients with systemic lupus erythematosus fails to degrade DNA from multiple clinically 
relevant sources." Arthritis Res Ther. 17: 205. 
303. Lewis RM, Schwartz, RS, Gilmore CE. 1965. "Autoimmune diseases in domestic 
animals." Ann N Y Acad Sci. 124: 178-200. 
304. Murtaugh RJ, Hacibs RM. 1983. "Antinucleolar antibody associated with lupus 
erythematosus in a dog." Vet Clin Pathol. 12: 29-31. 
74 
 
 
305. 313. Holloway SA, Meyer DJ, Mannella C. 1990. "Prednisolone and danazol for 
treatment of immune-mediated anemia, thrombocytopenia, and ineffective erythroid regeneration 
in a dog." J Am Vet Med Assoc. 197: 1045-8. 
306. Hasegawa T, Matsuoka K, Ono K, Watari T, Goitsuka R, Nishimura R, Nakayama H, 
Goto N, Hasegawa A. 1990. "Immune mediated skin lesions in a dog with autoimmune hemolytic 
anemia." Nihon Juigaku Zasshi. 52: 1001-6. 
307. Werner LL, Bloomberg MS, Calderwood Mays MB, Ackerman N. 1985. "Progressive 
polysystemic immune-mediated disease in a dog." Vet Immunol Immunopathol. 8: 183-92. 
308. Shearer LR, Boudreau AE, Holowaychuk MK. 2009. "Distal renal tubular acidosis and 
immune-mediated hemolytic anemia in 3 dogs." J Vet Intern Med. 23: 1284-8. 
309. Elie M, Hoenig M. 1995. "Canine immune-mediated diabetes mellitus: a case report." J 
Am Anim Hosp Assoc. 31: 295-9. 
310.  Pedersen NC, Liu H, Greenfield DL, Echols LG. 2012. "Multiple autoimmune diseases 
syndrome in Italian Greyhounds: preliminary studies of genome-wide diversity and possible 
associations within the dog leukocyte antigen (DLA) complex." Vet Immunol Immunopathol. 
145: 264-76. 
75 
 
CHAPTER 2.  DOGS CAST NETS TOO: NEUTROPHIL EXTRACELLULAR 
TRAP FORMATION BY HEALTHY DOGS AND PILOT DATA FROM 
IMMUNE-MEDIATED HEMOLYTIC ANEMIA CASES 
A paper published in Veterinary immunology and immunopathology1 
Unity Jeffery2, Kayoko Kimura3, Robert Gray4, Paul Lueth3, Bryan Bellaire3, Dana 
LeVine5 
Abstract 
     Neutrophil extracellular traps (NETs) are webs of DNA and protein with both anti-
microbial and pro-thrombotic properties which have not been previously reported in 
dogs. To confirm dog neutrophils can form NETs, neutrophils were isolated from healthy 
dogs, and stimulated in vitro with 2µM, 8µM, 31µM, and 125µM platelet activating 
factor (PAF) or 0.03µM, 0.1µM, 0.4µM, 1.6µM and 6.4µM phorbol-12-myristate-13-
acetate (PMA). Extracellular DNA was measured using the cell impermeable dye Sytox 
Green every hour for 4 hours. At 4 hours, extracellular DNA was significantly greater 
than non-stimulated cells at concentrations ≥31µM and ≥0.1µM for PAF and PMA 
                                                           
1 Reproduced with the permission of Veterinary Immunology and Immunopathology 2015, 168, 262-268. 
2 Department of veterinary preventative medicine and microbiology, Iowa State University. Primary 
researcher and corresponding author. 
3 Department of veterinary preventative medicine and microbiology, Iowa State University. Assisted with 
study design, experimental protocol development and manuscript preparation. 
4 MRC Centre for Inflammation Research, The Queen’s Medical Research Institute, University of 
Edinburgh. Assisted with study design, experimental protocol development and manuscript 
preparation. 
5 Department of veterinary clinical sciences, Iowa State University. Supervised study design, experimental 
protocol development and manuscript preparation. 
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respectively. Cells stimulated with 31.25µM PAF reached maximal fluorescence by 1 
hour, whereas maximal fluorescence was not achieved until 2 hours for cells stimulated 
with 0.1µM PMA. Immunofluorescent imaging using DAPI and anti-elastase antibody 
confirmed that extracellular DNA is released as NETs.  
     As NETs have been implicated in thrombosis, nucleosomes, a marker correlated with 
NET formation, were measured in the serum of dogs with the thrombotic disorder 
primary immune-mediated hemolytic anemia (IMHA) (n=7) and healthy controls (n=20) 
using a commercially available ELISA. NETs were significantly higher in IMHA cases 
than controls (median 0.12 and 0.90 respectively, p=0.01), but there were large positive 
interferences associated with hemolysis and icterus.  
     In summary, the study is the first to describe NET generation by canine neutrophils 
and provides preliminary evidence that a marker associated with NETs is elevated in 
IMHA. However, this apparent elevation must be interpreted with caution due to the 
effect of interference, emphasizing the need for a more specific and robust assay for 
NETs in clinical samples. 
Introduction 
     A wide range of infectious and inflammatory stimuli induce neutrophils to release 
webs of histone-associated DNA decorated with granular proteins (Remijsen et al, 2011). 
Pathogens become entangled in these neutrophil extracellular traps (NETs), where they 
are exposed to high concentrations of anti-microbial proteins such as bactericidal 
permeability increasing protein, neutrophil elastase, and myeloperoxidase (Urban, 2006). 
NETs are therefore important in controlling infection, but there is also growing evidence 
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that they contribute to inflammatory tissue damage and thrombosis (Brinkmann et al, 
2004; Knight and Kaplan, 2012; Martinod and Wagner, 2014). 
     NETs promote inflammatory tissue damage and thus contribute to pathology in a wide 
range of disorders. For example, NET components are important sources of autoantigens 
in autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis 
(Grayson and Kaplan, 2015). NETs also drive inflammation in these, and other diseases 
such as diabetes (Diane et al, 2013), sepsis (Luo et al, 2014) and transfusion related lung 
injury (Thomas et al, 2012), by mechanisms including complement activation (Wang et 
al, 2015), upregulation of IFNα (Diane et al, 2013) and inflammasome activation 
(Kahlenberg et al, 2013). 
     Neutrophil extracellular trap formation has not been previously investigated in dogs. 
Extracellular trap formation has been demonstrated in species ranging from invertebrates 
to humans, and it may seem safe to assume that dogs also form NETs (Robb et al, 2014; 
Remijsen et al, 2011). However, there are important species differences in the nature of 
NET formation, which limit the extent to which findings in one species can be 
extrapolated to another. For example, it has been recently demonstrated that 
myeloperoxidase inhibition greatly reduces NET formation in humans but has little 
impact in mice (Akong-Moore et al, 2012).   
     Future investigation of NET formation may have particular relevance to treatment of 
canine primary immune-mediated hemolytic anemia (IMHA). IMHA carries a grave 
prognosis, with mortality as high as 83% (Weinkle et al, 2005). Although the presenting 
signs of the disease are typically those of anemia due to autoantibody or complement 
mediated destruction of erythrocytes, the majority of these deaths are the result of 
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thrombosis (Carr et al, 2002; Kidd and Mackman, 2013).  Current understanding of 
thrombosis pathogenesis in IMHA is limited, and thromboprophylactic strategies are 
inadequate.   
     Conditions in IMHA are ideal for NET formation. Heme and hypoxia, both of which 
are generated in IMHA, are implicated in induction of NETs (Chen et al, 2014; McInturff 
et al 2012; Martinod and Wagner, 2013).  There is strong in vitro and in vivo evidence 
that NETs play multiple roles in induction, propagation and stabilization of thrombi 
(Martinod and Wagner, 2013; von Bruhl et al, 2012).  Elevations in markers correlated 
with NET formation, such as circulating DNA-histone complexes termed nucleosomes, 
are present in human patients with thrombotic diseases like thrombotic microangiopathies 
and ischemic stroke (Fuchs et al, 2012; Geiger et al, 2007). Most excitingly, murine 
models of stroke and deep vein thrombosis suggest DNase therapy to breakdown NETs 
has potential as a therapy to prevent thrombosis or reduce thrombosis induced tissue 
damage (De Meyer et al, 2012; von Bruhl et al, 2012).   
     Given that IMHA conditions can fuel NET formation and the established role of NETs 
in thrombosis, we hypothesized that nucleosomes, a marker associated with but not 
specific for NETs will be elevated in dogs with spontaneous IMHA. Specifically, this 
study aimed to (1) establish effective concentrations of two agonists for canine NET 
induction in vitro; (2) compare the kinetics of NET formation for the two agonists and (3) 
determine if serum nucleosomes were higher in dogs with primary IMHA compared to 
healthy controls. 
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Methods  
Animals 
     Iowa State University Institutional Animal Care and Use Committee approval and 
informed owner consent were obtained to collect blood from 20 healthy dogs belonging 
to staff and students and 11 dogs with primary immune-mediated anemia.   
     For the control dogs, health was confirmed by physical exam, complete blood count, 
biochemistry panel, and urinalysis. No dog was receiving any medication other than 
routine anti-parasite treatments. Eight dogs were spayed females and 12 castrated males. 
Median age was 4.5 years (range 1.5 to 9 years) and median body weight 25kg (range 7 
to 38kg). Breeds represented included 6 mixed breed dogs, 2 greyhounds, 3 Labrador 
retrievers, 2 Border collies, 3 American Staffordshire terriers and 1 each of Chesapeake 
Bay retriever, golden retriever, German shorthaired pointer, Rhodesian ridgeback. Based 
on availability, 5 of the control dogs were selected for use in each of the in vitro 
neutrophil stimulation studies. 
     Patients who fulfilled the criteria for primary IMHA were prospectively enrolled from 
the Lloyd Veterinary Medical Center, Iowa State University College of Veterinary 
Medicine between February and November 2014:  Primary IMHA was defined as 
hematocrit < 37% with one or more of the following: positive saline agglutination test, > 
5 spherocytes per high power field, or positive Coombs test. Dogs were excluded if 
routine diagnostic investigation revealed an underlying trigger for IMHA or if heparin 
had been administered prior to study enrollment. 
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Neutrophil stimulation assays 
Blood collection and neutrophil isolation 
     9ml of blood was drawn from a cephalic vein and immediately transferred to EDTA. 
Neutrophils were isolated as previously described (Nauseef, 2014). Briefly, erythrocytes 
were removed by dextran sedimentation, the leukocyte rich supernatant washed at 300 x 
g for 10 minutes and re-suspended in 10ml PBS before layering over 10ml Histopaque 
1077 (Sigma Aldrich, St Louis, MO). After 30 minutes centrifugation at 300 x g, the 
mononuclear cell layer was discarded and the granulocyte layer exposed to sterile water 
for 30 seconds to lyse remaining erythrocytes. Tonicity was restored with 1.8% saline 
before cells were washed and any large clumps removed using a 70µm sterile filter 
(Corning, Amsterdam). Cells were counted by electrical impedance (Beckman Coulter, 
Indianapolis, IN), and re-suspended in PBS ( Gibco®, Life Technologies, Grand Island, 
NY) at 5 x 106 cells/ml. Examination of cytocentrifuge preparations confirmed the 
resulting cells were > 95% granulocytes. 
DNA release assay 
     A previously described assay was modified for measurement of extracellular DNA 
release, a marker of NET generation (Gray et al, 2013). The effects of all agonist 
concentrations were measured using cells from 5 individuals in 4 separate experiments. 
Using 96 well plates, 5x104 cells per well were added to 40µl Roswell Park Memorial 
Institute-1640 medium (RPMI) (Gibco®, Life Technologies, Grand Island, NY) 
containing 0.5% heat inactivated FCS (Gibco®, Life Technologies, Grand Island, NY). 
Cells were incubated for 30 minutes at 39° C before addition of the cell impermeable 
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nucleic acid dye Sytox green (Molecular probes ®, Life Technologies, Grand Island, NY) 
to a final concentration of 6µM and PAF (Sigma Aldrich, St Louis, MO) or PMA (Sigma 
Aldrich, St Louis, MO) to final concentrations of 2µM, 8µM, 31µM, 125µM or 0.03µM, 
0.1µM, 0.4µM, 1.6µM, 6.4µM respectively. Final well volume was 200µl. Blank wells 
and non-stimulated cells from each dog were included in each experiment, and all 
conditions run in duplicate.  
     Fluorescence was read at excitation/emission maxima of 504/523nm every 60 minutes 
for 4 hours using a microplate spectrofluorometer (Synergy HT, BioTek Instruments, 
Winooski, VT). Results were expressed as mean fluorescence of activated cells divided 
by mean fluorescence of non-stimulated cells from the same individual at the same time 
point.  These experiments allowed us to identify optimum agonist concentration and the 
time for maximal NET release with each agonist. In order to determine the intra-assay 
coefficient of variation, 10 duplicates prepared using cells isolated from a single dog 
were stimulated with 0.1 µM PMA for 2 hours and the coefficient of variation calculated 
by standard deviation of fold changes in Sytox green fluorescence/mean fold change in 
Sytox green fluorescence.  
Immunofluorescent imaging 
     To identify NETs, the NET components DNA and neutrophil elastase were visualized 
simultaneously with fluorescent immunostaining.  Cells in RPMI with 0.5% FCS were 
seeded onto glass coverslips at a density of 5x105 cells. After a 1 hour incubation at 
39°C, PAF or PMA were added to final concentrations of 31µM and 6.4 µM respectively. 
Following a 2 hour incubation at 39°C, cells were fixed with a final concentration of 4% 
methanol free formaldehyde (Polysciences Inc. Washington, PA) for 20 minutes at room 
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temperature. After washing in PBS, cells were treated with a PBS solution containing 1% 
saponin (Sigma Aldrich, St Louis, MO) and 2.5% BSA (Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA) for 30 minutes at room temperature.  Coverslips were 
then treated with 0.01µg/µl rabbit anti-human neutrophil elastase (Bioss Antibodies, 
Woburn, MA) overnight at 4 °C, washed with PBS and incubated for 1 hour at room 
temperature  with 0.0075µg/µl Cy 5 conjugated goat anti-rabbit IgG (Jackson 
ImmunoResearch Laboratories Inc., West Grove, PA). Cells were washed with PBS 
before mounting using Prolong gold antifade mountant with 4', 6-diamidino-2-
phenylindole (DAPI) (Molecular probes ®, Life Technologies, Grand Island, NY). 
     Unstimulated cells and cells stained with secondary antibody alone were processed in 
parallel. Imaging was performed by laser scanning confocal microscopy Olympus 
Fluoview 2000 (Olympus Corporation, Melville, NY). Laser excitation and 
photomultiplier exposure parameters were maintained at identical settings across all 
samples to normalize image acquisition.  NETs were defined as extracellular string-like 
structures that were positive for both DNA and elastase.   
Measurement of serum nucleosomes 
     Blood was obtained from healthy controls and IMHA patients using a 21gauge 
butterfly catheter inserted into the cephalic, saphenous or jugular vein. Samples were 
processed and stored as recommended for human serum samples (Holdenrieder et al, 
2001). Briefly, serum was separated by centrifugation at 2000 x g for 15 minutes. 3 of the 
11 IMHA samples were visibly hemolyzed and icteric and one was visibly hemolyzed. 
EDTA (pH 8) was added to a final concentration of 10mM and samples stored at -80°C 
for analysis. Maximum storage time of any of the samples was 10 months, which has 
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previously been showed to an acceptable storage time for human serum samples 
(Holdenrieder et al, 2010).   
     The Cell Death Detection ELISAPlus (Roche Diagnostics Corporation, Indianapolis, 
IN), which contains biotin-conjugated anti-histone antibodies and horse radish 
peroxidase-conjugated anti-DNA antibodies, was prepared according to manufacturers’ 
instructions. All samples and controls were run in duplicate. Because absorbance 
exceeded the maximal reportable value for the positive control, the upper level of the 
linearity study and 1 IMHA sample, these samples were diluted 1:1 with distilled water 
and immediately reanalyzed.  
     The nucleosome assay was validated by determining intra-assay variability, linearity, 
recovery, and interference.  The intra-assay coefficient of variation was calculated by 
dividing the standard deviation by the mean for 8 replicates of the positive control diluted 
1:1 as described above. Assay linearity was assessed visually and by simple linear 
regression for 5 serial dilutions of the positive control using pooled normal dog serum. A 
spiked sample was prepared by adding 10µl of the positive control to 90µl of pooled 
serum, and a diluted sample by adding 10µl distilled water to 90ul pooled serum. 
Recovery was calculated by (spiked absorbance-diluted absorbance/absorbance of 
amount added)*100. Interference controls were prepared by adding 10µl of Intralipid 
(Sigma Aldrich, St Louis, MO), bilirubin (Acros Organics, Geel, Belgium) or washed and 
mechanically lysed erythrocytes to 90ul of pooled serum resulting in final concentrations 
of 0.35g/dL and 0.18g/dL for hemoglobin; 10g/L lipid; 50mg/dl  and 2mg/dL for icterus 
controls. Interference (%) was calculated by [(mean absorbance of interference control - 
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mean absorbance of the water diluted sample)/mean absorbance of water diluted 
control]*100. 
Statistical analysis 
     Statistical analyses were performed using Graphpad Prism version 6 for Windows 
(GraphPad Software, La Jolla, CA). Data was tested for normality by the Anderson 
Darling test.  
     Fold change in Sytox green fluorescence for cells treated with each concentration of 
PMA or PAF were compared to non-stimulated cells at 4 hours, using a repeated 
measures ANOVA. If means were significantly different (p<0.05), Dunnett’s multiple 
comparisons test was performed and multiplicity adjusted p values reported. To 
determine the optimal time for incubation with agonist, the fold change in Sytox green 
fluorescence for the lowest agonist concentrations able to induce a significant increase in 
fluorescence (31µM PAF or 0.1µM PMA) were compared between 1 and 2 hours, 2 and 
3 hours and 3 and 4 hours using a repeated measures one-way ANOVA. If means were 
significantly different (p<0.05), repeated t-tests with Bonferroni’s correction were 
applied and multiplicity adjusted p values reported. Serum nucleosome levels were 
compared between controls and IMHA cases by Mann U Whitney, and considered 
statistically significant if p<0.05. All data are expressed as mean ± SEM. 
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Results 
PMA and PAF induce canine NET formation in vitro 
DNA release assay 
     Intact cells membranes are impermeable to Sytox green, and its fluorescence therefore 
correlates with extracellular DNA and dead or dying cells. As shown in Figure 1, dog 
neutrophils treated for 4 hours with PAF concentrations of 31µM (p=0.04) and 125µM 
(p=0.03) or PMA concentrations of 0.1 µM (p=0.04), 0.4 µM (p=0.04), 1.2 µM (p=0.01) 
and 6.4µM (p=0.04) had significantly increased fold changes in Sytox green fluorescence 
compared with non-stimulated cells, confirming that two known NET inducers in other 
species can induce cell death and/or DNA release by dog neutrophils. 
Figure 1. DNA release from healthy canine neutrophils evaluated by fluorescence.   Cells were 
incubated with and without stimulants for 4 hours and Sytox green added to detect extracellular DNA.   
PMA concentrations of 0.1µM or more and PAF concentrations of 31µM or more induce significantly 
higher extracellular DNA release than unstimulated cells. (*) multiplicity adjusted p values <0.05; (**) 
multiplicity adjusted p value ≤0.01; error bars are mean +/- standard error for 5 individuals analyzed in 
4 separate experiments. 
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     Using the lowest concentration of PAF (31µM) to induce significant fold increases in 
Sytox green fluorescence, there was no increase in fluorescence after 1 hour (ANOVA 
p=0.71) whereas for 0.1μM PMA there was a significant increase between 1 and 2 hours 
(multiplicity adjusted p=0.04) but not between subsequent time points (Fig. 2). Similar 
time effects were observed for all concentrations tested (data not shown). The intra-assay 
coefficient of variation for 0.1µM PMA after 2 hours was 9%.  
Fluorescent imaging 
     In order to confirm that the extracellular DNA detected in the DNA release assay 
corresponded to NETs, we immunolabelled elastase, known to be associated with NETs.  
NET formation, as demonstrated by webs of extracellular DNA decorated with elastase 
and large numbers of cells with rounded or fragmented nuclei, was apparent after 
stimulation with 31.25µM PAF or 6.4µM PMA. Structures co-localizing with both 
extracellular DNA and the neutrophil elastase protein are consistent with prior 
Figure 2. Kinetics of DNA release induced by 0.1µM PMA (A) and 31µM PAF (B). Extracellular 
DNA was detected at the indicated times with Sytox Green and data is presented as fold change in 
fluorescence compared to unstimulated neutrophils. Sytox green fluorescence increased between 1 and 
2 hours for PMA treated cells but had reached a plateau by 1 hour for PAF treated cells. (*) multiplicity 
adjusted p=0.04; error bars are mean +/- standard error for 5 individuals. 
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descriptions of NETs. In contrast, non-stimulated cells typically had crisply lobulated 
nuclei and elastase remained intra-cytoplasmic (Figure 3). 
     Together the results of our DNA release assay and confocal microscopy show, for the 
first time, that canine neutrophils can form NETs in response to stimulation with PMA or 
PAF.  
 
 
 
Figure 3: Immunofluorescence confirms NET formation. Cells were incubated for 2 hours with 
no agonist (A), 6.4µM PMA (B) or 31µM PAF(C) before staining of DNA (DAPI, red in composite) 
and neutrophil elastase (Cy5, green in composite). Non-stimulated cells retained normal morphology 
whereas PAF and PMA stimulated cells displayed nuclear rounding or fragmentation with webs of 
extracellular DNA and elastase confirming NET formation. Images are average intensities through a 
z stack (x60, oil). 
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Canine IMHA is associated with increased levels of serum nucleosomes  
IMHA patient characteristics 
     Of the 11 IMHA cases, there were 6 spayed females and 5 castrated males.  Breeds 
included 2 Boston terriers, 2 mastiffs, 3 mixed breed dogs and 1 each of beagle, 
Pomeranian, Maltese, and miniature schnauzer. Median age was 7 years (range 3-12 
years); median weight 11.8kg (range 6 to 54kg). Three of the 11 dogs died within 3 
weeks of enrollment and thrombosis was confirmed at necropsy for all non-survivors. 
Validation of the Cell Death ELISAPlus for canine nucleosome measurement 
     CV was 15% and recovery 89%. The assay was non-linear over the tested range, 
based on inspection of graphically displayed data (not shown) and a correlation 
coefficient of 0.96 for simple linear regression. However, the need to dilute two of the 
linearity levels in order to bring their absorbance into the reportable range likely 
contributed to this lack of linearity. There were large positive interferences at 
concentrations of hemoglobin and bilirubin commonly found in IMHA patients (0.35g/dl 
hemoglobin: 365% increase; 0.18g/dl hemoglobin: 152% increase; 50g/dl bilirubin: 
101% increase; 2g/dl bilirubin: 87% increase and 10g/l lipemia: 78% increase). 
Comparison of healthy controls and IMHA cases 
     We hypothesized that IMHA patients would have increased nucleosome levels, a 
marker associated with, but not specific for NETs.  Of the 11 IMHA cases, 4 had to be 
excluded from statistical comparison to the 20 control dogs due to hemolysis alone (1/4) 
or icterus and hemolysis (3/4). Serum nucleosomes were significantly higher in the 7 
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remaining IMHA cases than normal controls [median absorbance (arbitrary units) 0.90 
and 0.12 respectively, p=0.01; Figure 4]. 
Discussion 
     This study is the first to describe in vitro generation of NETs by canine neutrophils. 
The method described for in vitro NET generation and the adaptation of a human rapid 
quantitative fluorometric assay will allow further investigation of triggers of NET release 
by dog neutrophils including more physiologic agonists such as activated platelets; the 
effect of various diseases on NET generating potential; and the effects of canine NETs on 
other components of the immune and coagulation systems. Our results demonstrate that 
 
Figure 4: Circulating nucleosomes are increased in dogs with IMHA (n=7) compared to healthy 
controls (n=20).  One dog was excluded from statistical analysis due to hemolysis alone (open 
triangle); 3 other excluded dogs had visible hemolysis and icterus (closed triangles). Because the non-
linearity of the assay prevented accurate assessment of nucleosomes in diluted samples, one excluded 
sample which required dilution is plotted as a star at the maximal reportable absorbance (4AU). AU: 
arbitrary units; (*) p=0.01. 
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both PMA and PAF can induce canine NET formation, although at the concentrations 
tested PMA acts more slowly than PAF. An interesting feature is the concentrations at 
which both agonists induce significant extracellular DNA release. PAF produced 
significant increases in extracellular DNA at 31µM, but not at concentrations of 8µM or 
below. While it is difficult to accurately estimate local concentrations of PAF at sites of 
inflammation or thrombosis, PAF in the nanomolar range has been shown to induce 
canine platelet activation, neutrophil migration and aggregation and in humans, 10nM 
PAF has been used to induce NETs (Strøm and Thomsen, 1990; Yost et al, 2009). 
Similarly, PMA at 0.04µM, a concentration similar to that previously used in human 
studies, produced only a marginal, non-significant mean increase in DNA release 
(Hazeldine et al, 2014). 
     While these differences may reflect variation in neutrophil isolation and culture 
methods, they also raise the possibility that canine neutrophils may be less responsive to 
NET inducing agonists than human neutrophils. This is of particular interest for PAF, 
which unlike PMA, is a physiological stimulus known to have pro-inflammatory and pro-
thrombotic effects in a wide range of conditions, including sepsis, sickle cell anemia and 
anaphylaxis (Oh et al, 1997; Yost et al, 2010). The PAF concentration at sites of 
thrombosis is difficult to accurately estimate, and is likely to vary considerably between 
thrombi depending on the relative concentrations and activation status of endothelial 
cells, platelets and leukocytes. However, the available experimental evidence suggests it 
is likely to be orders of magnitude lower than the concentration found to induce NET 
release in the current study (Prescott et al, 1984; Muller et al, 1995). The possibility that 
NETs are induced only by supra-physiological doses of PAF in dogs is therefore 
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deserving of further study, as it could hint at species differences in the pathophysiology 
of diseases in which NETs have previously been shown to be important. 
     Such diseases include thrombotic syndromes. While NETs were originally identified 
as an antimicrobial defense mechanism, NETs have recently been shown to promote 
thrombosis through multiple mechanisms. For example, negatively charged DNA acts to 
activate the contact pathway of coagulation; histones have been shown to directly activate 
platelets and NETs bind and thus locally concentrate a range of pro-coagulant and 
thrombus-stabilizing proteins such as tissue factor and fibronectin (Gould et al, 2014; 
Fuchs et al, 2010, Kambas et al, 2012). NET material has been shown within thrombi, 
both in laboratory animal models and in human patients, and depletion of neutrophils or 
dismantling NETs greatly reduces thrombus formation in vitro and in vivo (Fuchs et al, 
2010; Savchenko et al, 2014; von Brühl et al, 2012). 
     NETs therefore hold promise as markers of thrombotic risk in a variety of diseases as 
well as potential thrombolytic or thromboprophylactic targets. This is of particular 
interest in canine immune-mediated hemolytic anemia, a disease associated with high 
mortality, predominantly as a result of thrombosis (Kidd and Mackman, 2013). The 
breakdown of NETs by DNase therapy yielded encouraging results in a mouse model of 
deep vein thrombosis (von Brühl et al, 2012). If NET markers are increased in IMHA, 
this would pave the way for a clinical trial of such therapy in dogs. 
     Nucleosomes are DNA-histone complexes released during cell death, particularly 
apoptosis and NET formation (Brinkmann et al, 2004; Holdenrieder et al, 2001). 
Circulating nucleosomes were chosen as a marker of NET formation because, although 
nucleosomes are not specific for NETs, there is evidence both for their correlation with 
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NET formation and their elevation, often with prognostic significance, in a range of 
conditions, including rheumatoid arthritis, sepsis, deep vein thrombosis, sickle cell 
anemia and thrombotic microangiopathic anemia (Chowdhury et al, 2014; Chen et al, 
2012; Fuchs et al, 2012; van Montfoort et al, 2013; Schimmel et al, 2013). 
     We did find a significant elevation in circulating nucleosomes in canine IMHA 
patients. It is therefore tempting to conclude that nucleosomes and therefore possibly 
NETs contribute to the mortality and morbidity of IMHA. However, the apparent 
increase in nucleosomes should be viewed with caution. The number of IMHA cases in 
the current study is low and thus our findings may not be representative of the wider 
population of IMHA cases. Furthermore, validation of the Cell Death Detection 
ELISAPlus revealed major limitations of this assay when used in clinical samples. 
     IMHA is a frustrating disease for laboratory investigation as erythrocyte lysis or 
phagocytosis and subsequent breakdown of hemoglobin inevitably leads to significant 
hemolysis and icterus in the serum of many patients. Both hemoglobin and bilirubin can 
act as interferents, introducing systematic error in the measurement of the substance of 
interest (Flatland et al, 2010). Positive interference from hemolysis has been 
demonstrated in human samples using the Cell Death Detection ELISAPlus (Holdenrieder 
et al, 2001). To the authors’ knowledge this is the first study to assess interference from 
bilirubin and lipemia in the Cell Death Detection ELISAPlus, both of which also caused 
positive interference at the assessed levels. Although dogs with visible hemolysis or 
icterus were excluded from the statistical analysis, it is possible that interference occurs at 
levels of hemoglobin or bilirubin not detectable by eye and may be falsely increasing 
apparent circulating nucleosomes in IMHA. 
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     The Cell Death Detection ELISAPlus was selected for use in the current study because 
according to the manufacturer it is suitable for use in a range of species and has been 
validated for use with stored serum (Holdenrieder, 2010). Although the Cell Death 
Detection ELISAPlus has been used to measure circulating nucleosomes in a number of 
human studies, it is designed for assessment of apoptosis in cultured cells. Consequently, 
the kit is supplied without a standard and time for color change development is left at the 
operator’s discretion, preventing comparison of nucleosome levels between different 
plates. Not only does this limit our validation of the kit, for example by preventing more 
than 8 replicates for assessment of CV, but it also prevents comparison of the nucleosome 
levels observed in IMHA patients with those reported in various human studies and limits 
the use of the kit to assess the potential of nucleosomes to act as prognostic markers. 
Furthermore, although nucleosomes correlate with NET formation, they are not specific 
for NETs as nucleosomes can be released in other forms of cell death such as necrosis 
(van Montfoort et al, 2013).  Development of an assay for NET markers which is specific 
and robust in the face of interferents and transferable between centers is therefore a 
matter of urgency. A promising future method is a myeloperoxidase/DNA ELISA, which 
has been reported in humans (Caudrillier et al, 2012) but has not been validated for use 
with canine serum or plasma.   
Conclusion 
     The current study provides the first evidence for NET formation by canine neutrophils 
and a detailed description of a simple method for their in vitro generation. Assessment of 
a commercially available ELISA for circulating nucleosomes revealed important 
limitations of this method when used for clinical samples, particularly positive 
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interference from hemolysis and icterus.  This nucleosome ELISA generated preliminary 
evidence that a marker associated with, but not specific for, NET formation may be 
elevated in the pro-thrombotic condition, primary IMHA. Although the ELISA results 
must be interpreted with caution due to potential interferents, they suggest that the role of 
NETs in the outcome and pathogenesis in IMHA is worthy of further study. 
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CHAPTER 3. A SPECTROPHOTOMETRIC FIBRINOLYSIS ASSAY FOR DOG 
PLASMA 
A manuscript for submission to Veterinary Clinical Pathology1 
Unity Jeffery,2 Marjory Brooks,3 Dana LeVine4,5 
Abstract 
     Background: Altered fibrinolysis is an important contributor to bleeding and 
thrombotic syndromes. Although thromboelastography has demonstrated hypo- and 
hyper- fibrinolysis in dogs, availability of the technique is limited.  
     Objective: To develop a simple method for assessment of fibrinolysis in citrated dog 
plasma. 
     Method: Plasma was mixed with tissue factor, calcium, phospholipid and tissue 
plasminogen activator and light absorbance measured for 1 hour. Clot formation was 
assessed by peak absorbance (mAU), formation velocity (FV, mAU/s) and area under the 
curve (AUC, mAU.s). Clot lysis was assessed by lysis velocity (LV, mAU/s). 
Interferences and the effects of hematocrit, fibrinogen, heparin and aminocaproic acid 
                                                           
1 This work was presented at the American College of Veterinary Pathology Congress, Minneapolis, 2016. 
2 Department of Veterinary Microbiology and Preventative Medicine, College of Veterinary Medicine, 
Iowa State University 
3 Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell 
University, Ithaca, NY, USA 
4 Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University 
5 Dana LeVine and Marjory Brooks initiated the project. Dana LeVine supervised the project and critiqued 
the manuscript. Marjory Brooks was responsible for the fibrinogen measurement and critiqued the 
manuscript. Unity Jeffery performed the other laboratory investigations, was responsible for data 
interpretation and prepared the manuscript.  
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were assessed by spiking studies. A reference interval was constructed from 21 healthy 
dogs. 
     Results: Inter-day coefficients of variation were ≤ 15% for all parameters. Interference 
was absent for all parameters for bilirubin of ≤1.88mg/dl and hemoglobin of ≤0.09mg/dl. 
Aminocaproic acid (40µg/ml) and heparin (0.125U/ml) caused almost complete 
inhibition of fibrinolysis and coagulation respectively. All parameters were minimally 
affected by PCV (R2<0.3) but all parameters except LV (R2=0.08) had a strong 
exponential relationship with fibrinogen (R2>0.8). Comparison of 20 sick dogs to a 
reference interval derived from 21 healthy dogs detected evidence of hypofibrinolysis 
(decreased LV) in 2 and hyperfibrinolysis (increased LV) in 9 dogs. 
     Conclusions: This spectrophotometric assay allows fibrinolysis assessment in canine 
samples using commonly available equipment and reagents. Initial evaluation of the test 
in sick dogs provides encouraging early evidence that the assay will have clinical 
applications. 
Introduction 
     Fibrinolysis is the plasmin-mediated proteolysis of fibrin to form fibrin degradation 
products (Harvey JW 2012). Altered fibrinolysis is a recognized feature of many human 
bleeding and thrombotic syndromes. For example, hyperfibrinolysis often causes fatal 
hemorrhage in people with acute promyelocytic leukemia (Breen KA 2012) whereas 
hypofibrinolysis is a well-established contributory factor for venous and arterial 
thrombosis (Meltzer ME 2008) (Guimarães AH 2009) (Smalberg JH 2011). Evidence of 
hyperfibrinolysis in viscoelastic assays has been described in dogs with bleeding 
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tendencies, such as the hemorrhagic form of disseminated intravascular coagulation 
(Hosoya 2011). Hypofibrinolysis in dogs at risk of thrombosis has also been reported, 
based on a modified viscoelastic assay, configured with tissue plasminogen activator 
(tPA) to induce conversion of endogenous plasminogen to plasmin (Spodsberg EH 2013). 
     Turbidimetry has been widely used as a research technique to monitor plasma clot 
formation and lysis by changes in light scatter as fibrin fibrils form, aggregate and are 
subsequently degraded (Weisel JW 1992) (Carr ME 1978) (Hantgan RR 1979) (Zucker 
M 2014) (van Geffen M 2012). Turbidity is logarithmically related to light absorbance 
(Carr ME 1978), so similar information can be obtained from spectrophotometric assays 
performed using commonly available microplate readers and reagents (Wolberg AS 
2002). These assays have the potential for wider use to assess fibrinolysis in veterinary 
patients, as in contrast to viscoelastic techniques, they do not require expensive 
equipment or proprietary reagents. Furthermore, spectrophotometric, plasma-based 
assays are unlikely to be affected by fluctuating hematocrit or platelet count, which 
complicate the interpretation of whole blood viscoelastic assays in anemic or 
thrombocytopenic patients (Brooks AC 2014 ). 
     In the current study, we set out to develop a spectrophotometric assay to monitor clot 
formation and lysis in canine plasma. The influence of fibrinogen concentration and red 
cell count was evaluated in ex vivo spiking studies. A reference range was derived from 
healthy dog samples and compared with data from sick dogs as a preliminary evaluation 
of the assay’s performance in clinical patients representative of the disease population 
likely to be screened for fibrinolysis defects.   
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Methods 
Study population 
Healthy controls 
     Staff and student owned dogs were used for assay development and reference interval 
construction. Health was confirmed by history, physical exam, urinalysis, biochemistry 
and hematology. No dogs were receiving any medications other than routine anti-parasite 
prophylaxis. All samples were collected between 2.01.2014 and 8.31.2015 with owner 
consent and Iowa State University Institutional Animal Care and Use Committee 
approval (Protocol 12-13-7687-K).  
Clinical cases 
     Preliminary data from diseased dogs was generated using citrated plasma collected for 
coagulation panels as part of the diagnostic work-up for dogs admitted to Iowa State 
University (ISU) for a range of conditions. Cases were selected based on availability of at 
least 200µl of plasma after completion of diagnostic testing and permission from the 
primary clinician. Ethical approval was not sought for the use of these samples as no 
additional blood was collected for the study.  
Sample collection 
Healthy controls 
     A 21-gauge polypropylene butterfly catheter (SURFLO® winged infusion set, 
Terumo, NJ) was inserted into a cephalic, jugular or saphenous vein and, after collection 
of a serum sample or allowing a few drops of blood to fall, blood was drawn into a 
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syringe containing 3.8% sodium citrate, pH 8 (final citrate concentration: 0.38%). Blood 
was immediately transferred to a polypropylene tube and mixed by gentle inversion. 
Within 30 minutes, samples were centrifuged at 2500 x g for 20 minutes with no brake. 
The resulting platelet poor plasma was stored at -80oC until analysis. 
Clinical cases 
     After completion of clinical testing, samples were stored at -80 oC until use in the 
fibrinolysis assay. Details of sample collection were not available for each animal, but 
coagulation samples are typically collected directly into citrate Vacutainer™ tubes at 
ISU. Samples flagged as under- or over-filled in the clinical record were not included in 
the study. When requested as part of the patient’s diagnostic work-up, prothrombin, 
activated prothrombin times or d-dimers were measured by the Iowa State University 
veterinary clinical pathology laboratory or Lloyd Veterinary Medical Center intensive 
care unit using an IDEXX Coag Dx or an Instrumentation Laboratory ACL ELITE series 
coagulation analyzer. Platelets were measured by either Advia 120 or 2120 or Heska 
Hematrue and clumping assessed by manual smear exam. 
Fibrinolysis assay 
     Plasma was thawed in a 37oC water bath for 10 minutes prior to analysis. Using a 96 
well plate (Immulon 1B, Thermo ScientificTM, Waltham, MA), 75µl plasma was 
manually mixed with 5µl of 1:100 thromboplastin (Fisher DiagnosticsTM Pacific 
HemostasisTM Thromboplastin D, Waltham, MA); 20µl phospholipid (final concentration 
4µM, MP Reagent, Diagnostica Stago, Inc., Parsippany, NJ); 10µl tPA (final 
concentration 800ng/ml, Cathflo® Activase®, Genentech, Inc. San Francisco, CA) and 
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90µl calcium chloride (final concentration 9mM, Sigma Aldrich, St Louis, MO). Reagent 
concentrations were optimized based on titration experiments (data not shown).  
     Immediately after mixing, optical density (OD) at 390nm was measured every 8 
seconds for 1 hour by a multi-detection microplate reader (Synergy HT, BioTek 
Instruments, Winooski, VT). Wavelength was selected to maximize peak height in an 
interference free samples (Figure 1). 
     In preliminary experiments, the observed peak OD for canine plasma samples were 
considerably lower than previously reported values for human plasma in similar assay 
configurations. To investigate this difference, pooled normal human plasma (George 
King Biomedical, Overland Park, KS) was assayed as described for canine plasma. The 
peak OD for the human plasma was higher than canine plasma and comparable to 
 
Figure 1: The effect of measuring absorbance at increasing wavelengths for normal dog plasma. 
390nm was selected as the optimal wavelength for absorbance measurement as it produced the highest 
peak OD for normal dog plasma. The 96 well plates used are not designed for use with light outside the 
visible range and therefore lower wavelengths were not tested. Note that reading at multiple 
wavelengths simultaneously requires a longer inter-read interval, resulting in more irregular traces. 
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previous human reports (Goldenberg NA 2005) (He S 2001). Since these finding were 
consistent with a species difference rather than a failure of assay optimization, no further 
modifications were made to the canine assay (Figure 2). 
Assay parameters 
     Baseline was defined as the lowest value in the first 80 seconds of data collection and 
inflection point as the time at which absorbance increased from baseline by 10mAU. Clot 
formation was assessed by the parameters time to inflection (s), peak optical density (OD, 
mAU), clot formation velocity (FV, mAU/s) calculated by (Peak OD-10mAU/Time from 
inflection to peak) and area under the curve (AUC, mAU.s). Clot lysis was assessed by 
 
Figure 2: Comparison of human (blue) and dog (red) absorbance traces. The peak height of the 
human sample is similar to those reported for normal people for the Overall Hemostasis Potential and 
Clot formation and lysis assays.15,16 We therefore considered that the low peaks seen in dogs 
represented a genuine species difference rather than a problem with assay design 
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the parameters lysis velocity (LV, mAU/s) calculated by [(peak OD/2)/time from peak to 
50% lysis]. (Figure 3).  
     When peak OD was <50mAU, imprecision in absorbance measurements prevented 
reliable calculation of assay parameters and only peak OD and AUC are reported. When 
50% lysis was not reached within 1 hour, lysis velocity was calculated by [(peak OD-OD 
at 1 hour)/(3600s-time to peak)]. These adjustments were not required for normal dogs. 
Assay validation 
Assessment of Imprecision 
     Intra-day coefficient of variation (%) was calculated for aliquots of pooled normal dog 
plasma assayed 6 times (in duplicate) over 3 runs on a single day and duplicate 
determinations were performed 20 times in 10 runs over 4 days for calculation of the 
 
Figure 3. Assay parameters. FV: Formation velocity; LV: Lysis velocity; I: Inflection time; T1: Time 
from inflection to peak; T2: Time from peak to 50% lysis 
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inter-day coefficient of variation. Insufficient volume of plasma from diseased dogs was 
available to allow CV calculation for these states. 
Assessment of interference 
     For assessment of interference from hemolysis, a hemolysate was prepared by 
subjecting washed canine erythrocytes to osmotic shock followed by repeated freeze-
thawing before centrifugation to remove cellular debris. Hemoglobin was measured by 
the cyanmethemoglobin method (Advia 120 Hematology System, Siemens, Malvern, PA) 
and the concentration adjusted by adding HEPES saline so spiking pooled normal dog 
plasma with 10µl of the hemolysate resulted in hemoglobin concentrations of 0.09g/dl, 
0.18g/dl or 0.35g/dl in a 10% dilution of plasma. Interference from lipemia was assessed 
by spiking 190µl of pooled normal dog plasma with 10µl of phospholipid stabilized 
soybean oil (Intralipid 20%, Sigma Aldrich, St Louis, MO) diluted in HEPES saline to a 
final phospholipid concentration of 20g/L. Intralipid does not fully replicate physiologic 
lipemia (Dimeski 2008) so a patient sample with gross lipemia was assayed to compare 
with the spiked sample. Controls were prepared using a volume of HEPES saline equal to 
the spike volume. 
     Due to difficulties in achieving high bilirubin concentrations without excessive 
dilution of plasma, icterus controls were instead prepared by maintaining 75µl plasma per 
well and replacing the 90ul of calcium chloride solution with 45µl of a double strength 
solution and adding 45µl of a high bilirubin calibration/HEPES saline mixture (MASTM 
Bilirubin Controls, Thermo ScientificTM Waltham, MA) to produce bilirubin 
concentrations equivalent to plasma concentrations of 15mg/dl, 7.5mg/dl, 3.75mg/dl and 
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1.88mg/dl based on the bilirubin concentration supplied by the manufacturer. A control 
sample was prepared using 45µl HEPES saline. 
Effect of storage  
     Sample stability was assessed by plotting storage time against assay values for each of 
the 21 samples used in reference interval construction. Storage at -800C before analysis 
varied between 1 week and 15 months.  
Effect of alterations in packed cell volume 
     Plasma from a normal dog was used to investigate the effect of reducing hematocrit on 
assay results. Citrated blood was collected and split into 5 aliquots of 10ml, 1.75ml, 1ml, 
1.5ml and 0.5ml. Packed cell volume (PCV) was measured by the microhematocrit 
method for the 10ml aliquot before centrifugation to generate platelet poor plasma as 
described previously. The upper 300µl of plasma was reserved for analysis and the 
remaining plasma, other than the 1ml closest to the buffy coat added to the other 4 
aliquots to achieve a final volume of 2ml. PCV was measured for each of the 3 spiked 
aliquots prior to centrifugation and platelet poor plasma collected as described 
previously. Plasma was analyzed in duplicate. 
Ability to detect alterations in coagulation status 
     The influence of a known fibrinolysis inhibitor on the assay parameters was tested by 
the addition of aminocaproic acid (Sigma Aldrich, St. Louis, MO) a lysine analogue that 
binds to plasminogen and blocks its activation to plasmin. Aminocaproic acid was diluted 
in HEPES saline and added to pooled normal dog plasma as described for bilirubin spikes 
to yield final concentrations in the assay mixture of 0µg/ml, 40µg/ml, 80µg/ml, 250µg/ml 
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and 500µg/ml. Concentrations were selected based on a published report of the effects of 
aminocaproic acid on TEG tracings (Fletcher DJ 2014). 
     Similarly, the effects of varying fibrinogen concentration were assessed by adding 
0.04mg, 0.08mg, 0. 15mg, 0.3mg or 0.6mg (equivalent to increasing plasma 
concentration by 50mg/dl, 100mg/dl, 200mg/dl, 400mg/dl and 800mg/dl respectively) of 
plasminogen depleted bovine fibrinogen (Enzyme Research Laboratories, South Bend, 
IN) diluted in HEPES saline to pooled normal dog plasma. The influence of the 
fibrinogen content in the test plasma was also investigated in individual samples from 10 
dogs (3 apparently healthy controls and 7 clinical cases). The fibrinogen concentration in 
these samples was measured using a polyclonal anti-human fibrinogen ELISA 
(Lominadze DG 1996) configured with a canine plasma standard whose fibrinogen 
content was determined with a gravimetric assay.   
     The influence of a coagulation inhibitor was assessed by addition of sodium heparin 
(APP Pharmaceuticals LLC, Schaumburg, IL) diluted in HEPES saline to pooled normal 
dog plasma to achieve final heparin concentrations of 0.25, 0.5U/ml, 0.75U/ml and 
1U/ml. The concentration range was selected based on therapeutic targets for plasma 
heparin in a previously reported treatment trial (Helmond SE 2010). 
Statistics, quality targets and reference interval construction 
     Statistical analyses were performed using Microsoft Excel (Microsoft, Redmond, WA) 
and Graph Pad Prism version 6.00 for Windows (GraphPad Software, La Jolla, CA). 
Mean, median and coefficient of variation (CV) were calculated using conventional 
methods. In the absence of previous clinical or biological variation data for selection of 
110 
 
 
total allowable error, precision was considered acceptable if ≤10% for intra-day CV and 
≤15% for inter-day CV. These were considered reasonable stringent targets for a manual 
method based on reported 14% inter-day CV for Lysis AUC, a fibrinolysis parameter, 
assayed by tissue factor/tPA thromboelastography (Johansson PI 2008). 
     Interferences from the 15mg/dl bilirubin and the highest readable hemoglobin 
(0.18mg/dl) spike were considered present if a paired t-test for 5 replicates of the spike 
and control were significant (p<0.05). The samples containing varying concentrations of 
bilirubin and hemoglobin were then assessed to determine the concentration at which 
interference was no longer identifiable. As a meaningful total allowable error could not 
be defined prior to assay development, potentially important interference was considered 
absent if the percentage difference between spike and control, calculated by [(Spike-
Control)/Control]*100, was less than the total within-day error of the assay, estimated as 
Total Error observed (TEobs)=2*CV. (Harr 2013)  
     After visual inspection for linearity, simple linear regression was performed to 
determine the coefficient of determination (R2) for storage time, PCV, and fibrinogen for 
most assay parameters. For fibrinogen spikes and plasma concentrations, the relationship 
with AUC was exponential so natural logarithmic transformation was performed prior to 
linear regression. Significant associations were considered present if p<0.05. 
     ASVCP guidelines for reference interval construction for small sample sizes 
(Friedrichs KR 2012) were followed to construct a reference interval from 23 healthy 
dogs using the Reference Advisor plugin for Excel (Geffré A 2011). Samples were 
visually inspected for presence of interferents and excluded from analysis if present. 
Results were first visually inspected for obvious outliers. Normality was then tested by 
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Anderson-Darling. Non-normal data (p<0.05) underwent Box-Cox transformation and 
success of transformation was assessed by symmetry testing (p>0.05 consistent with 
symmetrical distribution). Tukey’s method was used to test for outliers and suspect 
values in transformed and non-transformed data. Reference intervals were constructed 
using the robust method for untransformed data if normally distributed and transformed 
data if non-normal. As recommended for reference intervals derived from small samples, 
reference intervals calculated by alternative methods are also provided (Geffré 2009).The 
fibrinolysis parameters from the 20 clinical samples were compared to this derived 
reference interval. 
Results 
Assay validation 
Imprecision assessment 
     As shown in Table 1, intra- and inter-day coefficients of variation met quality goals 
for all parameters except time to inflection which was therefore not included in further 
analysis. 
Table 1: Intra- and Inter-day Coefficients of Variation 
Parameter Intra-day CV (%) Inter-day CV (%) 
Time to inflection (s) 22 30 
Peak OD (mAU) 3 7 
AUC (mAU.s) 7 8 
FV (mAU/s) 4 15 
LV (mAU/s) 9 13 
 
Effect of interferents 
     When absorbance was read at 390nm, a hemoglobin concentration of 0.35g/dl 
exceeded maximum reportable absorbance. Measuring absorbance at 570nm did bring 
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severely hemolyzed samples into the reportable range of the plate reader, but large 
interferences were present for AUC (-59%) and LV (54%) and peak OD of the control 
was reduced by 63% compared with absorbance at 390nm so higher wavelengths were 
not explored further. The lipemia spike containing 20 g/L lipid and a grossly lipemic 
patient sample resulted in irregular traces with low OD, preventing reliable measurement 
of assay parameters (Figure 4). 
     Moderate hemolysis (0.18g/dl HGB) produced statistically significant negative 
interferences for peak (p=0.01, mean difference between pairs -7.7mAU or -7%) and FV 
(p=0.02, mean difference -0.10mAU/s or -16%). Significant differences were not present 
for LV (p=0.917, mean difference 0.002mAU/s), or AUC (p=0.068, mean difference -
2270). Severe icterus (bilirubin 15mg/dl) produced statistically significant negative 
interferences for peak (p=0.003, mean difference -55mAU or -31%); FV (p=0.003, mean 
difference -0.28mAU/s or -34%); and AUC (p=0.0005, mean difference=-19071mAU.s 
or -35%). 
     Percentage differences for peak, AUC, FV, and LV were less than or equal to the 
intra-day TEobs for mildly icteric (bilirubin 1.88g/dl) or mildly hemolyzed (HGB 
0.09g/dl) samples, but exceeded TEobs  for peak OD of moderately (bilirubin 3.76mg/dl 
or  7.5mg/dl) icteric samples (mean percentage difference -9% and -7% respectively). 
Representative curves for spikes and controls are shown in Figure 5. 
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 Effect of storage 
     No significant relationships were detected between storage time and any parameter 
(peak R2= 0.02 p=0.51, AUC R2= 0.1 p=0.16, FV R2= 0.01 p=0.63 and LV R2= 0.007 
p=0.72) for control samples stored at -80oC for between 1 week and 15 months (average 
storage: 11 months). 
Effect of hematocrit 
     Addition of plasma to blood with an initial PCV of 42% produced PCVs of 10%, 18%, 
30%, 35% and 42%. No significant relationships were detected between PCV and any 
assay parameters (peak R2= 0.07 p=0.68, AUC R2= 0.03 p=0.78, FV R2= 0.28 p=0.36 and 
LV R2= 0.007 p=0.89). 
 
 
Figure 4. Effect of lipemia. Highly irregular traces with low peak OD were generated by a lipemia 
spike resulting in lipid of 20g/L (orange) and a visibly lipemic patient sample (blue) 
Figure 5: Traces for interference spikes and controls. Representative absorbance curves are 
shown for normal dog plasma spiked with hemoglobin or bilirubin. Note that the hemoglobin curves 
were generated using two different plasma pools whereas all bilirubin spikes were prepared from the 
same pool. Differences between mildly hemolyzed (0.09mg/dl) and icteric samples (1.88mg/dl) and 
controls were within the expected error of the assay. 
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Ability to detect alterations in coagulation status 
     Heparin resulted in complete, or near complete absence of tissue factor –triggered clot 
formation for all concentrations of heparin tested (Figure 6). Aminocaproic acid caused 
an almost complete inhibition of fibrinolysis at all concentrations tested (Figure 6). 
In spiking experiments, fibrinogen was strongly predictive of all assay parameters (peak 
R2= 1.00 p<0.0001, AUC R2= 0.95 p=0.005, FV R2= 0.81 p=0.04) except lysis velocity 
(R2 = 0.08 p=0.65). For samples from clinical patients, significant relationships remained 
between plasma fibrinogen concentration and peak (R2= 0.85 p=0.0002), AUC (R2= 0.78 
p=0.0008) and FV (R2= 0.79 p=0.0006), but there was no significant relationship 
between fibrinogen and lysis velocity (R2 = 0.03 p=0.62). 
Reference Interval Construction 
Reference individuals 
     One of the 23 healthy control dogs was excluded from analysis due to presence of 
gross lipemia. Visual inspection of data from the remaining 22 controls revealed one 
Figure 6: Effect of aminocaproic acid and heparin. Spiking normal plasma with physiologically 
relevant concentrations of aminocaproic acid or heparin caused almost complete inhibition of 
fibrinolysis or coagulation respectively. 
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obvious outlier, with a Peak OD and AUC more than twice that of the next highest 
individual. Due to difficulties in blood collection and risk of sampling artifact, this dog 
was excluded from further analysis.  
     Reference intervals were constructed from the remaining 21 control dogs, whose age 
ranged from 1 to 9 years (median 5 years); sex distribution included 1 intact female, 10 
neutered females, and 10 neutered males, and they represented the following breeds 
(number):  mixed breed dogs (5), Labrador retrievers (3), American Staffordshire terriers 
(2), Chesapeake bay retrievers (2), golden retrievers (2), and 1 each of Australian 
shepherd, Border collie, German wirehaired pointer, greyhound, Rhodesian ridgeback, 
Shetland sheepdog and Hungarian vizsla.  
Reference Interval 
     Reference values and pertinent information regarding interval construction are 
summarized in Table 2. Histograms are shown in Figure 7 and reference intervals 
calculated by alternative methods are provided in Table 3. 
Table 2. Descriptive statistics and reference intervals. AD: Anderson Darling 
Parameter Normal/ 
Non-normal 
 
Mean Range Outliers
/Suspect 
data 
RI 
Upper 
limit 
90% CI 
RI 
Upper 
limit 
RI 
Lower 
limit 
90% 
CI RI 
Lower 
limit 
Peak (mAU) Normal (AD 
p=0.542) 
105 64-150 0/0 155 142-167 56 43-73 
AUC 
(mAU.s) 
Normal (AD 
p=0.543) 
51394 28344-
74124 
0/0 82941 71875-
90831 
21606 13718
-
29494 
Formation 
Velocity 
(mAU/s) 
Normal (AD 
p=0.485) 
0.600 0.38-
0.98 
0/0 0.92 
 
0.82-
1.02 
 
0.26 
 
0.16-
0.37 
 
Lysis 
Velocity 
(mAU/s) 
Normal (AD 
p=0.135) 
0.151 0.08-
0.25 
0/0 0.24 0.20-
0.27 
 
0.06 
 
0.03-
0.08 
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Table 3. Reference intervals calculated by alternative methods. When reference intervals are derived 
from small samples it is recommended to provide intervals calculated using multiple methods (25). Here 
reference intervals calculated using a parametric method or using a robust method after box-cox 
transformation are presented. To test the effect of transformation, pre- and post-transformation p values for 
symmetry testing are provided. All values calculated using robust method with box cox transformation 
were within the 90% confidence interval of the parametric reference interval. The lower limit of the 
parametric reference interval for formation velocity was slightly below the 95% confidence interval of the 
robust method with box-cox transformation (shown in red). We therefore used the robust method with 
transformation of non-normal data for evaluation of clinical cases because its 95% confidence intervals 
encompassed the upper and lower limits of the alternative reference intervals. LRL: lower reference limit; 
URL: upper reference limit; CI: confidence interval. 
 Parametric Robust, all box-cox transformed 
LRL 90% 
CI 
URL 90%  
CI 
Symmetry 
test p value 
 
LRL 90% 
CI 
URL 90% 
CI 
Pre  
 
Post  
Peak 
mAU 
57 44-72 154 139- 
169 
0.94 0.75 58 47-75 157 143-
171 
AUC 
mAU.s 
22188 
 
13940
- 
31161 
 
 
829383 
 
73509 
- 
91959 
 
 
0.59 0.87 22500 
 
15490
- 
30116 
 
 
83668 
 
72636
- 
92477 
 
 
FV 
mAU/s 
0.27 
 
0.18- 
0.37 
 
 
0.93 
 
0.83- 
1.03 
 
 
0.59 0.75 0.33 
 
0.30-
0.41 
1.02 
 
0.88- 
1.17 
LV 
mAU/s 
0.06 
 
0.04 
0.09 
0.24 
 
0.21 
0.27 
0.06 0.06 0.08 
 
0.06 
0.10 
0.26 0.21- 
0.31 
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 Results of clinical cases 
Population Characteristics 
     The 20 case patients’ ages ranged from 1 to 15 years (median 8 years), sex distribution 
included 1 intact female, 7 neutered females, 2 intact males and 10 neutered males, and 
they represented the following breeds: Australian shepherd (1), Bernese mountain dog 
(1), Boston terrier (1), doberman pinscher (1), lhasa apso (1), miniature schnauzer (4), 
mixed breed dogs (5), Pomeranian (1), Rhodesian ridgeback (1), shih tzu (1), weimeraner 
(1) and Yorkshire terrier (2). Their disease conditions included aspiration pneumonia (3), 
biliary mucocele (1), congenital portosystemic shunt (PSS) (2); gastric dilation and 
 
Figure 7. Histograms of reference results. Reference intervals were calculated using the robust 
method based on 21 healthy individuals. Dark blue: Observed distribution; Pink: fitted distribution; 
Light blue: reference limits; Dashed line: 90% confidence interval. 
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volvulus (GDV) (1), gastrointestinal foreign body (1), hemorrhagic cystitis (1), hepatic 
abscess (2), immune-mediated hemolytic anemia receiving heparin (1), microvascular 
dysplasia (1), necrotizing steatitis (1), nephrotic syndrome (1), neoplasia (5), prostatitis 
(1), anticoagulant rodenticide ingestion (2), septic abdominal effusion (2) and von 
Willebrand factor (vWF) deficiency. Samples were free from the interference criteria 
established in the assay validation tests, with the exception of one dog whose serum 
bilirubin of 2.6mg/dl exceeded the cutoff of 1.88 mg/dL considered “mild” icterus.  This 
animal’s results are identified as possibly affected by interference in Table 5. 
Assay results and preliminary interpretations 
      LV could not be calculated for 3/20 dogs because peak was <50mAU. LV was below 
reference interval in 2/20 and above reference interval for 9/20. Peak and FV were 
increased in 13/20. Patterns of results are reported in Table 4 and individual results 
together with platelet count, PT, PTT and D-Dimers if reported within 24 hours of citrate 
collection are included in Table 5. Representative traces are shown in Figure 8. 
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Table 4: Result patterns in clinical cases N: normal; R: reduced; I: increased; NC: not calculated because 
peak <50mAU; PSS: portosystemic shunt; FB: foreign body; MVD: microvascular dysplasia; ITP: 
immune-mediated thrombocytopenia; GDV: gastic dilation and volvulus; vWD: von Willebrand deficiency.  
(*) Icteric sample, peak may be reduced by negative interference; (#) hematuria was suspected to result 
from prostatitis or cystitis rather than a systemic bleeding disorder. 
Peak AUC FV LV Dogs Evidence of 
hemorrhage 
Evidence 
of 
thrombosis 
N N N N 2 (PSS) No No 
R R NC NC 3 (2 rodenticide; 1 heparin) 2 
(hemothorax, 
bicavity 
hemorrhagic 
effusion) 
0 
I I I N  4(neoplasia, prostatitis; 
pneumonia; sepsis) 
1 
(hematuria#) 
1 (PTE) 
I I  I I 9 (Mucocele*, pneumonia, post 
GDV surgery, necrotizing 
steatitis hepatoma; cystitis, PSS 
with MVD, ITP, intestinal 
perforation) 
3 (Major 
surgical 
bleeding; 
hematuria#, 
petechiation 
and 
ecchymosis) 
0 
N I R (1) 
or N 
(1) 
R 2 (Nephrotic syndrome; vWD) 1 (large 
hematoma at 
previous 
surgical site) 
1 (Multi-
organ 
thrombi) 
 
Figure 8. Traces from clinical cases. Displayed are a normocoagulable trace from a dog with a 
congenital portosystemic shunt and no reported excessive bleeding during surgical correction (purple); 
a hypocoagulable trace from a dog with hemoabdomen secondary to rodenticide ingestion (red); 
hypofibrinolytic trace from a dog with vWF deficiency (blue) and a hyperfibrinolytic and 
hypercoagulable trace from a dog with a hepatoma that bled heavily during surgery (green). 
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Table 5: Clinical details and fibrinolysis assay results for 20 abnormal dogs. () Reference range; (*) Accurate platelet count could not be obtained due to 
clumping, appeared decreased. NA: value not reported within 24 hours of fibrinolysis sample collection. INR: Inflection not reached. IP: inadequate peak (when 
peak OD<50mAU, no further values were calculated to prevent over-interpretation of random variations in OD. Lysis velocity: where 50% lysis was not reached 
within 1 hour, lysis velocity was calculated by [(Peak OD-OD at 1 hour)/(3600s-time to peak)]. PTE: pulmonary thromboembolism. Values may be falsely 
decreased by interference. Above RI. Below RI. 
Complaint Visible 
interferents 
Clinical signs of 
coagulation disturbance 
Platelet 
count 
(x103/µl) 
(200-500) 
D-Dimer 
(ng/ml) 
 
(0-400) 
PT 
(s) 
 
(5.5-
7.9) 
aPTT (s) 
 
 
(10.4-
19.3) 
Peak 
(mAU) 
 
(56-155) 
AUC 
(mAU.s) 
 
(21606-
82941) 
FV 
(mAU/s) 
 
(0.26-
0.92) 
 
LV 
(mAU/s) 
 
(0.06-
0.24) 
Liver 
abscess and 
septic 
abdomen 
None No Decreased
* 
NA 8.8 17.6 468 812854 2.49 0.15 
Porto- 
systemic 
shunt 
None No 224 708 8.2 14.4 105 53920 0.62 0.13 
IMHA 
receiving 
heparin 
None No 188 NA 7.9 19.3 3 556 INR INR 
Suspected 
rodenticide 
toxicity 
None Bicavity hemorrhagic 
effusions 
190 NA >50 83.6 1 56 INR INR 
Jejunal 
perforation 
due to 
foreign 
body 
ingestion 
None No 39 NA 8.4 21.0 514 675264 3.2 0.32 
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Table 5 continued 
Complaint Visible 
interferents 
Clinical signs of 
coagulation disturbance 
Platelet 
count 
(x103/µl) 
(200-500) 
D-Dimer 
(ng/ml) 
 
(0-400) 
PT 
(s) 
 
(5.5-
7.9) 
aPTT (s) 
 
 
(10.4-
19.3) 
Peak 
(mAU) 
 
(56-155) 
AUC 
(mAU.s) 
 
(21606-
82941) 
FV 
(mAU/s) 
 
(0.26-
0.92) 
 
LV 
(mAU/s) 
 
(0.06-
0.24) 
Hepatoma None Significant blood loss 
resulting in hypotension and 
requiring blood transfusion 
during surgical resection 
280 NA 7.0 20.5 692 288956 2.79 1.28 
Nephrotic 
syndrome 
None Necropsy confirmation of 
large atrial thrombus and 
thrombi in medium sized 
arteries of multiple organs 
141 9.6 20.8 79.6 77.5 264840 0.04 0.001 
Aspiration 
pneumonia, 
None Within 48h of sample 
collection, suspected PTE 
based on blood gas and 
radiographs and acute renal 
failure 
217 
(reduced 
to 116 
over next 
24 hours) 
469 
(increased 
to 4062 
within 
24hours) 
25.7 120 602 1626780 1.34 0.06 
Aspiration 
pneumonia 
None No 50 447 6.7 15.8 736 544528 3.37 0.57 
Prostatitis None Hematuria and penile 
petechiation 
215 8.4 13.2 NA 1044 3255548 3.95 0.07 
Leiomyosar
-coma 
None No 555 8.3 12.6 NA 476 
 
1240504 1.84 0.11 
vWD; large 
hematoma 
post 
operatively 
None Hematoma 249 7.2 19.1 NA 108 339110 0.29 0.007 
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Table 5 continued 
Complaint Visible 
interferents 
Clinical signs of 
coagulation disturbance 
Platelet 
count 
(x103/µl) 
(200-500) 
D-Dimer 
(ng/ml) 
 
(0-400) 
PT 
(s) 
 
(5.5-
7.9) 
aPTT (s) 
 
 
(10.4-
19.3) 
Peak 
(mAU) 
 
(56-155) 
AUC 
(mAU.s) 
 
(21606-
82941) 
FV 
(mAU/s) 
 
(0.26-
0.92) 
 
LV 
(mAU/s) 
 
(0.06-
0.24) 
Biliary 
mucocele, 
Liver 
abscess, 
Peritonitis, 
aspiration 
pneumonia 
Icterus: 
bilirubin 
2.6mg/dl 
No 52 NA 8.7 17.2 463 433496 2.04 0.318 
Congenital 
PSS with 
early 
cirrhosis 
None No 374 NA 7.9 16.6 132.5 58764 0.70 0.21 
PSS and 
microvascul
ar dysplasia 
None No 207 NA 10.6 18.8 265 89912 1.31 0.60 
ITP None Petechiation and ecchymosis 47 739 7.3 10.6 253.5 78740 1.12 0.71 
GDV  None No 131 1031 8.5 22.6 597.5 294212 2.96 0.88 
Necrotizing 
steatitis 
None No 342 NA 8.6 18.1 597.5 365138 2.13 0.70 
Rodenticide 
toxicity 
None Hemothorax 167 NA >50 47.8 21 
 
17200 
 
IP IP 
Urinary 
calculi and 
hemorrhagic 
cystitis 
None Hematuria 97 3122 9.4 15 521.5 201304 2.46 1.01 
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Discussion 
     The simple spectrophotometric assay described in this report evaluates fibrinolysis in 
small volume canine plasma samples using commercially available reagents and routinely 
available equipment. Method validation revealed acceptable inter- and intra-assay 
variability and the ability to analyze samples with mild hemolysis and icterus. Regression 
analyses showed that the parameters peak OD, AUC, and FV were strongly related to 
plasma fibrinogen content. However, LV appeared to be independent of fibrinogen and 
preliminary data suggests it represents a useful measure of fibrinolysis. 
     This assay shares similarities with a number of other spectrophotometric clot lysis 
assays. One such assay is the Overall Hemostasis Potential (OHP) which has been 
recently adapted for dogs (He S 2001) (Dengate AL 2013). The OHP uses a low 
concentration of thrombin to activate coagulation factors and co-factors, however the 
disadvantages of this approach include wide inter-individual variations in the rate of 
contact pathway activation and the influence of plasma fibrinogen content on the fibrin 
fibril structure and resultant turbidity endpoint (He S 2001) (He S 2007). The group that 
originally described the OHP in humans has therefore revised its configuration to use a 
tissue factor trigger reagent, and a more complex analysis based on plotting change in 
OD/s against time (He S 2007). We did not directly apply this data analysis method 
because the lower peak absorbance in dog versus human plasma results in very small 
changes in OD/s creating unacceptable imprecision (data not shown). 
     While tissue factor triggers are also used in other human turbidometric fibrinolysis 
assays, modifications are required to adapt any of these assays for veterinary patients. For 
example, the Clot Formation and Lysis assay (CloFAL) is based on concurrent 
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measurement of a human control plasma (Goldenberg NA 2005). Many assays require 
larger volumes of plasma as higher proportions of plasma are used in the reaction mixture 
(e.g. 67% to 95%) compared with our assay configured with (38%) (Zucker M 2014) 
(Gawlikowski T 2013) (Smith SA 2008). Increasing plasma dilution is advantageous for 
a clinical assay because of reduced influence of colorimetric interferents and the ability to 
modify the diluent reagent to include additives such as heparinase to use the assay in 
heparin-treated patients (Vonk AB 2014). 
     Spectrophotometric assays have advantages over viscoelastic testing, the other main 
clinical approach for assessing altered fibrinolysis. The equipment required is relatively 
inexpensive and such assays are readily automated. Unlike whole blood assays, the 
plasma based assay we describe can be performed on frozen samples (Furlanello T 2006) 
(Flatland B 2014). Furthermore, hematocrit does not directly influence the 
spectrophotometric fibrinolysis assay parameters, whereas hematocrit has a well-
documented effect on whole blood viscoelastic methods. This is a major disadvantage 
since the viscoelastic assay parameters may not reflect in vivo coagulation or fibrinolysis 
in patients with blood loss anemia or sighthounds with physiologically elevated 
hematocrit (Goggs R 2012) (Vilar P 2008) (Brooks AC 2014 ). It should be noted that the 
serial dilutions used in the current study to adjust PCV ex vivo do not reproduce the 
altered citrate to plasma ratio seen in patients with abnormal hematocrits. However, the 
effect of relative citrate deficiency in anemia is negligible for PT or aPTT (Siegel JE 
1998), and the clinical relevance of citrate excess in hemoconcentrated patients is 
contentious (Austin M 2013). 
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     The limitations of spectrophotometric analyses include colorimetric interference from 
hemolysis or icterus and random light scatter introduced by lipemia (Dimeski G 2008). 
Our results revealed that mild icterus or hemolysis did not introduce statistically 
significant interference, however more clinical data is required to define a meaningful 
total allowable error and determine levels of interference that preclude analysis. An 
inherent limitation of plasma based assays is their inability to assess erythrocyte and 
platelet contributions to clot formation and lysis (van Geffen M 2012). Furthermore, 
viscoelastic and spectrophotometric assays fail to integrate the effects of blood flow and 
are relatively insensitive to those components of the coagulation system which interact 
with endothelial proteins such as thrombomodulin (van Geffen M 2012). For example, 
both TEG and CloFAL do not reliably detect factor V Leiden mutation, which results in 
impaired protein C activation (Bombardier C 2012) (Koopman K 2009). 
     The qualitative and dynamic parameters of spectrophotometric fibrinolysis assays 
contrast with the currently available assays of fibrinolysis that measure end products of 
fibrin degradation (e.g. D-Dimers) (Olsen JD 2015) or assess single components in 
isolation (e.g. plasminogen activity). These assays are useful for detecting, for example, 
congenital deficiencies of fibrinolytic pathway proteins (Torres MD 2009) but are of 
limited value in interpreting the complex balance between pro- and anti- fibrinolytic 
factors in acquired conditions such as hepatic failure (Tripodi A 2011). Remaining assays 
are largely research tools. For example, the euglobulin lysis time is too time consuming 
for routine clinical use and is of limited physiological relevance as it uses a plasma 
fraction from which plasminogen inhibitors have been largely depleted (Smith AA 2003). 
There are a number of novel global coagulation assays, such as simultaneous thrombin 
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and plasmin generation techniques or magnetic resonance imaging, which offer exciting 
future possibilities but are not currently clinically available (van Geffen M 2011) (Skewis 
LR 2014). 
     Larger scale analysis of sick dogs and correlation with clinical evidence of bleeding 
and thrombosis are clearly needed, but initial evidence suggests that the current assay 
recognizes altered fibrinolysis. It is intriguing that one of the two hypofibrinolytic dogs 
was diagnosed with multi-organ thrombosis and three of the nine hyperfibrinolytic dogs 
had evidence of bleeding. The hypofibrinolytic dog with thrombosis had nephrotic 
syndrome, which in humans is associated with reductions in plasminogen directly 
proportional to proteinuria (Singhal K 2006). Reduced albumin also contributes to 
impaired fibrinolysis as it is a cofactor in the binding of plasminogen to fibrin and 
subsequent interaction with tPA (Singhal K 2006). The other dog with reduced 
fibrinolysis was referred for management of a post-surgical hematoma. Bleeding is not an 
expected result of hypofibrinolysis, but this dog suffered from vWF deficiency, and vWF 
has been shown to accelerate fibrinolysis in vitro (Marchi R 2015).  
     Increases in one or more clot formation parameter was common among clinical cases. 
We are however cautious about the value of these parameters, FV, peak OD and AUC, in 
detecting alterations in coagulation unrelated to fibrinolysis. The rodenticide cases show 
the assay is sensitive to marked hypocoagulability, but this was also detected by routine 
coagulation times. Detection of more subtle hypocoagulability remains untested, and 
concerns about the ability of global turbidity or absorbance assays to detect mild 
hemophilia in the face of hyperfibrinogenemia have been previously raised (Goldenberg 
NA 2005). Equally, the strong relationships between FV, AUC or peak OD and 
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fibrinogen may limit reliable detection of hypercoagulability because, while 
hyperfibrinogenemia is a population risk factor for various thrombotic disorders (Ariens 
RA 2013) it appears of little value in predicting thrombosis in an individual patient 
(Bartlett JW 2009). This reflects the many other factors, including thrombin generation, 
fibrin structure and endogenous pro- and anti-coagulant activity, contributing to clot 
formation and resistance to fibrinolysis (Harvey JW 2012). The assay will be useful for 
predicting thrombosis due to mechanisms other than hypofibrinolysis only if it detects the 
influence of such factors in the face of hyperfibrinogenemia. We are hopeful that this will 
be the case because hypercoaguability was detected in both normo- and 
hyperfibrinogenemic pediatric venous thromboembolism patients using the similar 
CloFAL assay (Bombardier C 2012).  
     We also suggest caution in transferring the reference interval to other situations. While 
useful in providing evidence that the assay can distinguish healthy versus sick dogs, it is 
based on the minimum number of animals recommended by the ASVCP (Friedrichs KR 
2012). Even when analyzed appropriately, small samples may not be fully representative 
of the general reference population (Geffré A 2009). Furthermore, all samples were 
analyzed by a single individual, on a single instrument using a single lot of each reagent.  
     Further investigations of pre-analytical influences are also clearly required before the 
assay could be used clinically. Weaknesses in the current study include lack of control 
over collection and processing of the clinical samples and the prolonged storage of some 
of the samples. Storage time was similar for control and clinical samples, so is unlikely to 
underlie the differences between of the two groups. Regression analysis also shows that if 
storage effects are present, they are not sufficient to introduce noticeable trends in results 
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for any parameter. However, this is likely to be less sensitive to small biases introduced 
by storage than repeated analysis of aliquots of a single sample.  
     In conclusion, we describe a simple fibrinolysis assay for use in dog plasma and 
present preliminary data from dogs with hemostatic and inflammatory disorders whose 
abnormal fibrinolysis parameters are compatible with enhanced or impaired fibrinolysis. 
We believe the technique merits further study to determine if it can predict bleeding and 
thrombosis in conditions known to result in disturbed fibrinolysis, such as DIC, venous or 
arterial thrombosis, cirrhosis, trauma and neoplasia. 
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CHAPTER 4. CANINE NEUTROPHIL EXTRACELLULAR TRAPS ENHANCE 
PLASMA CLOT FORMATION AND IMPAIR FIBRINOLYSIS 
A manuscript for submission to The Veterinary Journal 
Unity Jeffery,1 Dana LeVine2,3 
Abstract 
     Neutrophil extracellular traps (NETs) are webs of DNA and protein released in 
response to inflammatory and infectious stimuli. NET-releasing neutrophils promote 
thrombus growth, but there is evidence NETs may be less pro-thrombotic when not 
closely associated with neutrophils. This is potentially clinically relevant because NET 
fragments circulate during infectious and inflammatory disease. This study tested the 
hypothesis that canine NETs promote clot formation and impair clot lysis even in the 
absence of neutrophils.  
     Phorbol 12-myristate 13-acetate-induced NETs were added to re-calcified pooled 
canine platelet-poor plasma or fibrinogen with tissue-factor and tissue plasminogen 
activator or thrombin respectively. Clot formation and lysis were measured 
spectrophotometrically. NETs did not alter kinetics of fibrin clot formation. For plasma 
clots, NETs increased maximum clot formation velocity (192mAU/min +/-18 p=0.001) 
and time to 50% clot lysis (mean 448s +/-43 p=0.009) compared with supernatants from 
                                                           
1 Department of Veterinary Microbiology and Preventative Medicine, College of Veterinary Medicine, 
Iowa State University 
2 Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University 
3 Dana LeVine supervised the project; Unity Jeffery performed laboratory investigations, analyzed data and 
prepared the manuscript. 
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non-stimulated neutrophils (maximum formation velocity: 165mAU+/- 12; 50% lysis 
time 395s +/- 38). Peak optical density (pANOVA=0.288) and area under the curve 
(pANOVA=0.519) were not significantly altered. Increases in time to 50% clot lysis but not 
maximum formation velocity were reduced by DNase, suggesting the former was 
principally mediated by DNA and the later by protein. Candidate proteins responsible 
included histones and elastase. Elastase activity was greatly reduced by dog plasma and 
addition of histones (250µg/ml) to plasma did not increase formation velocity.  
     This study shows canine NETs enhance clot formation and impair clot lysis in canine 
platelet-poor plasma. Further investigation of NETs as triggers of thrombosis in canine 
patients is warranted. 
Introduction 
     In dogs, thrombosis is frequently a complication of another, often inflammatory 
disease (Palmer et al. 1998; Laurenson et al. 2010). Neutrophil extracellular traps (NETs) 
are webs of DNA and neutrophil proteins with multiple pro-thrombotic properties (Fig. 1) 
(Massberg et al. 2010, Brill et al. 2012, von Brühl et al. 2012) (Gould et al. 2014, Varjú 
et al. 2015 ). NETs are released in response to many inflammatory and infectious stimuli 
(Goldmann et al. 2013 ), so are a potential link between inflammation and thrombosis 
(Martinod et al. 2014).  
     Much of the evidence that NETs are pro-thrombotic derives from studies of 
neutrophils stimulated to release NETs (Gould et al. 2014, Varjú et al. 2015). Murine 
thrombosis models show recruitment of neutrophils and subsequent release of NETs at 
sites of vascular injury promotes thrombus growth (Massberg et al. 2010; von Brühl et al. 
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2012). Pro-coagulant and anti-fibrinolytic effects of NETing neutrophils have been 
replicated in vitro using human plasma (Gould et al. 2014, Varjú et al. 2015), and these 
effects can be reduced by antagonizing DNA or protein mediated pro-coagulant 
mechanisms using agents such as DNase or anti-toll-like receptor antibodies (Gould et al. 
2014 ).  
     NET fragments also circulate independently of neutrophils in infectious or 
inflammatory disease (Hirose et al. 2014). Few studies have addressed the role of NETs 
in the absence of neutrophils (Huang et al. 2015, Yang et al. 2015), but there is some 
evidence that isolated NETs are only pro-coagulant if derived from a diseased, rather than 
healthy, human (Yang et al. 2015).  Reported pro-coagulant effects of NETs may be lost 
when NETs are not protected from endogenous inhibitors by near-by neutrophils (e.g. 
tissue factor pathway inhibitor degradation by elastase (Massberg et al. 2010, Yipp and 
Kubes 2013 )), or if NETs circulate as relatively small fragments (e.g. DNA binding of 
fibrinolytic proteins (Gould et al. 2015 )). Determining the pro-coagulant effects of 
NETs, rather than NETing neutrophils, requires further investigation. 
     Differences between the pro-coagulant properties of NETs in the presence or absence 
of neutrophils may have considerable clinical relevance. Although markers associated 
with NET formation are elevated in many diseases (Sur Chowdhury et al. 2014, Zhang et 
al. 2014, Hashiba et al. 2015, Jeffery et al. 2015, Thålin et al. 2016), if circulating NETs 
lack pro-thrombotic properties, they are unlikely to be predictors of thrombosis or 
valuable anti-thrombotic therapeutic targets.  
     The current study tested the ability of canine NET fragments to enhance plasma clot 
formation and impair clot lysis, and by comparing the action of NETs before and after 
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digestion of DNA sought to determine if these effects were predominantly protein or 
DNA mediated.  
Methods 
Generating cell-free NETs 
     Blood was collected into EDTA from healthy pet dogs via cephalic or jugular 
venipuncture (Iowa State Institutional Animal Care and Use Committee protocol 12-13-
7687-K). 
     Neutrophils were isolated as previously described (Jeffery et al. 2015). After washing 
in PBS, neutrophils were seeded in Roswell Park Memorial Institute media (RPMI, 0.5% 
fetal calf serum, Gibco) in a 12 well polystyrene plate; incubated for 1 hour at 39oC to 
 
Fig. 1. Neutrophils release NETs, which promote thrombus growth and impair lysis through 
multiple mechanisms. The role of NETs in canine thrombosis has not been investigated, but a 
number of pro-thrombotic effects have been identified in human and murine studies. The exact 
nature of NETs likely varies with disease state but at least in sepsis, NETs contain tissue factor 
(TF) and so activate the tissue factor pathway of the coagulation cascade (Kambas et al. 2012). 
Negatively charged DNA activates the contact pathway (Gould et al., 2014 ). NET proteins such as 
histones and elastase inactivate endogenous anti-coagulants including tissue factor pathway 
inhibitor (TFPI) (Massberg et al. 2010) and impair activation of protein C (aPC) (Ammollo et al. 
2011). Histones also activate platelets (Gould et al. 2014) and damage endothelial cells 
(Saffarzadeh et al, 2012). DNA impairs fibrinolysis through multiple mechanisms, including 
forming inhibitory complexes with plasmin and fibrin (Gould et al. 2015). Histones may contribute 
to impaired fibrinolysis (Varjú et al. 2015).  
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allow attachment before 2 hours incubation with the NET agonist Phorbol 12-myristate 
13-acetate (PMA, Sigma Aldrich, final concentration 7µM). Supernatants containing 
NETs were obtained using a published method for generating large NET fragments 
(Barrientos et al., 2013). Briefly, culture medium was drawn off and replaced with 400µl 
of the restriction enzyme Alu1 (ThermoFisher, 4U/ml). After 30 minutes, supernatants 
were collected and centrifuged to remove intact cells.  
     Controls from non-stimulated neutrophils were prepared identically, except PMA was 
replaced by an equal volume of RPMI. To control for residual PMA or RPMI 
contaminating the ALU1 supernatants, PMA controls were prepared identically to the 
NETosis samples except that neutrophils were not present. To investigate the effects of 
intact NETs versus their protein components, a subset of ALU1 digested NETs were 
incubated with 100U/ml (final concentration) DNase 1 (Pulmozyme, Genentech) at 37oC 
for 30 minutes. To control for direct effects of DNase, DNase was added to ALU1 in the 
absence of NETs.  
DNA and protein quantification 
     DNA was measured in supernatants using PicoGreen (ThermoFisher) and protein 
concentration by a bicinchoninic acid assay (PierceTM BCA Protein Assay Kit) according 
to the manufacturers’ instructions.  
Assessing DNA digestion  
     To confirm ALU1 generates large fragments and DNase effectively degrades canine 
DNA, canine leukocytes were lysed by overnight incubation at 37C in lysis buffer 
(10mM TrisHCl, pH 8.5; 5mM EDTA; 0.2% SDS; 200mM NaCl in DNase free water). 
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DNA was purified from lysed cells and NET supernatants using silica membrane 
microcentrifuge tubes (QIAamp DNA Blood Mini Kit, Qiagen) according to the 
manufacturers’ instructions and concentrated by elution into half the volume of the 
original sample. Genomic DNA was subjected to ALU1 or DNase digestion at the same 
concentrations as in the NET experiments. Genomic DNA and NETs were run on a 0.5% 
agarose gel at 100V and imaged by ethidium bromide (Pierce) fluorescence. 
Effect of ALU1 and DNase digested NETs on fibrin or plasma clot formation and 
lysis  
     For plasma clot studies, pooled platelet poor plasma from healthy dogs supplemented 
with bovine plasminogen-depleted fibrinogen (Enzyme Research Laboratories, final 
concentration 4.2mg/ml) was incubated with an equal volume of NETs, DNase digested 
NETs or supernatants from non-stimulated cells for 15 minutes at room temperature. Clot 
formation and lysis were initiated by recombinant tissue factor (Dade Innovin, final 
dilution 1:10000), calcium chloride (final concentration 5mM), and recombinant tissue 
plasminogen activator (tPA, Activase, Genentech, 100µg/ml). 
     For fibrin clots, bovine plasminogen-depleted fibrinogen (final concentration 
4.5mg/ml) was incubated with an equal volume of NETs, DNase digested NETs or 
supernatants from non-stimulated cells. Clotting was induced by bovine thrombin in 
HEPES saline (final concentration 2U/ml) and calcium chloride in HEPES saline (final 
concentration 5mM). 
     Immediately after adding agonists, light absorbance (405nm) was measured every 10s 
for 25 minutes using a microplate reader (Biotek Synergy). Fibrin clots were blanked by 
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subtracting the absorbance of wells in which thrombin and calcium were replaced by 
HEPES saline. Plasma clots were blanked by subtracting the lowest recorded optical 
density (OD) for each well. Maximum formation velocity was calculated from a line of 
best fit based on 15 to 20 points; peak OD was the maximum absorbance achieved and 
area under the curve (AUC) calculated using the polyhedral method (Zucker et al. 2014 ). 
For plasma clots, 50% lysis time was the time from peak OD to a 50% reduction in OD. 
     Five to six technical replicates were prepared for each dog and the average value used 
in statistical analysis. To test for a significant effect of DNase or residual PMA/RPMI on 
fibrin or plasma clotting kinetics, five to six technical replicates of each control and 
ALU1 alone were performed.  
Determination of fibril thickness by turbidity 
     Fibrin fiber radius was estimated from turbidity using the method described by 
Yeromonahos et al. (2010). Fibrin clots were prepared as described and allowed to 
mature for 2 hours at room temperature. Light absorbance was measured at 400 to 
800nm. After subtraction of blanks prepared identically except thrombin and calcium 
were replaced by HEPES saline, turbidity (τ) was calculated by τ=OD.ln(10). τ λ5 was 
plotted against λ2 and the fiber radius (r, cm) calculated from the line of best fit using the 
equation τ λ5=Aµ(λ2-Br2) rearranged to produce r=√( intercept/slope*B) where λ is the 
wavelength of light (cm) and B is equal to 184/154 π2ns2 where ns=1.33. 
Effect of DNA or histones alone on clot formation and lysis 
     To investigate effects of DNA on clot formation and lysis, genomic DNA was 
extracted from canine leukocytes as above and eluted into saline (final concentration 
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0.9%). Plasma clots were prepared and analyzed as above, except NETs were replaced 
with either 50ul of saline or 50ul of DNA stock solution (final concentrations 200ng/ml 
or 1ug/ml). Eight technical replicates of each condition were performed.  
     To investigate effects of histones on clot formation, purified histones (H1,2,3,4; Sigma 
Aldrich) from calf thymus or PBS were added in a 1:1 ratio to pooled, fibrinogen-
supplemented normal dog plasma (end histone concentration 150ng/ml, approximately 
the concentration present in NET supernatants estimated from DNA concentration). 
Clotting was initiated with tissue factor and calcium chloride as above and light 
absorbance measured every 10s for 25 minutes. Maximum formation velocity was 
calculated using a line of best fit based on 15 points. Fourteen technical replicates were 
prepared for each condition.  
Elastase activity in dog plasma 
     Human neutrophil elastase (Sigma Aldrich, 1U-0.125U/ml) was incubated in a 
polypropylene 96 well plate in a 1:1 ratio with either PBS or pooled, normal dog plasma 
for 30 minutes at 37C before addition of the elastase colorimetric substrate, N-Succinyl-
Ala-Ala-Ala-p-nitroanilide (Sigma Aldrich, final concentration 1.3mg/ml in 100mM Tris 
HCl, pH8). Light absorbance at 410nm was measured every 25s for 10 minutes, and 
elastase activity measured by the increase in light absorbance between the first and last 
reading. To determine if NETs prevent inhibition of elastase, plasma was also incubated 
with PBS or NETs (1:2 ratio) for 30 minutes before addition of 1U/ml elastase.  
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Statistical analysis 
     Repeated-measures ANOVA was used to compare between dogs for supernatant DNA 
concentrations, fibrin and plasma clot studies. One-way ANOVA was used to assess the 
effect of DNA on plasma clotting kinetics and to test for effects of DNase or residual 
RPMI/PMA on clotting studies.  Multiple comparisons with Tukey’s correction were 
performed if alphaANOVA<0.05. Unpaired t-test was used to assess the effect of histones 
on maximum formation velocity and the effect of NETs on plasma’s inhibition of 
elastase. Analytical coefficients of variation were calculated from 10 replicates to which 
PBS (rather than NETs or controls) were added. Analysis was performed using GraphPad 
Prism 6.  
Results 
PMA increases DNA and protein concentrations of supernatants 
     Mean protein concentration of PMA stimulated supernatants was 55µg/ml (s.d. 21) 
and was below the linear range of the assay (20µg/ml) for supernatants from non-
stimulated cells (n=5 dogs). Mean DNA concentration was higher in Alu1 digested, PMA 
stimulated supernatants (mean 401ng/ml s.d. 94) than Alu1 digested supernatants from 
non-stimulated cells (mean 106ng/ml; s.d. 49; p=0.0004) (Fig. 2C). DNase digestion of 
PMA stimulated supernatants reduced DNA concentration (mean 113ng/ml; s.d. 18; 
p=0.0005) to levels not significantly different from non-stimulated supernatants 
(p=0.9873). Agarose electrophoresis revealed DNA in supernatants from PMA and 
ALU1 was predominantly between 600 and 1000bp, equivalent to approximately 3 to 5 
nucleosome units in length and in the range known to bind human fibrin and plasmin 
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(Gould et al. 2015 )(Fig. 2B). DNase digestion successfully removed large DNA 
fragments (Fig. 2A).  
     As these data are consistent with successful induction of NETosis and collection of 
NET fragments by Alu1 digestion, supernatants from PMA stimulated cells will be 
referred to as NETs for the remainder of the paper.  
NETs increase the speed of plasma clot formation and slow lysis 
     As summarized in Table 1, NETs increase maximum formation velocity and 50% lysis 
time. There were no significant differences (pANOVA≥0.717) between clots formed in the 
 
Fig. 2. Effects of restriction enzymes on canine DNA. A. Genomic DNA before and after 
digestion, imaged by ethidium bromide fluorescence. Undigested canine genomic DNA produces a 
high molecular weight band. Digestion with Alu1 (4U/ml) produces fragments of variable size 
resulting in a smeared band. DNase almost completely digests genomic DNA, resulting a faint low 
molecular weight band. B. Supernatants from neutrophils treated with PMA (7µM) and Alu1 
(4U/ml) contain DNA that is predominantly between approximately 600 and 1000 base pairs. C. 
DNA concentration, quantified using the nucleic acid dye Picogreen, was higher in supernatants 
from cells treated with PMA and Alu1 than from cells treated with Alu1 alone. DNase digestion 
reduced DNA concentration in PMA stimulated cells. * p<0.001, n=5 dogs, error bars: mean and 
s.d.  
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presence of Alu1, residual PMA or DNase (5-6 technical replicates). The CV of 10 
technical replicates was 5% (maximum formation velocity); 3% (Peak OD); 6% (AUC) 
and 4% (50% lysis time). 
Table 1. Effect of NETs on tissue-factor induced plasma clot formation and tPA induced clot lysis. 
Five to six technical replicates were performed for each condition, and the average value for each dog 
(n=5) compared by a repeated-measures one-way ANOVA. If the ANOVA was significant (p<0.05), 
conditions were compared by Tukey’s multiple comparison test. Results were considered significant 
(shown in bold) if the multiplicity adjusted p-value was <0.05.  DNase/Alu1 and RPMI/PMA/Alu1 
containing controls were not significant different from Alu1 alone (one-way ANOVA, 5-6 technical 
replicates, pANOVA≥0.717) 
Parameter Mean +/- standard deviation p value 
Non-
stimulated 
Alu1 
NETs 
DNase 
NETs 
ANOVA Non-
stimulated 
vs Alu1 
NETs 
Non-
stimulated 
vs DNase 
NETs 
Alu1 
NETs vs 
DNase 
NETs 
Peak OD 
(AU) 
0.504 
(0.017) 
0.503 
(0.025) 
0.495 
(0.027) 
0.288 - - - 
AUC 
(OD.min) 
317 (30) 324 (25) 317 (13) 0.519 - - - 
Maximum 
formation 
velocity 
(mOD/min) 
165 (12) 192 (18) 184 (15) 0.0012 0.0011 0.0089 0.2747 
50% lysis 
time (s) 
395 (38) 448 (43) 428 (37) 0.0112 0.0093 0.0826 0.3333 
 
DNA alone slows clot lysis and has a concentration dependent effect on plasma clot 
kinetics 
     To explore the discrepancy between the reported ability of DNA to activate the 
contact pathway and the lack of effect of DNase on maximum clot velocity, kinetic 
assays were repeated in the presence of DNA. At 200ng/ml (approximately equal to the 
DNA concentration using Alu1 NETs), DNA increased time to 50% clot lysis but did not 
significantly alter any other parameter. At 1µg/ml, DNA increased time to 50% clot lysis 
and maximum clot formation velocity (Table 2).  
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Effect of DNA alone on tissue-factor induced plasma clot formation and tPA induced clot lysis.  Eight 
technical replicates were performed for each DNA concentration and results compared using a one-way 
ANOVA. If the ANOVA was significant (p<0.05), conditions were compared by Tukey’s multiple 
comparison test. Results were considered significant (shown in bold) if the multiplicity adjusted p-value 
was <0.05. 
Parameter Mean +/- standard deviation p value 
0ng/ml 
DNA 
200ng/ml 
DNA 
1µg/ml 
DNA 
ANOVA 0ng/ml 
vs. 
200ng/ml 
0ng/ml 
vs. 
1µg/ml 
200ng/ml 
vs. 
1µg/ml 
Peak OD 
(AU) 
0.541 
(0.079) 
0.519 
(0.060) 
0.537 
(0.056) 
0.055 - - - 
AUC 
(OD.min) 
470 
(109) 
462 (91) 482 (99) 0.251 - - - 
Maximum 
formation 
velocity 
(mOD/min) 
129 (12) 123(11) 137 (9) 0.0008 0.106 0.038 0.0006 
50% lysis 
time (s) 
547 (99) 570 (104) 600 
(106) 
<0.0001 0.041 <0.0001 0.0076 
 
Interactions between NET proteins and plasma 
     After 30 minutes incubation with canine plasma, elastase activity was undetectable for 
all elastase concentrations tested (Fig. 3A). Pre-incubation of plasma with NETs did not 
reverse inhibition of elastase activity (Fig. 3B).  
     Influence of elastase on maximum formation velocity was not investigated further. 
Mean maximum formation velocity was not significantly increased by addition of 
 
Fig. 3. Elastase is inactivated by pre-incubation with canine plasma. A. Human elastase was 
incubated with PBS (circles) or pooled normal dog plasma (squares) before addition of the 
colorimetric elastase substrate, N-Succinyl-Ala-Ala-Ala-p-nitroanilide. Elastase activity, as 
measured by change in absorbance at 410nm over 10 minutes, was almost completely abolished by 
pre-incubation with plasma. B. Addition of NETs to plasma prior to incubation with elastase 
(1U/ml) did not significantly increase change in absorbance (p=0.071; n=4 technical replicates).  
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150ng/ml purified histones (mean maximum formation velocity histones: 101 mAU/min 
s.d. 12.03; PBS: 98.86 s.d. 14.16, p=0.66). 
NETs do not alter the kinetics of fibrin clot formation or fibrin fiber radius 
     There were no differences (pANOVA >0.05) between kinetics of fibrin clots formation in 
the presence of NETs or DNase digested NETs and non-stimulated supernatants for 
AUC, peak OD or maximum formation velocity (Table 3, n=4 dogs). There were no 
differences (pANOVA >0.09) between clots formed in the presence of ALU1, residual PMA 
or DNase (5 technical replicates). The CV of the method was ≤3% for all parameters 
based on 10 technical replicates.  
Table 3. Effect of NETs on thrombin-induced clotting of purified fibrinogen. Five to six technical 
replicates were performed for each condition, and the average value for each dog (n=4) compared by a 
repeated-measures one-way ANOVA. Comparisons between conditions were not performed because 
pANOVA >0.05.  DNase/ALU1 and RPMI/PMA/ALU1 containing controls were not significant different 
from ALU1 alone (one-way ANOVA, 5 technical replicates, pANOVA>0.09). 
Parameter Mean +/- standard deviation pANOVA 
Non-
stimulated 
Alu1 
NETs 
DNase 
NETs 
Peak OD 
(AU) 
1.544 
(0.089) 
1.517 
(0.105) 
1.555 
(0.086) 
0.180 
AUC 
(OD.min) 
1643 (124) 1640 
(142) 
1665 
(117) 
0.306 
Maximum 
formation 
velocity 
(mOD/min) 
293 (24) 291 (29) 295 (23) 0.790 
 
     There was no detectable difference (pANOVA=0.2117) between the mean fiber radius of 
clots prepared in the presence of NETs (mean 73nm; s.d. 3.9) or DNase digested NETs 
(mean 73nm; s.d. 4.5) and non-stimulated supernatants (mean: 75nm; s.d. 3.0) (n=4 
dogs). There was no evidence of an effect of ALU1, PMA/RPMI or DNase on fibrin clot 
radius (pANOVA=0.5153; n=5 technical replicates). The CV for the method was 1.7% 
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based on 10 clots formed with PBS.  The R2 for the line of best fit from which radius 
were calculated was >0.990 in all cases, confirming that Yeromonahos et al.’s (2010) 
model adequately fitted the data.  
Discussion 
     Canine NET fragments increased maximum clot formation velocity and slowed clot 
lysis in platelet poor plasma. Increased maximum clot formation velocity but not slowed 
lysis remained significant after DNase digestion of NETs, consistent with the former 
effect being largely mediated by NET proteins and the latter by DNA. The effect of NETs 
on maximum clot formation velocity was absent when added to purified fibrinogen and 
thrombin, and there was no turbidimetrically detectable effect of NETs on fibrin clot 
structure. This suggests that in this in vitro model, NET proteins did not increase clot 
formation velocity by direct interactions with thrombin or fibrinogen. However, bovine 
fibrinogen and thrombin were used for fibrin clot studies so interactions between NETs, 
canine fibrinogen and thrombin cannot be completely ruled out.  The protein(s) 
responsible for increasing maximum clot formation velocity in the presence of NETs 
were not identified, but at tested concentrations histones alone were not responsible and 
elastase activity was minimal. 
     To the authors’ knowledge, the effect of NET fragments on fibrinolysis has not been 
previously investigated, but the ability of canine NET fragments to slow clot lysis is 
similar to the effect of NETing neutrophils on human plasma (Varjú et al. 2015 ). 
Impaired fibrinolysis by both canine NET fragments and NETing human neutrophils is 
largely mediated by DNA (Varjú et al. 2015 ). The ability of DNA to impair fibrinolysis 
appears multi-factorial, with evidence that DNA intercalates with fibrin providing a 
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scaffold stabilizing clot structure (Fuchs et al. 2010); reduces plasminogen activation 
(Varjú et al. 2015 ) and forms inhibitory tertiary complexes with plasmin and fibrin 
(Gould et al. 2015 ).  
     The ability of canine NET fragments to increase maximal clot formation velocity is 
somewhat at odds with findings using human NETs in the absence of neutrophils. Yang 
et al. (2015) found that NETs generated from the neutrophils of gastric cancer patients, 
but not healthy human controls, increased clot formation using a similar 
spectrophotometric method to the current study. The possibility that in the absence of 
neutrophils, NETs are pro-coagulant only in certain disease states was also raised by the 
ability of a tissue factor inhibitor to reverse the pro-coagulant effect of NET fragments 
collected from human neutrophils treated with complement and anti-neutrophil 
cytoplasmic antibodies (Huang et al. 2015 ). While this may represent a genuine species 
difference, it is possible that by measuring maximum clot formation velocity, we were 
able to detect a subtle effect of NET fragments which was not evident using thrombin-
antithrombin complex generation or peak OD (Huang et al. 2015, Yang et al. 2015). 
     In human platelet poor plasma, increased thrombin generation induced by NETing 
neutrophils from healthy volunteers is reversed by DNase therapy (Gould et al., 2014). 
This, together with reversal of the effect of NETs on human plasma by factor XII 
inhibition (Gould et al. 2014 ), suggests the effect of NETing human neutrophils is due to 
contact pathway activation by negatively charged DNA. While we have shown that DNA 
at microgram concentrations can increase maximum clot formation velocity in canine 
plasma, the effect of NET fragments persisted after DNA digestion. Identifying the 
protein or proteins responsible is challenging, because previously proposed pro-coagulant 
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NET proteins do not act via the tissue factor or contact pathway alone, but affect multiple 
pathways. For example, histones impair protein C activation which impacts both the 
common and contact pathway (Ammollo et al. 2011). This limits the extent to which the 
protein(s) responsible for enhancing clot formation can be identified using specific 
inhibitors or factor deficient plasma. 
     We therefore investigated specifically the effects of two previously proposed pro-
coagulant NET proteins, histones (Gould et al. 2014) and elastase (Massberg et al. 2010). 
While histones alone were not responsible for the enhanced maximum clot formation 
velocity, it should not be assumed that canine histones have no pro-coagulant effects. 
Their impact on platelets (Gould et al. 2014) and endothelial cells (Saffarzadeh et al., 
2012) is well established in human and murine studies, but these effects could not be 
investigated in the current platelet poor plasma model. Furthermore, the concentration of 
histones was selected based on the amount of DNA present in the current study. The 
200ng/ml DNA concentration is similar to that reported in human lupus patients (Zhang 
et al. 2014), but is lower than in other diseases such as sepsis where histone 
concentrations may more closely approximate those used in previous in vitro studies 
(Gould et al. 2015; Wildhagen, 2015; Varjú, 2015 ). 
     The greatly reduced activity of elastase after incubation with canine plasma is not 
unexpected, as it is known that alpha1 anti-trypsin rapidly inhibits elastase in human 
plasma (Ohlsson 1971, Yipp and Kubes 2013 ). However, it does suggest that elastase in 
NET fragments was unlikely to be contributing to increased maximal clot formation. This 
is not incompatible with the observation in a mouse arterial thrombosis model that 
elastase degraded tissue factor pathway inhibitor (TFPI) and thus promoted thrombosis, 
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because in this situation NETs were closely associated with neutrophils and thus 
potentially protected from inhibitors (Massberg et al. 2010 ). It is also interesting to note 
that a recent study failed to replicate the importance of elastase for thrombosis in a 
venous injury model (Martinod et al. 2016). 
     It is intriguing that circulating NETs could contribute to a hypercoagulable state in 
inflammatory or infectious diseases, and thus act as markers of thrombotic risk or 
prophylactic targets. The effects of NET fragments were subtle, as evidenced by the lack 
of significant changes in the marker of overall clot size, area under the curve. However, 
the magnitude of effect is similar to the differences between healthy humans and patients 
with various hemostatic disorders. For example, the mean difference between non-
stimulated supernatants and Alu1 NETs was 17% for maximum clot formation velocity 
and 12% for time to 50% lysis. Women with heavy menstrual bleeding have a mean -
17% change (Szczepaniak et al. 2015 ) and patients with antiphospholipid antibody 
syndrome a 10% change in clot lysis time (Celińska-Lowenhoff et al. 2014 ), a 
spectrophotometric measure of clot lysis.  
Conclusions 
     This study shows NETs impair fibrinolysis and enhance maximum clot formation 
velocity in canine platelet poor plasma. It must be emphasized that conclusions about the 
physiologic relevance of these changes cannot be drawn. In addition to the limitations of 
a plasma system, evidence regarding the size and integrity of circulating NETs in various 
diseases is lacking. The extent to which NETs used in this study recapitulate those found 
in diseased dogs therefore cannot be assessed. Despite these limitations, the current study 
151 
 
 
15
1 
demonstrates further investigation of the nature of circulating NETs and their interactions 
with the canine coagulation system is warranted.  
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CHAPTER 5. NEUTROPHIL EXTRACELLULAR TRAPS ACTIVATE CANINE 
PLATELETS 
A manuscript for submission to Veterinary Clinical Pathology 
Unity Jeffery1, Dana LeVine2,3 
Abstract 
     Background: Neutrophil extracellular traps (NETs) are webs of DNA and protein 
released in response to many inflammatory and infectious stimuli. NETs induce platelet 
activation in humans, and experimental models suggest this is important in propagating 
thrombosis. If NETs have a similar effect in dogs, NETs could provide a marker of 
thrombotic risk and potential therapeutic target in canine infectious and immune-
mediated disease. 
     Objectives: To test the hypothesis that NETs activate canine platelets, as demonstrated 
by an increase in the percentage of platelets positive for P-selectin and phosphatidylserine 
exposure. 
     Methods: Canine neutrophils were induced to produce NETs in vitro using phorbol-
12-myristate 13-acetate. Platelets from healthy dogs (n=5) were incubated with intact 
NETs, NETs digested by DNase 1 and supernatants from non-stimulated neutrophils. P-
                                                           
1 Department of Veterinary Microbiology and Preventative Medicine, College of Veterinary Medicine, 
Iowa State University 
2 Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University 
3 Unity Jeffery performed the laboratory work and prepared the manuscript. Dana LeVine supervised the 
project and assisted with protocol development and data analysis. 
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selectin and phosphatidylserine positive platelets were measured by flow cytometry. Both 
a large platelet population and an all platelet population gated to include microparticles 
were analyzed. 
     Results: Intact NETs increased the percentage of all platelets (P-selectin mean 68%, 
s.d. 13%, p<0.0001; phosphatidylserine mean 35%, s.d.8%, p=0.0016) and large platelets 
(P-selectin mean 88%, s.d. 6%, p<0.0001; phosphatidylserine mean 26%, s.d.7%, 
p=0.0028) positive for P-selectin or phosphatidylserine exposure compared with 
supernatants from non-stimulated neutrophils (P-selectin all platelets mean 7%, s.d.6%; 
large platelets 6%, s.d. 5%; phosphatidylserine all platelets mean 15%, s.d. 9%; large 
platelets 9%, s.d. 7%). DNase digestion did not alter the effect of NETs on either marker 
(p>0.7). 
     Conclusions: Canine NETs activate platelets, and as this effect persists after DNase 
digestion, it is likely predominantly mediated by NET proteins.  
Introduction 
     Inflammation is a risk factor for thrombosis (van Aken et al. 2000 , Tichelaar et al. 
2012 ). Neutrophil extracellular traps (NETs) provide one link between inflammation and 
coagulation (Fuchs et al. 2010 , Massberg et al. 2010 , von Brühl et al. 2012). When 
neutrophils encounter a wide variety of infectious or inflammatory stimuli they respond 
by releasing these structures composed of DNA decorated with nuclear, cytoplasmic and 
granular proteins (Brinkmann et al. 2004, Gupta et al. 2005 , Urban et al. 2006 , Parker et 
al. 2012, Alemán et al. 2016). NETs may have beneficial antimicrobial effects 
(Brinkmann et al. 2004, Urban et al. 2006 ), but also contribute to tissue damage 
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(Kolaczkowska et al. 2015, Merza et al. 2015 ) and autoimmunity (Lande et al. 2011 , 
Pratesi et al. 2014 ) in addition to promoting thrombosis (Fuchs et al. 2010 , Massberg et 
al. 2010 , von Brühl et al. 2012 ).  
     The pro-thrombotic effect of NETs is multifactorial (Martinod et al. 2014 ), but there 
is evidence that human NETs can activate platelets (Fuchs et al. 2010 , Gould et al. 
2014). Platelet activation is increased when the DNA backbone of NETs is digested, 
showing the effect is mediated by the protein component of NETs (Gould et al. 2014 ). 
Histones are the likely protein responsible because they are both present in NETs and 
known to activate platelets (Semeraro et al. 2011, Carestia et al. 2013, Gould et al. 2014). 
Therefore, blocking histone/platelet interactions has been proposed as a 
thromboprophylactic strategy in humans (Esmon et al. 2011). Preliminary evidence 
suggests NETs may be elevated in dogs with immune-mediated hemolytic anemia 
(Jeffery et al. 2015 ), and similar strategies may therefore be beneficial in reducing the 
high rates of thrombosis associated with this disease (McManus et al. 2001, Carr et al. 
2002 ). However, there are species variations in responsiveness to platelet agonists 
(Pelagalli et al. 2002) so it is important to confirm canine NETs can activate canine 
platelets.  
     The current study tested the hypothesis that NETs induce platelet activation, as 
measured by P-selectin and phosphatidylserine exposure, and that this effect will persist 
after degradation of DNA by the enzyme DNase 1. 
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Methods 
Dogs 
     Six healthy dogs belonging to staff and students were used according to IACUC 
protocol 12-13-17687-K. They were 2 unrelated Australian shepherds, 2 mix breed, 1 
Labrador retriever and 1 greyhound; 3 neutered females and 3 neutered males with mean 
age of 4 years (range 1-9 years). One dog was used to generate NETs, and 5 to test the 
effects of NETs on platelets. These numbers were sufficient to detect a 10% difference in 
P-selectin exposure between resting and histone stimulated platelets with 80% power and 
an alpha of 0.05 if standard deviation was 6% for stimulated and 1% for resting cells. 
These values were determined using G*Power (v. 3.1) (Faul et al. 2007) based on 
published variability in P-selectin exposure for thrombin-stimulated and resting canine 
platelets (Knudsen et al. 2011) and P-selectin exposure induced by human platelets by 
purified histones (Carestia et al. 2013). 
Generation of NETs 
     NETs were generated as previously described (Jeffery et al. 2015) and collected using 
a modification of a published method (Barrientos et al. 2013). Briefly, neutrophils were 
isolated from EDTA blood using dextran sedimentation, osmotic lysis of erythrocytes and 
a Histopaque 1077 gradient (Sigma-Aldrich Corp., St. Louis, MO). Neutrophils were 
seeded onto polystyrene 12 well plates (Corning Inc, Corning, NY) at a density of 2 x 105 
per well in Roswell Park Memorial Institute medium (RPMI, HyClone, GE Healthcare 
Life Sciences, South Logan, UT) with 0.5% fetal calf serum (Gibco, ThermoFisher 
Scientific, Waltham, MA). Cells were stimulated with 7μM Phorbol 12-myristate 13-
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acetate (PMA, Sigma-Aldrich Corp., St. Louis, MO) (a concentration previously shown 
to induce NET release by canine neutrophils (Jeffery et al. 2015)) for 3 hours at 39oC. To 
release NETs into solution, RPMI was gently removed and replaced with the restriction 
enzyme Alu1 (4U/ml) (Invitrogen, ThermoFisher Scientific, Waltham, MA) for 20 
minutes at 39oC. The supernatant was collected and centrifuged at 300 x g for 10 minutes 
to remove cells from the NET rich supernatant. 
     To control for contaminating cells, non-stimulated neutrophils were treated identically 
except PMA was replaced by phosphate buffered saline (PBS, Gibco, ThermoFisher 
Scientific, Waltham, MA). To control for any residual RPMI or PMA contaminating the 
Alu1 digested supernatants, wells were treated identically except that neutrophils were 
not added. NETs and controls were aliquoted and stored at -80oC until use in platelet 
studies. We have previously shown that this method produces NET fragments of around 
1000 base pairs (Jeffery 2016). DNA was measured using the double strand DNA dye 
QuantIT Picogreen (Invitrogen, ThermoFisher Scientific, Waltham, MA) and protein by a 
BCA assay (Pierce BCA Protein assay kit, ThermoFisher Scientific, Waltham, MA) 
according to the manufacturers’ instructions.  
Platelet flow cytometry 
     Blood was drawn directly into acid-citrate-dextrose in a 1:9 ratio and added to an 
equal volume of BSGC buffer (129mM NaCl, 14mM Na3citrate, 11mM glucose, 10mM 
NaHPO4). Blood was processed and assays set-up within 30 minutes of blood collection. 
Platelet-rich plasma was separated by centrifugation at 170 x g for 8 minutes and added 
in a 1:50 ratio to annexin binding buffer (final calcium chloride concentration after 
addition to stimuli 1.7mM, TACS Annexin V-FITC apoptosis detection kit, R &D 
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Systems, Minneapolis, MN) with gly-pro-arg-pro amide (0.5mM Sigma-Aldrich Corp., 
St. Louis, MO). Intact NETs, NETs digested for 30 minutes at 37oC by DNase (1U/ml, 
Pulmozyme, Genentech, San Francisco, CA) or supernatants from non-stimulated 
controls were added to this mix in a final volume of 50%. Controls for residual RPMI, 
PMA or ALU1 were prepared using equal volumes of the supernatants from acellular 
wells and a 1U/ml DNase control was diluted in PBS. A 0.09U/ml bovine calcium 
ionophore (Sigma-Aldrich Corp., St. Louis, MO) positive control for phosphatidylserine 
and a PBS resting control were included in each experiment.  
     After incubation of platelets with stimulants for 20 minutes at 37oC, platelets were 
incubated for a further 20 minutes at room temperature with APC conjugated-mouse anti-
human CD61 (10μl of 25μg/ml working concentration; clone Y2/51, Dako, Carpinteria, 
CA) to label platelets, PE-conjugated mouse anti-human-P-selectin (8μl of 6.25μg/ml 
working concentration; Clone AK-4, BD biosciences, San Jose, CA ) and FITC 
conjugated bovine lactadherin (10μl of 0.04μM working solution; Haematologic 
Technologies Inc., Essex Junction, VA) as markers of P-selectin and phosphatidylserine 
exposure respectively. Fluorescence was quenched using 500μl HEPES saline, and flow 
cytometry performed on unfixed samples within 2 hours. Unstained, lactadherin-FITC 
fluorescence minus one and P-selectin isotype (Mouse IgG1κ isotype control, BD 
biosciences, San Jose, CA) controls were included in each experiment. Flow cytometry 
data was collected using a BDFACS Canto (BD biosciences, San Jose, CA), and samples 
analyzed using Flowjo (v. 10; TreeStar, Ashland, OR).  
     Platelets were initially gated based on forward scatter height (FSC-H) and CD61. 
Events brighter or equal to low intensity CD61 events in the resting platelet population 
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were defined as platelets (Figure 1A). The platelet population was then divided into 
quadrants based on lactadherin or P-selectin intensity and FCS-H (Figure 1B, C). The 
negative population was defined using the fluorescence minus one control for lactadherin 
and the isotype control for P-selectin. The high forward scatter quadrants included the 
main platelet population and the low forward scatter quadrants small 
platelets/microparticles (Figure 2).  
 
 
 
 
Figure 1. Example of gating and controls. For each dog, a resting control in which platelets were 
incubated with PBS; a thrombin (IIa) positive control for P-selectin and a calcium ionophore (CaI) 
positive control for phosphatidylserine was performed in addition to stimulation of platelets with NETs. 
Representative results for controls and NETs are shown here. Gating was performed as follows: A. 
Platelets were defined as CD61 positive events, with an intensity equal to, or brighter than the resting 
platelet population (x axis CD61; y axis FSC-H); Platelets were then gated based on FSC-H (x-axis) 
and staining for P-selectin (y axis, B) and lactadherin (y axis, C) as a measure of phosphatidylserine 
exposure. 
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     Statistical analyses were performed using GraphPad Prism v.6. The percentage of 
large platelets positive for P-selectin or phosphatidylserine (i.e. quadrant 2/quadrant 2+3) 
were compared between platelets incubated with supernatants from resting neutrophils, 
NETs or DNase digested NETs using a repeated measures one-way ANOVA. To screen 
for phosphatidylserine exposure on particles below the FSC threshold for the main 
platelet population, the percentage of all platelets positive for P-selectin or 
phosphatidylserine (i.e. quadrant 1+2/quadrant 1+2+3+4) was analyzed identically. If 
pANOVA was <0.05, percentage of positive platelets was compared between groups by 
repeated paired t-tests with Tukey’s correction for multiple comparisons. To determine if 
residual RPMI/PMA or restriction enzyme controls induced platelet activation, control 
tubes were compared to platelets incubated with PBS alone using a repeated measures 
 
Figure 2. Defining large platelet and all platelet populations. Platelets incubated with PBS (A) or 
thrombin (B) are shown with FSC-H on the x axis and Lactadherin intensity on the y-axis. Platelets 
with similar FSC-H properties to the resting (PBS) platelet population were defined as large platelets 
(quadrant 2 and 3). Because phosphatidylserine exposure is concentrated on microparticles, an 
additional analysis of all platelets, which included smaller CD61 positive events (quadrant 1 and 4) was 
also performed. 
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one-way ANOVA. If pANOVA was <0.05, percentage of positive platelets was compared to 
the PBS tube by repeated paired t-tests with Dunn’s correction for multiple comparisons. 
Multiplicity adjusted p values are reported and p<0.05 considered significant. 
Results 
Characterization of NET supernatants 
     Supernatants collected from PMA stimulated, Alu-1 treated cells contained 561ng/ml 
DNA, which reduced to 90ng/ml after DNase digestion, and 88μg/ml protein.  
P-selectin exposure is increased by NETs 
     NETs significantly increased the percentage of all platelets (mean 68%, s.d. 12.5%; 
p<0.0001) and large platelets (mean 88%, s.d. 6.1, p<0.0001) positive for P-selectin 
exposure compared to supernatants from non-stimulated neutrophils (mean for all 
platelets 7%, s.d. 6.2; mean for large platelets 6%, s.d. 5.3%). For both all platelets (mean 
65; s.d. 13.2%; p<0.0001) and large platelets (mean 86%, s.d. 5.6%; p<0.0001), the effect 
persisted after DNase digestion of the NET backbone (Figure 3A, B). Thrombin 
stimulation, performed as a positive control, resulted in 67-89% of all platelets and 90-
95% of large platelets positive for P-selectin. Incubation with PBS, performed as a 
negative control, resulted in 0.2-6% of platelets positive for P-selectin. DNase alone or a 
combined control for Alu1 and any residual PMA or RPMI was not significantly different 
from PBS alone (pANOVA=0.767) (Figure 4A, B). 
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Phosphatidylserine exposure is increased by NETs 
     Phosphatidylserine externalization, as measured by the percentage of platelets positive 
for FITC labelled lactadherin, was significantly increased by NETs for both all platelets 
(mean 35%, s.d. 8.3%; p=0.0016) and large platelets (mean 26%; s.d. 7.5%; p=0.0028) 
compared to supernatants from non-stimulated neutrophils (mean for all platelets14%, 
s.d. 8.9%; mean for large platelets 9%, s.d. 7.2%). The effect of NETs persisted after 
DNA digestion for all platelets (mean 35%; s.d. 8.9%; p=0.0015) and large platelets 
(mean 26%, s.d. 10.1%; p=0.0028) (Figure 3 C, D). Calcium ionophore, included as a 
positive control, induced 84-100% positivity for all platelets and 92.8-100% positivity for 
 
Figure 3. Effect of NETs on platelet activation. The percentage of all platelets (A) and large platelets 
(B) positive for P-selectin exposure was increased by NETs and DNase digested NETs compared with 
supernatants from non-stimulated neutrophils. The percentage of all platelets (C) and large platelets (D) 
positive for lactadherin as a measure of phosphatidylserine exposure was increased by NETs and 
DNase digested NETs compared with supernatants from non-stimulated cells. There were no significant 
differences between intact and DNase NETs for either marker (p>0.7). (Repeated measures one-way 
ANOVA followed by paired t-tests with Tukey’s correction; n=5; ** multiplicity adjusted p < 0.0001; * 
<0.003). 
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large platelets, but the number of events in the large population gate was small (Figure 
1C). For all platelets 0.65-1.66% and for large platelets 0.41-1.3% were positive for 
lactadherin after incubation with PBS as a negative control. Comparison of the platelets 
incubated with DNase alone or a combined control for Alu1 and any residual PMA or 
RPMI to platelets incubated with PBS revealed no significant difference for large 
platelets (pANOVA=0.055) but the ANOVA was borderline significant (p=0.046) for all 
platelets. When each control was compared to PBS by t-test, neither control had a 
significant effect (DNase versus PBS: mean difference 0.25%, p=0.113; 
RPMI/PMA/Alu1 versus PBS mean difference 0.06%; p=0.834).  
 
 
 
Figure 4. Effects of reagent controls on platelet activation. Alu1, residual PMA or RPMI and DNase 
1 did not increase percentage of all platelets (A) or large platelets (B) positive for P-selectin or 
phosphatidylserine compared with PBS alone (pANOVA or p value for individual comparisons by paired 
t-test >0.05). 
 
165 
 
 
16
5 
Discussion 
     The current study shows neutrophil extracellular traps can activate canine platelets, as 
measured by percentage of platelets positive for externalization of P-selectin and 
phosphatidylserine. P-selectin, an important mediator of platelet aggregation and platelet 
interactions with endothelial cells and leukocytes, is stored principally within alpha 
granules. Its exteriorization therefore provides a measure of platelet granulation secretion 
in response to agonists (Merten et al. 2000, Mumford et al. 2015). In resting platelets, the 
negatively charged phospholipid phosphatidylserine is sequestered in the inner leaflet of 
the plasma membrane by ATP-dependent translocases (Lhermusier et al. 2011). Upon 
platelet activation, if intra-cellular calcium concentrations rise sufficiently, this 
membrane asymmetry is destroyed by scramblase (Lhermusier et al. 2011). 
Exteriorization of phosphatidylserine is an important link between platelet activation and 
the enzymatic coagulation cascade because it provides a negatively charged surface for 
efficient assembly of the pro-thrombinase and tenase complexes (Lhermusier et al. 2011).  
Increased externalization of both markers persisted after degradation of the DNA 
backbone of NETs by DNase 1, consistent with activation of platelets by the protein 
component of NETs. 
     This is similar to reported effects of neutrophil extracellular traps in in vitro human 
studies. When human platelets are perfused over neutrophils stimulated to form NETs, 
platelets adhere to and aggregate upon NETs (Fuchs et al. 2010 ). Filiopod formation 
shows these platelets are activated (Fuchs et al. 2010). Gould et al (2014) provided 
further evidence that NETs induce platelet activation and this contributes to a 
hypercoagulable state. When human platelet rich plasma was incubated with neutrophils 
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stimulated to form neutrophil extracellular traps, thrombin generation was increased 
compared with exposure to non-stimulated neutrophils (Gould et al. 2014). This effect 
was enhanced by digestion of NETs by DNase, suggesting that liberation of NET proteins 
from the DNA backbone allows more efficient interactions with platelets (Gould et al. 
2014).  
     In the current study, we did not attempt to identify the specific interaction responsible 
for platelet activation. Histones have been proposed as the major NET protein responsible 
for activation of human platelets (Gould et al. 2014 , Fuchs et al. 2010). Neutrophil 
extracellular traps generated from nuclear DNA contain high concentrations of these 
small basic proteins (Brinkmann et al. 2004, Barrientos et al. 2013). Histones alone can 
induce platelet aggregation and spreading, degranulation and phosphatidylserine 
exposure (Fuchs et al. 2010 , Semeraro et al. 2011 , Carestia et al. 2013). Given the 
intimate links between platelet and enzymatic coagulation factor activation (Smith 2009), 
it is unsurprising that histone-induced platelet activation also enhances thrombin 
generation in platelet rich plasma consistent with histones contributing to a global 
hypercoagulable state (Semeraro et al. 2011). Specific effects of histones, such as P-
selectin exposure, and histone-induced increases in thrombin generation are reduced by 
blockade of toll-like receptor (TLR) 2 and 4 (Semeraro et al. 2011, Carestia et al. 2013). 
Gould et al (2014) demonstrated a similar reduction in the effect of NETs on thrombin 
generation by blockade of TLR 2 and 4, adding further credence to the role of histones as 
a key component of the mechanism by which NETs induce platelet activation. 
     The potential clinical relevance of the ability of histones and neutrophil extracellular 
traps to induce platelet activation has attracted interest in human medicine (Esmon et al. 
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2011). NETs not only induce platelet activation but activated platelets also induce NETs 
(Clark et al. 2007, Maugeri et al. 2014). Breaking this cycle can reduce pathology 
associated with thrombosis, as shown by improved outcome in murine models of 
thrombosis and disseminated intravascular coagulopathy when anti-histone treatments, 
such as anti-histone antibodies (De Meyer et al. 2012) and recombinant thrombomodulin 
(Nakahara et al. 2013), are delivered. The commonly used anticoagulant heparin is 
another agent able to binds histones and inhibit their damaging effects, including platelet 
activation (Fuchs et al. 2010, Iba et al. 2015). This is a double edged sword, as this 
interaction also reduces the anti-Xa activity of heparin (Longstaff et al. 2016), but the 
loss of this effect when agents such as Dabigatran (Ammollo et al. 2016 ) risks leaving 
histone induced platelet activation uninhibited (Esmon et al. 2011).  
     The ability of neutrophil extracellular traps to induce canine platelet activation 
suggests anti-histone therapies may also be relevant to veterinary patients. As NETs are 
induced by many infectious and inflammatory stimuli, it is likely they are elevated in 
numerous canine diseases. This is particularly true of immune-mediated hemolytic 
anemia, which is associated with high rates of thrombosis (Carr et al. 2002). Preliminary 
evidence shows nucleosomes (DNA/histone complexes) are elevated in IMHA (Jeffery et 
al. 2015), and triggers of NETosis including hypoxia (De Meyer et al. 2012, McInturff et 
al. 2012) and elevated free heme (Chen et al. 2014) are commonly present in affected 
dogs (Holahan et al. 2010, Lobetti et al. 2012). Platelet activation has been repeatedly 
shown to contribute to the hypercoagulable state in dogs with IMHA (Weiss and Brazzell 
2006 , Ridyard et al. 2010 , Hamzianpour et al. 2016), and heparin is associated with 
improved survival (Helmond SE 2010). 
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     The findings of the current study do suggest that further evaluation of NETs as 
potential markers of thrombotic risk or therapeutic targets is warranted in dogs with 
infectious and inflammatory disease. However, it should be stressed that this in vitro 
study is not without limitations. Firstly, to limit the exposure of platelets to PMA (a 
known platelet activator (Gould et al. 2014)) and to differentiate the effect of NETs from 
neutrophils, a NET rich supernatant was produced by replacing the culture media with the 
restriction enzyme Alu1 diluted in phosphate buffered saline. This was successful in 
reducing PMA concentration to below that capable of activating platelets (Figure 4), but 
does generate only relatively small NET fragments (Jeffery 2016). These small fragments 
may not retain all the properties of the large structures released at sites of thrombosis. 
Secondly, although a control was prepared using non-stimulated cells, we cannot be sure 
that some of the effects attributed to NETs in the current study were not actually induced 
by membrane fragments or other cellular components not removed by centrifugation. 
Thirdly, our analysis used both a wide gate designed to capture all platelet events and a 
more tightly defined gate including only high CD61 structures with forward scatter 
characteristics consistent with intact platelets. The all platelet gate was used because 
phosphatidylserine exposure is concentrated on microparticles, so analyzing only large 
platelets may have led us to falsely conclude that an agonist or control was not inducing 
phosphatidylserine exposure (Delaney et al. 2014). However, the small size of 
microparticles makes their accurate detection by flow cytometry challenging (Helmond et 
al. 2013). We did not use strategies to improve the accuracy of microparticle detection, 
such as comparison of forward scatter characteristics to calibration beads (Lacroix et al. 
2010). However, for the large platelet and all platelet populations results were similar, so 
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inaccuracies in defining microparticles is unlikely to have influenced our finding that 
NETs activate canine platelets. 
     In conclusion, the current study demonstrates canine NETs induce platelet activation 
and suggests a novel component of hypercoagulability associated with canine 
inflammatory or infectious disease. 
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CHAPTER 6. CELL-FREE DNA AND DNASE ACTIVITY IN DOGS WITH 
IMMUNE-MEDIATED HEMOLYTIC ANEMIA 
Modified from a paper for submission to the Journal of Veterinary Internal Medicine 
Unity Jeffery1, Laura Ruterbories2, Rita Hanel2, Dana LeVine3,4 
Abstract 
     Background: Canine immune-mediated hemolytic anemia (IMHA) carries a high risk 
of thrombosis and is associated with marked neutrophilia and tissue necrosis. Cell death 
and release of neutrophil extracellular traps contribute to cell-free DNA, and in human 
autoimmune disease reduced DNase activity further increases cell-free DNA. Circulating 
DNA has multiple pro-thrombotic properties and could contribute to hypercoagulability 
in IMHA.  
     Hypothesis: Cell-free DNA will be elevated in IMHA cases compared with healthy 
controls, and this may be due to reduced DNase activity. 
     Animals: Dogs presenting to 2 referral hospitals with IMHA (n=28) and healthy pet 
dogs (n=20). 
                                                           
1 Department of Veterinary Microbiology and Preventative Medicine, College of Veterinary Medicine, 
Iowa State University 
2 Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University 
3 Department of Clinical Sciences, College of Veterinary Medicine, Iowa State University 
4 Unity Jeffery (graduate student) participated in study design, collected samples, performed laboratory 
work and prepared the manuscript. Laura Ruterbories collected samples and critiqued the manuscript; Dana 
LeVine (major professor, study originator) and Rita Hanel participated in study design, sample collection 
and critique of the manuscript.  
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     Methods: EDTA plasma and serum were prospectively collected and mortality and 
thrombotic events occurring in the first 14 days after hospitalization recorded. DNA was 
extracted from plasma using a commercial kit and quantified by PicoGreen fluorescence. 
DNase activity of serum was measured by radial diffusion assay.  
     Results: Cell-free DNA was significantly higher in cases (median: 45ng/ml, range: 10-
2334ng/ml) than controls (26ng/ml, range 1-151ng/ml, p=0.0084). DNase activity was 
not different between cases median: 0.359cm2, range: 0.229-0.750 cm2) and controls 
(median: 0.365cm2, range: 0.157-0.456cm2; p=0.359). Four dogs died and there were 5 
suspected or confirmed thrombotic events. Cell-free DNA was associated with death 
(odds ratio for upper quartile: 15; 95% confidence interval 1.62-201; p=0.03) but not 
thrombosis (p=0.57). 
     Conclusions: Cell-free DNA is elevated in IMHA and this appears to reflect increased 
production rather than impaired degradation. This study provides pilot data suggesting 
cell-free DNA is associated with mortality but this requires confirmation in a larger 
population. 
Introduction 
     Approximately 30% of dogs affected by immune-mediated hemolytic anemia (IMHA) 
die or are euthanized during, or shortly after, initial hospitalization.1,2,3 Thrombosis, 
necrosis and neutrophilic inflammation are common post-mortem findings,4 which 
suggests cell-free DNA as a potential contributor to thrombosis in IMHA. Both necrotic 
cells and activated neutrophils release DNA, either as a consequence of cell membrane 
rupture or, in the case of neutrophils, through organized release of neutrophil 
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extracellular traps (NETs).5,6,7,8Reduced break down of DNA by endogenous DNase 1 
further contributes to elevated cell-free DNA in human autoimmune diseases.9.10  
     Cell-free DNA has multiple pro-thrombotic properties, including activation of the 
contact pathway11,12 and inhibition of fibrinolysis.13,14 Increased circulating DNA is 
associated with poor prognosis in humans with a variety of conditions including 
disseminated intravascular coagulopathy15 and sepsis16, and levels of cell-free DNA are 
associated with disease severity in sick dogs.17 Furthermore, digestion of DNA by DNase 
improves outcome in murine models of thrombosis.18,19,20 Cell-free DNA may therefore 
provide a marker of thrombotic risk and a novel therapeutic target in dogs with IMHA. 
     This study tests the hypothesis that cell-free DNA is increased in IMHA compared 
with healthy control dogs, and seeks to determine if any increase is at least partially 
explained by reduced endogenous DNase activity. A preliminary analysis of the 
association between cell-free DNA and survival or thrombosis in the first 14 days after 
admission is also presented. 
Methods 
Ethical permissions 
     Samples were collected with ethical permission from the Iowa State and North 
Carolina State University institutional animal care and use committees (healthy controls: 
ISU 12-13-17687-K; IMHA cases: NCSU 14.110-O, ISU 1-14-7693K). 
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Inclusion criteria for clinical cases 
     Clinical cases presenting to Iowa State University or North Carolina State University 
veterinary specialist hospitals were prospectively enrolled between 1.2.14 or 8.26.14 
respectively and 5.27.16, providing they met the following criteria: (1) anemia with one 
or more of (a) positive saline agglutination test, (b) positive Coombs’ test or (c) ≥5 
spherocytes per x100 field; (2) no evidence of underlying disease; (3) no heparin 
treatment prior to sample collection; (4) at least 3kg body weight or if concurrently 
enrolled in a second study at NCSU, at least 7kg and (5) informed consent obtained. 
Dogs which met these requirements but were not enrolled were recorded. A copy of the 
consent form is presented in Appendix A. 
     Saline agglutination test was considered positive if macro- or microscopic 
agglutination was present after adding 4 drops of saline to a single drop of EDTA blood. 
When performed, Coombs’ tests were submitted to diagnostic laboratories at the 
submitting universities, and considered positive if the titer was above the cut-off 
established by that laboratory. All blood smears were examined by a single board 
certified clinical pathologist (UJ). Diagnostic investigations to confirm IMHA was 
primary were at the discretion of the attending clinician. Prior heparin treatment was 
selected as an exclusion criterion because of the potential for heparin to degrade 
neutrophil extracellular traps.21 Treatment after sample collection was at the discretion of 
the attending clinician. Diagnostic investigations and treatments after sampling were 
recorded from electronic medical records with further clarification from the attending 
clinician where necessary.  
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Inclusion criteria for healthy controls 
     Healthy control dogs were pets of staff or students at Iowa State University, inclusion 
criteria were: (1) between 1 and 9 years old; (2) >5kg body weight; (3) normal physical 
exam, hematology and biochemistry and (4) not receiving medication other than routine 
anti-parasite treatment. 
Sample collection 
     Samples were collected via 21 gauge winged infusion sets5 with 9cm tubing inserted 
into a jugular, saphenous or cephalic vein for all control dogs and either using the same 
method or via central sampling catheters in IMHA cases. Sampling via central lines was 
permitted only if flushed with saline rather than heparin. Blood was transferred 
immediately to K2EDTA for measurement of cell-free DNA and a non-coagulated sample 
collected for the DNase assay. Immediately after collection, EDTA samples were 
centrifuged at 2500 x g for 20 minutes and serum samples for 1000 x g for15 minutes. 
Plasma or serum was divided into aliquots and stored at -800C until analysis. The sample 
processing standard operating procedure is presented in Appendix B. 
Follow up 
     Dogs were followed for 14 days after admission by clinical record review or 
contacting the owner or attending clinician. Survival to 14 days or date of 
death/euthanasia; suspected or confirmed thrombotic events; transfusion; and therapy 
                                                           
5 Surflo winged infusion set, Terumo, Tokyo, Japan 
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with immunosuppressants, heparin, aspirin, clopidogrel, or intravenous immunoglobulin 
were recorded.  
Power calculation 
     The study was initially designed principally to evaluate the association between cell-
free DNA and related analytes on survival with comparison between controls and cases 
as a secondary analysis. This would have required at least 80 IMHA cases. After 27 
months, case recruitment was considerably below targets and study design was revised to 
determine only if analytes differed between cases and controls. To determine if case 
numbers were sufficient for this comparison, a power calculation based on reported cell-
free DNA concentrations and standard deviations for healthy humans and systemic lupus 
patients22 was performed using G*Power v. 3.1.96.23 For cell-free DNA, at least 12 cases 
and 12 controls were needed to detect a 49ng/ml difference between the mean of cases 
and controls with an alpha of 0.05 and power of 80% assuming a standard deviation of 
40ng/ml.  
Cell free DNA 
     DNA was extracted from EDTA-plasma samples using a silica-membrane based 
nucleic acid purification kit7 according to the manufacturer’s instructions. Eluted DNA 
was quantified using the fluorescent double stranded DNA PicoGreen8. Where necessary, 
samples were diluted to bring results into the linear range of the assay. All results are 
                                                           
6 G*Power version 3, Universität Düsseldorf, Germany 
7 QIAamp DNA Blood Mini kit, Qiagen, Valencia, CA 
8 Quant-iT Picogreen, Thermofisher scientific, Waltham MA 
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reported after correction for any dilutions. Validation in our hands is presented in 
Supplementary Table 1 (Appendix C). 
DNase activity 
     DNase activity was measured using a method modified from Macanovic and 
Lachmann (1997) and is summarized in Figure 1.24 300μl of a solution containing calf 
thymus DNA9 (final concentration 0.25mg/ml); DNase reaction buffer (final 
concentrations 20mM TrisHCl; 1mM CaCl2; 1mM Mg Cl2); low melting point agarose9 
(final concentration 1% weight by volume) and ethidium bromide10 (final concentration 
1μg/ml) was added to each well of a 24 well plate11 and allowed to set. Serum (2μl/well) 
was injected into the center of each test well and plates incubated for 19 hours at 37oC. 
Blank wells in which no solution was injected were included in each plate. Fluorescence 
of DNA-bound ethidium bromide was imaged by UV trans-illumination. Controls and the 
first 25 cases were prepared on a single day and camera settings were constant between 
each plate. The final 3 IMHA cases were analyzed as a separate experiment together with 
serum from a previously assayed control dog. Results were normalized to the previous 
result from the control dog. Wells were set up in duplicate for each dog and the average 
result used in statistical analysis.  
                                                           
9 DNase free low melting point agarose, Sigma-Aldrich Corp, St. Louis, MO 
10 Ethidium Bromide 0.625mg/ml solution, Thermofisher scientific, Waltham, MA 
11 Corning Inc., Corning, NY 
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     Images were analyzed in Image J.12 Histogram analysis was performed for a blank 
well on the plate of interest, and the threshold of the entire image adjusted so pixels equal 
to or brighter than the lowest grey value of the blank well were fully saturated. The image 
was calibrated using known dimensions of the plate. Conversion to a binary image was 
the performed and the Analyze Particles plug-in for Image J used to measure the area of 
the black circle at the center of the test well, which corresponds to the area of DNA lysis.   
 
Figure 1: Automated quantification of DNase activity. Within a 24 well plate, serum was injected into 
an agarose gel containing DNA and ethidium bromide. After overnight incubation, plates were imaged by 
UV trans-illumination. Where DNA is present, light is emitted by ethidium bromide complexed with DNA. 
Where DNase has digested DNA, light is no longer emitted resulting in a dark region. Using Image J, the 
threshold of the image was adjusted so a blank well, and any pixels in other wells equal to or brighter than 
pixels in the blank well, were completely saturated. The image was then converted to binary. A 
representative binary image is shown in A. The image was calibrated using the known dimensions of the 
plate and the Analyze Particles plug in for image J used to calculate the area for zones of lysis in each test 
well (B). 
     To determine the coefficient of variation, 10 duplicates were prepared using 1U of 
DNase per well. To confirm the method could identify differences in DNase activity, a 
standard curve was prepared using 0.125, 0.25, 0.5, 0.75, 1 and 2U of DNase per well. 
Attempts were made to assess effects of hemolysis and icterus using 0.5U/μl DNase 
                                                           
12 National institutes of health, Bethesda, MD 
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diluted in a 9 to 1 ratio with DNase free water, a commercial bilirubin control13 (final 
concentration 2.5mg/dl) or hemoglobin (final concentration 0.18g/dl or 0.35g/dl) 
prepared from washed canine red cells by repeated freeze thaw cycles and osmotic lysis. 
Statistical analysis  
     All analyses were performed using GraphPad Prism (v.7)14. Distribution was tested by 
the D'Agostino and Pearson normality test, and as one or both populations were non-
normal for cell-free DNA and DNase activity, healthy controls and IMHA cases were 
compared by Mann Whitney. Spearman’s correlation coefficient was calculated for 
correlation between cell-free DNA and DNase activity. Odds ratios and 95% confidence 
intervals were calculated for death and thrombosis by 14 days for IMHA cases in the 
upper quartile (n=7) for cell-free DNA concentration compared with those in the lower 3 
quartiles (n=21). Fisher’s exact test was used to calculate p-values for odds ratios. 
Receiver operator characteristic (ROC) curves were automatically constructed for cell-
free DNA as a predictor of death or thrombosis within 14 days, and the area under the 
curve compared to 0.5 (i.e. expected area if the ability of cell-free DNA to predict 
outcome was no better than chance). For all analyses, p<0.05 was considered significant. 
 
 
 
                                                           
13 MAS Bilirubin (level 3); Thermoscientific, Waltham, MA 
14 GraphPad Software Inc., La Jolla, CA 
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Results 
Study population and healthy controls 
     Thirty dogs were initially recruited. One dog recruited based on spherocytosis was 
subsequently excluded because on blood-smear exam, the cut-off of 5 spherocytes per 
high power field was not reached. One other enrolled dog was not included because 
EDTA plasma was not collected. During the study period, 10 other potentially eligible 
dogs were not enrolled because caregivers did not consent to enrollment (n=2); death 
before diagnostic investigations could be performed (n=1) or lack of available personnel 
to process samples (n=7). Demographic information for cases and controls are presented 
in Table 1.  
Table 1. Demographic information for cases and controls. Fn: female neutered; Mn: male neutered; Me: 
male entire. 
 IMHA cases (n=28) Healthy controls for 
cell-free DNA (n=20) 
Healthy controls for 
DNase activity (n=20) 
Age (years) median, 
(range) 
8 (0.3-14) 4.5 (1-9) 4 (1-9) 
Bodyweight (kg) 
median (range) 
15 (6-52) 28.5 (8-37) 30.5 (8-37) 
Gender Fn 14; Mn 12; Me 2 Fn 8; Mn 12 Fn 8; Mn 12 
Breed Australian shepherd 
(n=1); beagle (n=2); 
bichon frise (n=1); 
Boston terrier (n=2); 
Cardigan corgi (n=1); 
dachshund (n=1); 
German shorthaired 
pointer (n=1); keeshond 
(n=1); Labrador (n=3); 
Maltese (n=1); mastiff 
breeds (n=2); miniature 
schnauzer (n=2); mix 
(n=6); Pomeranian 
(n=1); rat terrier (n=1); 
rottweiler (n=1); 
springer spaniel (n=1) 
Border collie (n=1); 
Chesapeake bay 
retriever (n=1); German 
wirehair pointer (n=1); 
golden retriever (n=1); 
greyhound (n=3); 
Labrador (n=3); mix 
(n=5); pitbull terrier 
(n=3); Rhodesian 
ridgeback (n=1); rough 
collie (n=1) 
Australian shepherd 
(n=1); Border collie 
(n=1); Chesapeake bay 
retriever (n=1); German 
wirehair pointer (n=1); 
golden retriever (n=1); 
greyhound (n=3); 
Labrador (n=3); mix 
(n=5); pitbull terrier 
(n=3); rough collie 
(n=1) 
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     For the 28 included dogs, median hematocrit at enrollment was 18% (range 8-28, 
reference interval 37-55%). All dogs with a hematocrit ≥ 25% had either received a 
transfusion (3/4) or long term immunosuppression (1/4) before enrollment. Saline 
agglutination was positive for 24/28 and negative for 4/28. Of those dogs with negative 
saline agglutination tests, 1/4 had historically been positive and had been treated for 56 
days prior to admission. Five or more spherocytes per high power field were present in 
18/28. Of the 4 dogs undergoing Coombs’ testing, 1 was positive. 
     Median time from initial clinical signs to sample collection was 3 days (range 1-168). 
Samples were collected on day of admission for 18/28; the following day for 8/28; 3 days 
later for 1/28 and 4 days later for 1/28. Samples were collected from a peripheral vein in 
22/28 IMHA cases and via central line sampling catheters for 6/28 IMHA cases. All dogs 
were considered most likely primary rather than secondary IMHA cases by the attending 
clinician, based on diagnostic investigations including abdominal radiographs and/or 
ultrasound 27/28; thoracic radiographs and/or ultrasound 20/28; cytology of one or more 
body system 5/28 (spleen 3/5; liver 1/5; lymph node 1/5; cutaneous masses 1/5, bone 
marrow 1/5); biochemistry 28/28; complete blood count 28/28; coagulation times 18/28 
and infectious disease testing 27/28 (IDEXX Snap 4Dx and/or PCR and indirect 
fluorescent antibody testing for tick borne disease 24/27; leptospirosis titers or PCR 
3/27).  
     Prior to sample collection, 17/28 had received corticosteroids; 3/28 azathioprine; 3/28 
cyclosporine; 16/28 one or more antibiotic; 10/28 intravenous fluid therapy; 7/28 blood 
transfusion; 3/28 clopidogrel; 16/28 one or more other drug. After sample collection, 
26/28 received corticosteroids; 6/28 azathioprine; 11/28 cyclosporine; 3/28 
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mycophenalate; 4/28 intravenous human immunoglobulin, 24/28 clopidogrel; 13/28 
unfractionated heparin; 2/28 aspirin; 13/28 at least one transfusion of packed red cells; 
1/28 whole blood and 1/28 fresh frozen plasma. 
Cell-free DNA  
     Median cell-free DNA was significantly higher in dogs with IMHA (45ng/ml, range 
10-2334ng/ml, n=28) than healthy controls (26ng/ml, range 1-151ng/ml, p=0.0084) 
(Figure 2).  
 
Figure 2. Cell-free DNA was higher in dogs with IMHA than healthy controls. Cell-free DNA was 
extracted from EDTA plasma using a commercial silica membrane based kit and quantified by PicoGreen 
fluorescence. Cases and controls were compared by Mann Whitney (P<0.05 significant; healthy n=20; 
IMHA n=28); error bars are median and inter-quartile range. Results plotted in red are from 4 dogs who did 
not survive to 14 days; those in blue are from 2 dogs who survived to 14 days but had suspected (n=1) or 
confirmed (n=1) thrombosis. 
DNase activity 
     DNase activity was measured by area of lysis in an ethidium bromide DNA gel.  Area 
of lysis was not significantly different between cases (median 0.359cm2, range 0.229-
0.750 cm2) and healthy controls (median 0.365cm2, range 0.157-0.456cm2; p=0.359) 
(Figure 3 A). Spearman’s correlation coefficient (r) for cell-free DNA and DNase activity 
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was 0.38 (95% confidence interval -0.0006-0.67; p=0.045) but visual inspection of the 
correlation plot revealed an obvious outlier (Figure 4A). Correlation was no longer 
significant after exclusion of this dog (r 0.32, 95% confidence interval -0.08-0.63, 
p=0.106) (Figure 4B). 
     Validation of the DNase assay produced a coefficient of variation of 6.5% based on 10 
duplicates. R2 for linear regression performed on a standard curve created using DNase 
concentrations from 0.125U/well to 2U/well was 0.94. Compared with water, 0.18g/dl 
and 0.35g/dl hemolysis and 2.5mg/dl bilirubin spikes increased areas of lysis by 140%, 
412% and 112%. As presence of DNase within the biologically derived control 
specimens could not be ruled out, area of lysis for IMHA cases with (median 0.348 cm2, 
range 0.229-0.724cm2; n=18) and without (median 0.406cm2; range 0.294-0.750cm2; 
n=10) visible hemolysis and/or icterus were also compared by Mann Whitney and were 
not significantly different (p=0.191; Figure 3B). 
 
Figure 3. Serum DNase activity as measured by area of DNA lysis. A. Area of lysis was not 
significantly different between IMHA cases (n=28) and controls (n=20) (p=0.359). B. Analysis of 
interference spikes suggested hemoglobin and bilirubin may both falsely increase area of DNA lysis, but 
both were biologically derived and may have spontaneous DNase activity. There was no significant 
difference between area of lysis for IMHA cases with (n=18) or without (n=10) visible hemolysis and/or 
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icterus (p=0.191). Comparisons were by Mann Whitney (p<0.05 significant); error bars are median and 
inter quartile range.  
 
Figure 4. Correlation between cell-free DNA concentration and area of DNA lysis. A. Initial analysis 
suggested there was a positive correlation between cell-free DNA concentration and DNase activity 
measured by area of lysis (Spearman’s r 0.38; p=0.045). However, this was largely the result of a single 
outlier. B. Re-analysis after exclusion of the outlier found no evidence of a correlation between the two 
parameters (p=106). 
 
Preliminary analysis of relationship between cell-free DNA concentration and 
outcome 
     At day 14 post-admission, 25 dogs were alive, 2 dogs had died (day 3 and 6) and 2 
had been euthanized (day 1 and 7). There were 5 suspected or confirmed thrombotic 
events. Necropsy was performed in 3 out of 4 non-survivors and confirmed thrombosis in 
3/3 (1/3 leptomeningeal vessels only; 1/3 jugular vein and multiple pulmonary thrombi; 
1/3 pulmonary, splenic, hepatic, adrenal and renal thrombi). The other non-survivor was 
euthanized due to financial constraints and permission for necropsy was not granted; 
thrombosis was not suspected based on clinical signs. For survivors, in the first 14 days 
thrombosis was suspected in 2 dogs based on acute onset neurological signs. One of these 
dogs was euthanized after the 14 day follow up period (day 16). Cerebral and renal 
arteriolar thrombi were confirmed at necropsy. 
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     The odds ratio for death or euthanasia in dogs in the highest quartile for cell-free DNA 
was 15 (95% confidence interval 1.62-201; p=0.03) and ROC curve analysis (Figure 5A) 
found that the area under the curve was significantly different from 0.5 for prediction of 
death by 14 days (area 0.86, 95% confidence interval 0.69-1, p=0.02).  The odds ratio or 
suspected or confirmed thrombosis was 2.4 (95% confidence interval 0.34-14.3, p=0.57) 
and the area under the ROC curve was not significantly different from 0.5 (area 0.57, 
95% confidence interval 0.26-0.89, p=0.61) (Figure 5B). 
 
Figure 5. ROC curve analysis for cell-free DNA as a predictive marker for death (A) or thrombosis 
(B). Area under the ROC curve was significantly greater than 0.5 for the ability of cell-free DNA to predict 
death/euthanasia by day 14 post admission (4 died/euthanized; 24 survived; p=0.02); but was not 
significantly different from 0.5 for prediction of confirmed or suspected thrombotic events (7 affected; 21 
unaffected; p=0.61). 
Discussion 
     Cell-free DNA concentration is increased in dogs with IMHA compared with healthy 
controls. DNase activity was not decreased in IMHA nor was it negatively correlated 
with cell-free DNA concentration. This suggests that the increase in cell-free DNA is the 
result of increased production rather than impaired degradation. The analysis of the 
ability of cell-free DNA to predict death or thrombosis should be viewed as pilot data as 
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the number of negative outcomes was low resulting in wide confidence intervals for both 
odds ratios and estimated of the area under the ROC curves. With this caveat, elevated 
cell-free DNA was associated with increased odds of mortality in the first 14 days, and as 
the area under the ROC curve was significantly greater than 0.5, it may have value as a 
prognostic indicator. 
     Potential sources of cell-free DNA include necrosis5, apoptosis5 and release of 
extracellular traps by leukocytes, particularly neutrophils.25,26,27 Necrosis is well 
documented in IMHA at necropsy, with moderate to severe necrosis present in one or 
more organ in 82% of dogs.4 Elevated cardiac troponin I in 74% of IMHA dogs suggests 
that necrotic tissue damage is common even in surviving dogs.28 Apoptosis is also likely 
to contribute to cell-free DNA, as it can be induced both by effects of the disease itself, 
such as oxidative stress29,30, and by therapy. Sixty-one percent of dogs enrolled in the 
current study has received glucocorticoids, a stimulus for lymphocyte apoptosis, prior to 
sample collection.31  
     In humans circulating markers associated with the other major potential contributor to 
cell-free DNA, neutrophil extracellular traps (NETs), are increased in many diseases 
including rheumatoid arthritis;32 systemic lupus erythematosus (SLE);22 transfusion-
related acute lung injury;26 cancer33 and in intensive care patients.34 Marked neutrophilia 
is a common feature of IMHA,2,35,36 sometimes to the point of a leukemoid response,37 
and neutrophilic tissue inflammation is frequent in post-mortem specimens.4 Canine 
neutrophils release NETs in vitro 38 and stimuli known to induce NET formation, 
including free heme/hemin;39,40 immune complexes41 and hypoxia,42 are likely often 
elevated in IMHA.43,44,45 In addition to elevated triggers for NET-release, in human SLE 
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there are increased low density granulocytes which very readily release NETs.46 These 
cells have yet to be investigated in dogs but may be another factor contributing to cell-
free DNA elevations in canine autoimmune disease. 
     Cell-free DNA could also be increased by impaired clearance. Reduced DNA 
degradation by endogenous DNase enzymes is reported in human SLE10,47,48 and 
antiphospholipid syndrome9 and is associated with disease severity.10,49 DNA degradation 
was not significantly decreased in IMHA cases compared with controls, and correlation 
between cell-free DNA concentration and DNA lysis was absent after exclusion of an 
outlier, or positive if this dog was included. It therefore appears that impaired DNA 
degradation does not contribute to elevated cell-free DNA in IMHA. It is however 
possible that interference from hemolysis or icterus may have falsely elevated the 
apparent DNase activity of IMHA sera.  
     We measured DNase activity using a simple ethidium bromide radial diffusion assay 
adapted from a previous report24 to allow more automated quantification. Hemoglobin 
and bilirubin spikes did increase the area of lysis. Absorption peaks for hemoglobin are at 
415, 540 and 570nm50and for bilirubin the peak varies with matrix but is between 415 
and 440nm.51 Therefore, the apparent increase in DNA lysis associated with particularly 
hemoglobin may be a genuine interference due to absorption of light emitted by ethidium 
bromide at close to its emission peak of approximately 600nm.  However, both hemolysis 
and icterus controls were derived from biological specimens and so may contain DNase 1 
activity. Statistical comparison of results for dogs with or without visible hemolysis or 
icterus did not reveal a significant difference in DNA lysis and serum was diluted 150 to 
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1, but interference cannot be ruled out. Effects of lipemia were not investigated as it was 
not visible in any control or case samples.  
     Methodological issues can influence cell-free DNA isolation. EDTA plasma was used 
because levels of DNA in serum are elevated by DNA released from dying cells.52 
Contamination of plasma by leukocytes or delayed plasma separation can also contribute 
to apparent increases in cell-free DNA.53 All samples were separated considerably less 
than 2 hours post collection, which is the time interval recommended for human samples 
and validated by other investigators for use with canine samples.17,54 Centrifugation speed 
was optimized for collection of platelet-poor plasma (data not shown) so should have 
consistently removed leukocytes. DNA concentration also reduces with prolonged 
storage or repeated freeze-thaw cycles.55 Samples were stored without freeze-thaw, but 
delay between plasma collection and DNA extraction did exceed the recommended 
interval of 9 months for 2 dogs (both IMHA cases).55 The difference between cell-free 
DNA in cases and controls remained significant after excluding these dogs 
(supplementary Table 2). It has also been suggested that direct measurement of DNA in 
plasma may be preferable in canine samples, as there is some loss of DNA during 
extraction.17 Direct measurement of cell-free DNA in plasma by PicoGreen fluorescence 
is a simple assay which correlates well with qPCR56 but we found that direct 
measurement of DNA in plasma was not reliable in IMHA due to marked interference 
from hemolysis and icterus with the Picogreen dye (supplementary Table 1). It is also 
notable that although Picogreen has been used in human studies without prior isolation of 
DNA,22,57 the product’s datasheet reports interferences from both albumin and IgG.58  
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     The time required for DNA isolation and quantification would be acceptable for 
clinical use and the equipment required readily available. The possible association 
between cell-free DNA and survival is therefore intriguing, but it should again be 
emphasized that the number of dogs that died or were euthanized is low. Not only does 
this mean that the point estimate of prognostic value provided by the area under the ROC 
curves and odds ratios are inaccurate (as shown by their wide confidence intervals), but 
there is also a high risk of a false positive result.59 The possibility that this may be a 
spurious result is also suggested by the lack of relationship between cell-free DNA and 
thrombosis, but accurate diagnosis of thrombosis in dogs is notoriously difficult.60 
However, this is not the first report of a relationship between cell death and prognosis in 
dogs:  cell-free DNA has a reported negative predictive value of 97% for death in a 
population of dogs with various diseases,17 and high cell-free DNA was a negative 
prognostic indicator in canine lymphoid neoplasia.61  
     A relationship between cell-free DNA and survival is biologically plausible. This is in 
part because DNA provides an indirect measure or cell death, and it will be important in 
future studies of its prognostic ability to compare performance with simpler measures of 
hypoxia and tissue damage such as lactate.45 However, DNA itself also has deleterious 
effects. Most notably in IMHA, a disease with a high rate of thrombosis, DNA can 
contribute to hypercoagulability. The negative charge of DNA provides a surface for 
contact pathway activation,11,12 and the DNA backbone of neutrophil extracellular traps 
may provide a scaffold locally concentrating tissue factor in association with a potential 
activator, protein disulfide isomerase.18 DNA is also anti-fibrinolytic, at least in part 
through formation of inhibitory complexes with fibrin and plasmin.13,14 In experimental 
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models of venous thrombosis, DNase therapy improves outcome18,19 and in a proof-of-
concept trial, metformin (which reduces mitochondrial neutrophil extracellular trap 
release), reduced SLE flare-ups in human patients.62 Although the current study does 
show overlap between IMHA survivors, non-survivors and healthy dogs, one individual 
had a very marked increase, suggesting therapies that reduce DNA release or accelerate 
its breakdown may have potential at least in a subset of cases. 
     In conclusion, this study demonstrates that cell-free DNA is increased in IMHA 
compared with healthy controls and this is likely due to increased production not reduced 
degradation. Preliminary data suggests that cell-free DNA may have value in predicting 
death or euthanasia, but this requires confirmation in a larger number of patients. 
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CHAPTER 7.  USING THE LABORATORY TO PREDICT THROMBOSIS IN 
DOGS: AN ACHIEVABLE GOAL? 
Modified from a paper published in The Veterinary Journal1 
Unity Jeffery, 2 Janice Staber, 3 Dana LeVine 4 
Abstract 
     Thrombosis is a major cause of mortality and morbidity in humans and dogs; however 
anti-thrombotic drugs carry a risk of bleeding and increase the cost of patient care. The 
ability to identify individuals at high risk of thrombosis would allow targeting of anti-
coagulant therapy at those most likely to derive a net benefit. Significant advances have 
been made towards predicting thrombotic risk in humans using laboratory tests 
individually and as part of risk prediction models. Assays which have shown potential in 
humans include D-dimers, activated partial thromboplastin time and viscoelastic testing, 
all of which are available to veterinarians. This review discusses the extent to which these 
assays are likely to predict thrombosis in dogs, and introduces new research techniques 
which may have future clinical value.   
                                                           
1 Jeffery U, Staber J, LeVine D. Using the laboratory to predict thrombosis in dogs: An achievable goal? 
The Veterinary Journal. 2016 Epub ahead of print (doi: 10.1016/j.tvjl.2016.03.027). Reproduced 
with permission. 
2 Department of Veterinary Preventative Medicine and Microbiology, Iowa State University. Primarily 
responsible for research and manuscript preparation; corresponding author. 
3 Pappajohn Biomedical Institute and Stead Family Department of Pediatrics, University of Iowa, Iowa 
City, IA 52242, USA. Provided manuscript review. 
4 Department of Veterinary Clinical Sciences, Iowa State University. Provided manuscript review and 
contributed a section on microparticles not included in the version modified for inclusion in this 
thesis. 
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Introduction 
     Thrombosis causes a staggering number of human deaths; venous thromboembolism 
(VTE) alone causes over 500,000 deaths annually within Europe (Cohen et al., 2007). 
Estimates of canine thrombosis mortality rates are lacking, but thrombosis is the leading 
cause of death in immune-mediated hemolytic anemia (IMHA) (Carr et al., 2002). Many 
other diseases are linked to increased thrombotic risk in dogs (e.g. protein losing 
nephropathy or enteropathy, neoplasia, and pancreatitis) (Palmer et al., 1998; Laurenson 
et al., 2010) and it is likely that rates of thrombosis are underestimated in such veterinary 
patients because of difficulty in ante mortem diagnosis (Goggs et al., 2014) and rapid 
dissolution of thrombi after death (Moser et al., 1973). 
     Unfortunately, anticoagulant therapy, although it prevents thrombosis, carries a risk of 
serious haemorrhage. The exact rates of bleeding vary between human patient 
populations (Agnelli et al., 2013) and anti-coagulant regimes (Robertson et al., 2015), but 
severe haemorrhage is generally uncommon (0.2-2% of humans) (Kearon, 2004; Carrier 
et al., 2010; EINSTEIN–PE Investigators, 2012; Gómez-Outes et al., 2015). Although 
anti-coagulant-associated haemorrhage has been reported in dogs (Scott et al., 2009), the 
rates associated with unfractionated or low molecular weight heparins are reportedly low 
(Breuhl et al, 2009; Lynch et al, 2014). Despite its infrequency, the risk of severe 
bleeding cannot be ignored because fatality rates are high, with a death rate of 11.3% 
(95% confidence interval: 7.5-15.9%) among human patients who develop a major bleed 
while receiving anti-coagulants (Carrier et al., 2010).  
     Ideally, anticoagulants would be administered only if the risk of thrombosis without 
treatment outweighs the risk of bleeding with treatment for an individual patient. In 
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human medicine, there is considerable interest in laboratory testing to stratify patients 
according to thrombosis risk so as to target anticoagulants to high-risk individuals 
(Baglin, 2011; Prandoni et al., 2014). In veterinary medicine, the ability to predict which 
dogs are at high risk of thrombosis would offer similar benefits in the management of 
IMHA. Furthermore, it would ensure the costs of anti-coagulant therapy and its 
associated monitoring are only incurred when the treatment is likely to be beneficial, thus 
potentially reducing financially driven euthanasia in this often highly expensive disease.  
     Additionally, for conditions in which the rate of thrombosis is too low to justify 
routine anti-coagulation, an inexpensive test capable of identifying dogs at high 
thrombotic risk could trigger treatment which protects these individuals from the 
mortality and morbidity of thrombosis. Beyond personalised therapy, risk stratification 
would allow investigators to selectively recruit high-risk animals, potentially resulting in 
smaller, more efficient clinical trials (Mandrekar and Sargent, 2010). Although a large 
number of potential markers of future thrombosis have been identified in human studies, 
in the current review, we will focus primarily on those available as clinical veterinary 
tests before briefly discussing promising novel developments. 
How accurate does a useful thrombosis predictor need to be? 
     The ideal marker would identify patients who will eventually develop thrombosis 
without anti-coagulant therapy with 100% sensitivity and specificity. Realistically, it is 
unlikely that future thrombosis can ever be predicted with absolute certainty. Instead, to 
be clinically useful a marker or multi-factorial model must separate patients into those for 
whom the risk of anti-coagulant-associated bleeding outweighs the risk of thrombosis 
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without treatment and those for whom the reverse is true (Kyrle and Eichinger, 2012; 
Rodger et al., 2014).  
     The balance between the risk of anticoagulation and the risk of thrombosis tips 
depending on the patient population and treatment regime. In human medicine, particular 
interest exists in identifying which patients with unprovoked (i.e. without underlying 
cause) VTE will benefit from long-term anticoagulation (Rodger et al., 2008; Marcucci et 
al., 2015; van Hylckama Vlieg  et al., 2015). Controversy exists about precisely how low 
the thrombotic risk must be to justify stopping anticoagulant therapy after unprovoked 
VTE. Markers which can identify a low risk population for whom the rate of thrombosis 
without therapy is less than 3-5% are generally considered useful (Kearon et al., 2010; 
Rodger et al., 2014). In veterinary medicine this cut-off value has not yet been calculated.  
Collecting high-quality data about the relative risks and costs of thrombosis versus anti-
coagulation will be important in discovering predictors of thrombosis in veterinary 
patients. 
Risk prediction models: important considerations 
     Development of risk prediction models is a complex process, which has been 
extensively reviewed elsewhere (Moons et al., 2012a; Moons et al., 2012b; Holmberg and 
Vickers, 2013). Two points are particularly relevant to our discussion. First, many of the 
studies discussed assess the risk associated with changes in a particular marker using an 
optimal cut-off determined for the study population. To avoid overestimating the 
performance of the marker, it is important to validate such cut-offs in an independent 
population (Holmberg and Vickers, 2013). Second, risk models are only useful if they 
alter clinicians’ behavior and improve outcome for individual patients (Holmberg and 
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Vickers, 2013). The impact on clinical outcome or treatment cost effectiveness has not 
been meaningfully assessed for any of the markers or models discussed in the current 
review; however these will be important in assessing future veterinary prediction models. 
Are markers identified in human studies likely to be of value in dogs? 
     A large number of markers have been associated with thrombosis risk in humans 
(Lijfering et al., 2010). Although there are a number of veterinary predictive models for 
death or euthanasia, models or markers that predict thrombosis have yet to be developed 
for canine patients (Hayes et al., 2010; Ishihara et al., 2010; Goggs et al., 2015).  
Identifying which human markers most likely to predict thrombosis in dogs requires 
careful consideration of several factors. There are major species differences in the 
patterns of thrombotic disease. In humans, arterial thromboembolic events (i.e. 
myocardial infarction and stroke) comprise the most common causes of death worldwide 
between 2000 and 2012 (World Health Organization, 2014). Accurate veterinary 
prevalence data is lacking but arterial thromboembolism is recognized to be uncommon 
in dogs (Lake-Bakaar et al., 2012). When arterial thrombosis does occur, low rates of 
atherosclerosis (Hess et al., 2003) in dogs suggest that the underlying pathogenesis is 
likely to be considerably different from humans (Farb et al., 1995; Gongora-Rivera et al., 
2007). In contrast, VTE is a frequent complication of the most common cause of severe 
anemia in dogs (Chervier et al., 2012), IMHA (Palmer et al., 1998; Carr et al., 2002; 
Laurenson et al., 2010). This review will therefore focus on markers which show promise 
for prediction of venous rather than arterial thromboembolism in humans.  
     Within VTE patients, there are important epidemiological differences. Unprovoked 
VTEs are important causes of morbidity and mortality in humans (Tagalakis et al., 2013) 
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whereas VTE in dogs appears to be principally a complication of a primary disease 
(Palmer et al., 1998; Laurenson et al., 2010; Respess et al., 2012). Therefore, although 
elevated acute phase proteins (e.g. fibrinogen [Kamphuisen et al., 1999], factor VIII 
[Kamphuisen et al., 1999] and C-reactive protein [Folsom et al., 2009]) indicate risk for 
human thrombosis with varying degrees of certainty, poor specificity may limit their 
usefulness in dogs since they may already be increased due to the underlying disease (de 
Moerloose et al., 2010).  
     There is insufficient data to determine if dogs have similar genetic mutations to those 
responsible for heritable increases in thrombotic risk in humans (e.g. factor V Leiden 
[Rosendaal et al., 1995], antithrombin [Martinelli et al., 1998] and protein C or S 
deficiency [Pabinger et al., 1994]) These factors will therefore not be discussed further in 
the this comparative review, but it should be noted that these proteins are also influenced 
by non-genetic factors. As there is evidence for associations between reduced 
antithrombin (Kuzi et al., 2010) and protein C (Goddard et al., 2013) and mortality in 
dogs, they merit further investigation as predictors of thrombosis in veterinary patients. 
Other human risk factors including anti-phospholipid antibodies (Miller et al., 2012) and 
hyperhomocysteinemia (Patterson et al., 2013) will not be considered further as 
preliminary canine data are not encouraging.  
     Additionally, an important consideration in selection of candidate markers is the 
feasibility of their use in a veterinary setting. In order for a marker to be useful in guiding 
therapeutics, it must not only provide acceptable sensitivity and specificity in the target 
species but also be: a) timely enough to inform treatment options b) easily interpreted by 
the clinician; and c) affordable when comparing increased diagnostic costs to reduced 
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drug expenditure. Therefore, our focus is on existing veterinary point of care (POC) tests 
and future technologies which have POC potential, rather than more laborious research 
techniques such as soluble P-selectin immunoassays, which although promising in some 
human studies (Kyrle et al., 2007; Ay et al., 2010) requires platelet-poor plasma 
processed under tightly controlled conditions (Amin et al., 2000). 
Clinical assays 
D-Dimers 
     During thrombosis thrombin cleaves fibrinogen into fibrin monomers composed of D 
and E domains (Figure 1) (Mosesson, 2005). These monomers aggregate to form 
hydrogen-bonded protofibrils. Simultaneously, Factor XIII is activated by thrombin and 
catalyses the formation of covalent bonds between the gamma chains of adjacent fibrin 
D-domains (Greenberg et al., 1985). These covalently-linked D-dimers convert the 
unstable protofibrils into a stronger cross-linked fibrin polymer (Mosesson, 2005). 
Plasmin and other proteases (Seitz et al., 1995) break down the fibrin polymers into 
smaller fragments which are successively cleaved until terminal degradation products, 
composed of one D-dimer and a single E group, are produced (Francis et al., 1980).                                                                                                     
     Understanding the mechanism of D-dimer production is vital for interpretation. Since 
D-dimers are generated only by lysis of cross-linked fibrin, they are markers of 
coagulation activation. This distinguishes D-dimers from fibrin(ogen) degradation 
products (FDPs) which can also be produced during primary fibrinogenolysis either by 
plasmin activated independently of thrombin or by other proteases (Gaffney, 1975; 
Kakishita et al., 1989; Bos et al., 1997). However, the specificity of D-dimers for 
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diagnosis of an existing thrombus is highly variable and often <50% in humans for DVT 
(Heim et al., 2004) and dogs for PTE (Epstein et al. 2013). Therefore, elevated D-dimers 
are generally considered of limited value in confirming thrombosis in either species 
(Heim et al., 2004; Epstein et al., 2013). The veterinary literature includes a number of 
examples of increase in D-dimers without pathological thrombosis due to breakdown of 
clots formed during hemorrhagic episodes (e.g. post-operatively [Sobiech et al., 2011], 
hemoabdomen [Nelson and Andreasen, 2003; Fletcher et al., 2015]). Reduced renal 
clearance has also been suggested to contribute to non-specific increase of D-dimers 
(Stockham and Scott, 2008), although this is disputed based on data from human patients 
with renal disease (Dubin et al., 2011). However, increases of D-dimers are also well 
documented in hypercoagulable humans without detectable thrombosis such as those with 
inflammatory disease (Wu et al., 2008), malignancy (Lippi et al., 2007) or normal 
pregnancy (Sattar et al., 1999). 
     Instead of reflecting a shortcoming of the D-dimer assay, increases in D-dimers in the 
above patients might actually reflect the assay’s sensitivity for a prothrombotic state.  In 
these individuals, elevated D-dimers without clinically-relevant thrombosis may reflect 
the fact that thrombi are not first fully formed then later broken down (Brummel et al., 
1999). Instead in vitro studies using human plasma show plasmin begins to cleave soluble 
cross-linked fibrin polymers before they are incorporated into a fibrin gel, thereby D-
dimer-containing fragments are not necessarily a marker of lysis from a stable clot 
(Francis et al., 1989; Brummel et al., 1999). This implies that D-dimers are a marker of 
hypercoagulability that could increase prior to, and thus potentially predict, thrombosis.  
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 Do D-dimers predict future thrombosis in humans?  
     There are a number of human studies documenting a statistical association between 
elevated D-dimers and increased risk of subsequent thrombosis at a population level. For 
example, in a prospective population-based study of 923 participants, higher baseline D-
dimers were associated with an increased risk of a thromboembolic event over the next 8 
years (Cushman et al., 2003). This association between elevated D-dimers and long term 
risk of first VTE has recently been replicated in a larger number of participants (>12,000) 
using a commercially available assay, rather than the research assay used in Cushman et 
al’s original 2003 study (Folsom et al., 2015). Similar associations between baseline D-
dimers and subsequent thrombosis risk have been demonstrated in cancer (Arpaia et al., 
Fig. 1. D-dimer formation. Fibrinogen contains D and E domains. Thrombin (IIa) 
cleaves fibrinogen to fibrin monomers which aggregate to form protofibrils. Factor 
XIII covalently cross-links D-domains producing crosslinked fibrin fibers. Plasmin 
breaks down crosslinked fibrin chains into progressively smaller fragments containg 
crosslinked D-domains, termed D-dimers. D-dimer containing fragments, but not 
other fibrin or fibrinogen breakdown products are recognised by anti-D-dimer 
monoclonal antibodies used in D-Dimer immunoassays.   
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2009; Ay et al., 2009) and surgical patients (Bongard et al., 1994; Cofrancesco et al., 
1997; Shimoyama et al., 2012).  
     For individual patients, D-dimers have been proposed as a marker to determine when 
anti-coagulation therapy can be discontinued after an initial VTE event. A systematic 
review of data from 1880 patients with unprovoked VTEs found that elevated D-dimers 
measured within 2 months of stopping anti-coagulant therapy were associated with an 
8.9% (95% CI 5.8%-11.9%) annual recurrence rate compared with 3.5% (95% CI: 2.7-
4.3%) for patients with normal D-dimers (Verhovsek et al., 2008). Meta-analyses of data 
from 15539 patients (Bruinstroop et al. 2009) and 1881 patients (Douketis et al., 2010) 
were similar: elevated D-dimers were associated with an odds ratio of 2.36 (95% 
Confidence interval 1.65- 3.36) or a hazard ratio 2.59 (95% Confidence interval 1.90-
3.52) for recurrence of unprovoked VTE respectively. Authors of all three studies 
concluded that D-dimers aided in determining duration of anti-coagulant therapy as part 
of multi-factorial clinical prediction rules rather than a stand-alone test (Verhovsek et al., 
2008; Bruinstroop et al. 2009; Douketis et al., 2010). 
     Several such multi-factorial models have been proposed to determine the duration of 
anticoagulation therapy following a VTE event, including the Vienna (Eichinger et al., 
2010), DASH (D-dimer, Age, Sex, Hormonal therapy) (Tosetto et al., 2012) and 
HERDOO2 (Hyperpigmentation/ edema/redness, D-dimer, obesity, older age) schemes 
(Rodger et al., 2008). Promising evidence points to the usefulness of such scoring 
schemes in at least some subgroups but the only models that have been externally 
validated are the Vienna scheme and a modification of this scheme.  The original Vienna 
model underestimated cumulative 12 month recurrence rates in the validation cohort 
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(Marcucci et al, 2015), and the modified scheme failed to discriminate between elderly 
patients who developed VTE recurrence after stopping anti-coagulants and those who do 
not (Tritschler et al, 2015).  
Could D-dimers predict future canine thrombosis? 
     The ability of D-dimers to predict future thrombosis or determine if anticoagulant 
therapy can be discontinued has not been directly assessed in dogs in large scale studies. 
One prospective study of nine dogs with parvoviral diarrhea did not identify elevations in 
D-dimers at study entry in any dog, although five thrombotic events occurred (Otto et al., 
2000). The authors therefore concluded that D-dimers could not detect a hypercoagulable 
state, but did stress the limited sensitivity of the particular assay used (Otto et al., 2000). 
In contrast, more recent studies suggest that D-dimers may be capable of detecting 
hypercoagulability before development of an overt thrombus.  These studies documented 
elevated D-dimers in dogs with diseases associated with a hypercoagulable state without 
clinically-identifiable thrombi, including cancer (Andreasen et al., 2012), adulticide 
heartworm treatment (Carretón et al., 2014) and extra-hepatic biliary obstruction 
(Mayhew et al., 2013). D-dimers can be measured using commercially available 
relatively inexpensive assays; therefore, evaluation of their ability to predict future 
thrombosis in high-risk dogs or to guide withdrawal of anti-coagulants in IMHA is 
appealing. 
     An argument against evaluation of D-dimers in dogs is the suggested kinetics of D-
dimer elevation in dogs: a rapid rise within 1 hour of thrombosis followed by return to 
baseline by day 7 (Goggs et al, 2014).  In contrast, in some humans, D-dimers remain 
elevated up to 1 year after initial thrombosis (Meissner et al, 2000). However, the time 
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course of D-dimer elevation in dogs was extrapolated from an experimental study in 
which blood clots were formed ex vivo using dog blood and human fibrinogen before 
infusion back into experimental dogs (Ben et al, 2007). Antibodies capable of identifying 
human (but not canine) D-dimers were then used to track clot lysis. This study does not 
account for ongoing fibrin formation and breakdown present in a naturally occurring 
hypercoagulable state.  
     Other arguments against the potential predictive value of D-dimers are more 
compelling.  A difficulty in using D-dimers in human risk prediction models is that 
different assays can report markedly different values for the same sample. For example, 
eight different D-dimer tests demonstrated poor correlation when compared in a study of 
290 consecutive human patients with suspected venous thrombosis (Oude Elferink et al, 
2015). Veterinary studies often involve semi-quantitative kits and so focus on agreement 
between kits in their classification of D-dimers as normal or elevated, rather than direct 
comparisons of measured values (Stokol et al, 2000; Griffin et al, 2003; Boutet et al, 
2009). These studies have also demonstrated limited agreement between assays. Stokol et 
al (2000) reported that when D-dimers were measured in dogs with disseminated 
intravascular coagulopathy, concordance between a latex agglutination and an 
immunoturbimetric assay was 65% when the upper reference limit was used to define 
elevated D-dimers by the immunoturbimetric method. 
     This marked variation in assay performance leads to complexity in applying the cut-
off for elevated thrombotic risk determined in one study to results generated by another 
laboratory (Dempfle et al, 2001; Adam et al, 2009). Limited agreement between assays 
reflects both the lack of standardized calibrators and the variable sensitivity and 
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specificity of the antibodies used in different assays. This variability in antibody 
performance is a major issue for D-dimer assays, because the antibodies are not specific 
for terminal D-Dimer fragments and vary considerably in their ability to recognise other 
higher molecular weight fibrin degradation products. 
     It is likely that differences in antibody performance will be an even greater problem in 
veterinary than human risk prediction models because current commercially available 
assays rely on anti-human antibodies. One reason D-dimers have largely superseded 
FDPs for evaluation of thrombotic disease is their specificity for fibrin, rather than 
fibrinogen, breakdown (Rose and Caveen, 2005). However, this apparent specificity 
cannot be taken completely for granted in the veterinary context, because most studies 
have not confirmed that the anti-human antibodies used in commercial assays reliably 
distinguish canine D-Dimers from FDPs (Caldin et al, 2000; Stokol et al, 2000; Nelson 
and Andreasen, 2003; Dewhurst et al, 2008). A need to document antibody performance 
in dog plasma is suggested by the recent report that a monoclonal human antibody was 
specific for, but less sensitive to canine than human D-dimers (Miura et al, 2013). 
     Potentially these hurdles could be overcome by standardisation of veterinary assays. 
However, even then D-dimers may not perform as well as a predictor of thrombosis in 
dogs compared to humans. As discussed, many human thromboembolic events are 
apparently without underlying cause, whereas in dogs, thrombosis is often associated 
with systemic illness. Evaluation of D-dimers as predictors of thrombosis in humans with 
underlying disease appears to be useful, however the studies are small and only support 
use in some diseases (e.g. systemic lupus erythematosus [Wu et al, 2008]) with no 
evidence of value in others (e.g. nephrotic syndrome [Sexton et al., 2012]). These data 
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suggest that prior to evaluating D-dimers as a predictor of thrombosis in dogs, the study 
population needs to be carefully defined and results from one population may be poorly 
generalizable to others. 
Activated partial thromboplastin time (aPTT) 
     aPTT is a measure of the activity of coagulation factors of the intrinsic and common 
pathways.  Investigation as a predictor of thrombosis started because increases in the 
activity of intrinsic and common pathway factors increases thrombotic risk (Tripodi et al, 
2004). Reduced aPTT has been identified as a risk factor for first or recurrent VTE in 
several human studies (Tripodi et al, 2004; Hron et al, 2006a; Zakai et al, 2008; Senthil et 
al, 2014).  However, the ability of shortened aPTT or reduced aPTT ratio (an index 
calculated in human medicine by comparison of patient aPTT to reference material) to 
discriminate between patients with a high and low risk of thrombosis appears modest. For 
example, in a prospective study of 918 patients with a previous history of unprovoked 
VTE, probability of recurrent VTE within the four year follow up was 15.6% (95% CI: 
11.4–19.9%) for patients with a ratio < 0.95, and 8.5% (95% CI: 5.5–11.5%) for patients 
with a ratio ≥ 0.95 (Hron et al, 2006a). 
     aPTT has received less attention than D-Dimers as a predictor of thrombotic risk. This 
reflects both the failure to replicate an association between aPTT and thrombosis in some 
populations (Aldawood et al, 2011) and the fact that an 8.5% recurrence rate is too high 
to justify stopping anti-coagulant therapy in the patients classified as low-risk (Kearon et 
al, 2010).  However, aPTT is used in a recently proposed thrombosis prediction risk-
scoring model in human Cushing’s disease (Zilio et al, 2015). 
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     There are several reasons to be sceptical about the value of aPTT in veterinary models. 
Firstly, none of the cut-offs proposed in human studies have been prospectively validated 
in independent populations. This may be a reflection of the considerable variability in 
sensitivity of aPTT reagents which in turn limits the generalisability of cut offs proposed 
(Brandt et al, 1990). Secondly, dogs have shorter aPTT times than humans (Feingold et 
al, 1986), so discriminating between normal dogs and those with shortened times may 
challenge the precision and sensitivity of current assays. Thirdly, most dogs with 
thrombosis have normal aPTT (Johnson et al, 1999; Boswood et al, 2000; Otto et al, 
2000) and although one study identified prolonged aPTT as associated with a mildly 
increased hazard ratio for death in IMHA (Piek et al, 2008), shortened aPTT has not been 
identified as a risk factor (Swann and Skelly, 2015). 
Viscoelastic testing (Sonoclot, TEG, and ROTEM) 
     Viscoelastic techniques, which measure changes in the mechanical properties of blood 
during clotting, have been extensively reviewed (McMichael and Smith, 2011; Karon, 
2014). The precise mechanism varies between the three analysers reported in the 
veterinary literature: Sonoclot, TEG and ROTEM (McMichael and Smith, 2011). Each 
analyser provides slightly different indices. The indicators most commonly used in 
thrombosis risk models are the indicators of overall clot strength termed peak amplitude, 
maximal amplitude (MA) or maximal clot firmness (MCF) by the respective assays 
(McMichael and Smith, 2011) (Fig. 2). 
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Can viscoelastic testing predict thrombosis? 
     Despite an explosion of interest in viscoelastic testing over the last decade, evidence 
that it predicts thromboembolic events is relatively weak and evidence that it improves 
outcomes is lacking (Dai et al, 2009; Harr et al, 2013). Viscoelastic testing has 
demonstrated a hypercoagulable state in a wide range of canine diseases, including 
cancer (Andreasen et al, 2012), hyperadrenocorticism (Park et al, 2013), IMHA (Sinnott 
et al, 2009; Goggs et al, 2012) and protein losing nephropathy (Lennon et al, 2013). 
However, at the time of writing there is no large scale prospective study evaluating the 
ability of viscoelastic studies to identify dogs at high risk of future thrombosis. Without 
such a study, definitive conclusions cannot be drawn, but there is some evidence to 
suggest that viscoelastic testing is not a “silver bullet” for prediction of canine 
thrombosis. A recent retrospective study of 39 dogs found no association between any 
TEG parameter and the presence of thrombosis at post-mortem (Thawley et al, 2016). 
Figure 2. Examples of normo- (A) and hyper-coagulable (B) canine kaolin activated TEG traces. 
Human studies suggest elevated maximal amplitutde (MA) (as seen in B) may be predictive of future 
thrombosis.  Images courtesy of Dr. Rita Hanel, North Carolina State University. 
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Similarly, in dogs with IMHA undergoing CT angiography to identify pulmonary 
thromboembolism, MA was within normal limits for 2/3 with thrombosis and increased 
in ¾ without thromboembolism (Goggs et al, 2014). 
     Many human studies have focused on prediction of thromboembolic events using TEG 
or ROTEM in post-operative or trauma patients. In these populations, most (Kashuk et al, 
2009; Cotton et al, 2012; Hincker et al, 2014) but not all (Van Haren et al, 2014) studies 
show at least some degree of association between a hypercoagulable 
thromboelastometry/thromboelastography trace and increased risk of thrombosis. 
However, the performance of viscoelastic parameters as predictors of thrombosis is 
highly variable (Dai et al, 2009). Estimates of diagnostic accuracy for elevations in 
indices of clot strength range from low to high, as demonstrated by areas under ROC 
curves of 0.57 to 0.91 in papers included in a systematic review of TEG as a predictor of 
post-operative thrombosis (Dai et al, 2009). 
     This extreme variability in diagnostic performance highlights potential problems in 
using viscoelastic testing as a tool for identifying high-risk populations. Firstly, 
viscoelastic testing is strongly influenced by sample collection, sample processing and 
analytical variables (McMichael and Smith, 2011). For example, results generated by 
ROTEM are not interchangeable with TEG (McMichael et al, 2014); results generated 
using different activators are not interchangeable (deLaforcade et al, 2014); and 
significant inter-operator variability has been reported (Anderson et al, 2014).  These 
factors combine to produce relatively poor inter-laboratory agreement, as shown by the 
large coefficients of variation for TEG quality assurance data (9-45%) compared with 
routine coagulation testing (typically < 5 %) (Karon, 2014). Therefore, development of 
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algorithms for use at multiple institutions would require a large effort to standardise pre-
analytical and analytical factors. 
     Secondly, viscoelastic testing is affected by many patient factors. Therefore, a 
parameter that successfully predicts thrombosis in one population may perform poorly in 
another. For example, Bolliger et al (2012) draw attention to the differences between 
human post-operative patients and those with heparin-induced thrombocytopenia (HIT), 
both of whom are at increased risk of thrombosis. Post-operative patients often have 
increased fibrinogen and platelet counts, which lead to increases in clot strength indices 
such as MA. In contrast, HIT is associated with high risk of thrombosis, but low platelet 
counts frequently result in normal to low MA (Bolliger et al, 2012). This raises doubts 
about the ability of viscoelastic testing to identify thrombosis risk in HIT, although the 
results of a proposed study investigating this have yet to be reported (Kouerinis et al, 
2008).  Unsurprisingly this leads to identification of different parameters as indicators of 
thrombosis risk in different populations (Dai et al, 2009). Most intriguingly, a flat line 
TEG trace (generally interpreted as evidence of marked hypocoagulability or 
hyperfibrinolysis) was an independent predictor of pulmonary thromboembolism in a 
study of human liver transplant patients (Sakai et al, 2012). 
     Similar examples of the importance of patient variables are present in veterinary 
medicine. Perhaps most importantly IMHA cases have a high risk of thrombosis and can 
have large fluctuations in haematocrit associated with disease progression and transfusion 
therapy. Reductions in haematocrit increase viscoelastic clot strength indices (e.g. MA) 
(Bochsen et al, 2011), which is now largely accepted to represent an artefact of 
viscoelastic testing rather than a true in vivo change (Brooks et al, 2014).  Developing a 
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helpful algorithm to guide anti-coagulant use in these patients based on whole blood 
viscoelastography could prove challenging. 
Novel tests 
     Haemostasis is a rapidly evolving research area. Biomarkers and technologies 
currently confined to the research laboratory have the potential to enhance our ability to 
predict future thrombosis. These include techniques that have been used in dogs, such as 
thrombin generation potential (Allegret et al., 2011). 
     Thrombin generation is of particular interest, as it represents a readily automated assay 
integrating the influence of multiple factors on coagulation (van Geffen and van Heerde, 
2012). The assay uses a chromogenic or fluorogenic thrombin substrate to measure 
thrombin generation after initiation of coagulation using tissue factor (van Geffen and 
van Heerde, 2012). Several studies suggest that thrombin generation parameters are 
associated with thrombotic risk in humans (Hron et al, 2006b; Eichinger et al, 2008; 
Tripodi et al, 2008). However, there is yet to be a large scale prospective trial to validate 
a previously proposed cut-off in an independent population. Furthermore, prediction of 
thrombosis recurrence is inconsistent and based on a recent study by van Hylckama Vlieg 
et al (2015), not as reliable as D-dimers. In its currently available commercial format, the 
assay fails to assess the contributions of erythrocytes or altered fibrinolysis to 
hypercoagulability which is a disadvantage compared to viscoelastic testing (van Geffen 
and van Heerde, 2012). However, modifications in which there is concurrent 
measurement of plasmin activity (van Geffen et al, 2011) or where electrochemical 
detection of thrombin generation allows the use of whole blood (Thuerlemann et al, 
2009) offer potential solutions to these limitations. 
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     Other exciting new assays of global clot formation and structure have yet to be 
validated in clinical veterinary patients. These include microfluidic devices and magnetic 
resonance imaging. Microfluidic devices use various detection methods to measure clot 
formation and requires only small volumes of blood or plasma that move through 
channels. The major use of such technology in veterinary medicine is the PFA-100, a 
platelet aggregometer, which is primarily used in the context of human thrombosis to 
identify non-responders to anti-platelet drugs (Montalescot et al, 2014). In a research 
setting, the PFA-100 has been used to identify aspirin resistant dogs (Dudley et al, 2012) 
and to assess platelet reactivity in potentially pro-thrombotic states such as cancer (Eberle 
and Mischke, 2010), hyperadrenocortisim (Kol et al, 2013) and cardiac disease (Tarnow 
et al, 2003; Clancey et al, 2009). These studies have not demonstrated platelet hyper-
reactivity in affected dogs. While there may be genuine lack either of a hypercoagulable 
state or of a platelet contribution to hypercoagulability in tested patients, it also likely 
reflects the influence of pre-analytical factors and the insensitivity of the technique to 
subtle increases in platelet reactivity due to relatively high concentrations of agonists 
(Gorog and Fuster, 2013). 
     The next generation of microfluidic technology is considerably more sophisticated and 
can be engineered to mimic both normal and disturbed blood flow in different vessels and 
even include endothelial cells (Branchford et al, 2015). There is a considerable body of 
evidence for the modification of coagulation by shear rate (Cosemans et al, 2013), shear 
stress (Tsai, 2003) and endothelial interactions (Aird, 2015). Therefore, development of 
clinical assays integrating these factors could considerably improve our understanding of 
overall coagulation status in individual patients. 
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     Skewis et al (2014) have recently published a global assay which may identify novel 
components of hypercoagulability. The assay uses a bench-top T2-weighted magnetic 
resonance (T2WMR) instrument to measure proton T2 relaxation times of water in small 
volumes (0.04 ml) of clotting whole blood.  Preliminary data suggests that T2WMR can 
identify tightly contracted, lysis resistant clots which the authors postulate may be a 
future clinical marker of hypercoagulability (Skewis et al, 2014).  
     In addition to such new technologies, new studies in clot formation identified potential 
novel biomarkers of hypercoagulabilty. For example, neutrophil extracellular traps 
(NETs) are webs of DNA and protein released by neutrophils in response to infectious 
and inflammatory stimuli (Brinkmann et al, 2004). NETs are involved in infection control 
and are highly pro-thrombotic (von Brühl et al, 2012). It has been recently demonstrated 
that dogs release NETs and, in a preliminary study, nucleosomes (a marker correlated 
with NET formation) were elevated in the serum of dogs with IMHA (Jeffery et al., 
2015). Similar elevations have been found in human patients at risk of thrombosis, and 
there is considerable interest in their use as predictors of thrombotic risk (Fuchs et al., 
2012; van Montfoort et al., 2013). 
Conclusions 
     Development of individual markers or risk stratification models for predicting 
thrombotic risk has the potential to improve veterinary care. In humans, many markers 
are associated with increased thrombotic risk. However, statistical association at the 
population level is no guarantee that a marker will adequately predict thrombosis risk for 
an individual.  Systematic reviews and meta-analyses of human markers concluded that 
development of models which integrate laboratory results, clinical findings and 
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signalment are more likely to accurately predict thrombotic risk than laboratory data 
alone. Development of risk stratification models for death in canine patients show this 
approach is possible in dogs. None of the markers discussed are without limitations, but 
of the three widely available clinical assays, D-dimers and viscoelastic testing appear 
more promising than aPTT as components of veterinary thrombosis prediction models. 
However, markers are unlikely to be successful unless adequately standardized and 
applied only to clearly defined populations. Even after doing this, a number of hurdles 
must be overcome before prediction of thrombosis becomes an achievable veterinary 
goal, not least the need to develop robust methods for diagnosis of thrombosis. 
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CHAPTER 8. CONCLUSIONS 
Summary of findings 
     The research presented in this thesis demonstrates that canine neutrophils can release 
NETs in response to agonists known to induce NETosis in other species. In vitro 
investigations confirmed that NETs have pro-coagulant effects on canine enzymatic 
coagulation factors, platelets and fibrinolysis. Cell-free DNA, a marker correlated with, 
but not specific for NETs, was increased in dogs suffering from IMHA, a disease 
associated with high risk of thrombosis. This increase could not be explained by impaired 
degradation, supporting the conclusion that there is increased release of DNA in IMHA.  
Possible implications  
     The ability of canine neutrophils to form NETs is not unexpected, as release of 
extracellular traps has been demonstrated in a wide range of species including 
invertebrates (1). However, development of a protocol for inducing NETosis by canine 
cells was necessary for subsequent investigations of interactions between NETs and the 
canine coagulation system. The protocol presented here is straightforward and could be 
readily used to investigate other effects of canine NETs. 
     Interactions between NETs and the canine coagulation are broadly similar to those 
reported in human studies (2,3). Minor differences, such as persistence of increased clot 
formation velocity after digestion of NETs by DNase, likely represent technical 
differences in assay set-up rather than true species differences. This work though does 
add a novel element to the literature, because NETs were used in the absence of 
neutrophils. This is in contrast to most previous studies which have exposed plasma or 
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platelets to neutrophils induced to form NETs (2,3). The data presented here therefore 
provides confirmation the pro-coagulant properties attributed to NETs are directly related 
to NETs rather than other products of activated neutrophils. 
     The finding that NETs have pro-coagulant properties suggests that therapeutic 
strategies targeted at NETs may improve outcome in canine inflammatory diseases 
associated with high risks of thrombosis. Based on the findings of this thesis, 
investigation of strategies that target DNA or protein components may both be of value in 
diseases including IMHA. The source of cell-free DNA in dogs with IMHA was not 
identified during the current study, but this it should be emphasized that, provided 
concentrations were high enough, DNA alone promoted increased maximum clot 
formation velocity and impaired clot lysis. The specific protein components of NETs 
responsible for the pro-coagulant properties that persisted after DNase digestion were not 
identified during this research. However, human studies suggest that histones are the 
most likely activator of platelets and contribute to other pro-coagulant actions of NETs 
(2,3). Obviously neither histones nor DNA are exclusive to NETs, but will be released 
during other forms of cell death. Therefore, the finding that DNA promotes canine clot 
formation and impair lysis is relevant to IMHA even if DNA is not released by NETosis. 
     The spectrophotometric assay described in chapter 3 was originally intended to be 
used to assess relationships between markers of NET formation and clot formation and 
lysis kinetics in the plasma of dogs with IMHA. This was not possible due to 
interferences from hemoglobin and bilirubin. However, preliminary data does suggest 
that this assay can recognize altered fibrinolysis in interferant-free specimens, and that 
this is a potential predictor of bleeding and thrombosis. If this is replicated in a larger 
237 
 
 
number of cases, this could be very valuable in identifying dogs at high risk of surgical 
bleeding.  
     This assay was not the only technique assessed during the course of this thesis which 
was unacceptably influenced by interferents. Previous human and experimental animal 
studies which used these techniques have not discussed the effects of interference (4,5,6). 
Therefore, although interference complicated data analysis in the current work, 
recognizing its effects could have important implications for interpretation of other 
studies performed using these techniques. 
Limitations  
     The in vitro studies presented here suffer from limitations that are common to most 
research involving NETs. There is always the difficulty of how pure a population of 
neutrophils is pure enough? The density gradients used to separate neutrophils in the 
work presented here will not remove other granulocytes but will lose low density 
neutrophils. Therefore, the extracellular traps used here likely include at least some 
contribution from eosinophils and other granulocytes, and may not represent the full NET 
producing capacity of canine neutrophils. Perhaps more importantly, it is unclear to what 
extent the form of NETosis induced by PMA (the major agonist used here) in low serum 
concentration culture conditions is physiologically relevant. As discussed in the 
introduction, NETs are a morphologic description rather than the outcome of a single, 
well defined cell death program (7). If the NETs released by dogs in vivo more closely 
replicate forms of NETosis other than that induced by PMA, their properties, including 
pro-coagulant effects, may differ from those reported here.  
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     Similarly, it is difficult to claim with any certainty that the NETs used in the 
coagulation studies truly recapitulate NETs found in circulation. I opted to use NET 
fragments, rather than NETing neutrophils, to try to bridge the gap between experimental 
studies showing pro-coagulant properties of NETing neutrophils and observations that 
circulating markers of NET formation are elevated in humans with thrombosis (8). While 
it seems unlikely that NETs are circulating as large structures under conditions of shear 
stress, it must be acknowledged that the extent to which the NET fragments used in these 
studies mimic circulating NETs is unknown. Equally, the rationale for using NET 
fragments was in part to remove other effects of neutrophils. A published protocol was 
used to generate the NET-rich supernatants but this involves only centrifugation (9). It is 
likely that the supernatants also contain neutrophil degranulation products, and possibly 
cell fragments other than NETs, which may have contributed to the apparent 
hypercoagulable effect of NETs.  
     When interpreting the coagulation experiments and the spectrophotometric assay, it is 
also important to recognize that the conditions do not fully recapitulate coagulation in 
vivo. A number of important components are missing, particularly endothelial cells and 
the effects of shear stress. When thrombi are induced in mice experimentally, NETs 
released at sites of vascular damage are able to interact with coagulation components 
(10). It is less clear if these interactions would persist in general circulation, and the 
effect of NET fragments under conditions of shear stress is therefore debatable. 
     The perhaps most serious limitations of the work presented here relate to the 
challenges of conducting research using clinical patients. Dogs are particularly difficult to 
work with due to limited availability of commercial reagents and established assays, and 
239 
 
 
the frequent presence of hemolysis and icterus in IMHA samples prevents the use of 
many colorimetric assays. Efforts to specifically measure NETs in canine samples were 
unsuccessful, and the source of cell-free DNA in IMHA cases remains unclear. Limited 
case numbers also prevented firm conclusions from being drawn regarding the 
relationship between cell-free DNA concentration and outcome in IMHA. In hindsight, 
the power of the study could have been increased by following dogs for longer than 14 
days, as at least 2 dogs died after this point. As dogs were not systematically followed 
beyond 14 days, including these events in data analysis would potentially have 
introduced bias. 
Further studies 
     The work presented here does suggest several other areas of research. There is clearly 
a need to better understand the nature of NET formation and degradation in vivo, both in 
dogs and other species. Characterizing the size and composition of circulating NETs in 
inflammatory disease should be a priority as it would allow more accurate assessment of 
the ability of NET fragments to promote a global hypercoagulable state. This is clinically 
relevant as it could determine if therapies to neutralize NETs are useful in preventing 
thrombosis or only in reducing pathology associated with an existing thrombus. 
     Studies of interactions between NETs and the components of the coagulation system 
did not identify specific proteins involved in effects that persisted after DNase digestion. 
The extent to which neutrophil specific proteins are involved deserves further 
investigation. Although early research did show a specific role for elastase in promoting 
thrombosis (10), this has not been replicated in another thrombosis model (11). If NETs 
promote thrombosis solely due to the properties of chromatin, specifically measuring 
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NETs and attempting to reduce NET release 
may be less effective strategies for predicting 
or preventing thrombosis than targeting cell-
death more generally. 
     Despite that caveat, it would be interesting 
to determine the source of increased cell-free 
DNA in dogs with IMHA. Development of a 
specific marker for NETosis is an obvious 
goal, but is challenging as NETs are 
relatively fragile and it is unclear to what 
extent they survive intact in circulation. Other 
groups have published ELISAs capable of detecting DNA and myeloperoxidase 
simultaneously but extensive validations of this technique have yet to be published 
(12,13,14). Development of such an ELISA for use in canine plasma was attempted 
during the course of this research but was unsuccessful. One simple strategy for 
distinguishing apoptotic from necrotic fragments is gel electrophoresis of plasma derived 
DNA. This was performed on the dog with the highest DNA concentration in the study 
presented here, and was most consistent with low molecular weight apoptotic fragments 
(Figure 1). However, it should be emphasized this was performed on a stored sample and 
future studies in which electrophoresis is run shortly after collection of samples are 
required. 
     Evaluation of cell-free DNA as a predictor of death in IMHA needs to be conducted in 
a larger group of animals. Based on the data presented here, there is overlap between cell-
 
Figure 1. Plasma derived DNA from an 
IMHA case is largely present as low 
molecular weight fragments. DNA from the 
plasma of the case with highest DNA 
concentration was run on a 10% agarose gel. 
Most DNA is present as a band of 
approximately 180kDa, suggestive of 
chromatin fragmentation during apoptosis. 
However, the plasma sample had been stored 
at -80oC for several months and degradation 
of large necrotic or NET fragments by 
endogenous DNases cannot be ruled out as a 
source of the low molecular weight DNA. 
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free DNA in survivors and non-survivors. It is therefore unlikely that cell-free DNA 
alone will reliably predict death, but our preliminary data suggests it may have prognostic 
ability which could be improved by inclusion in a model with other factors. Similarly, the 
spectrophotometric method for assessing fibrinolysis needs to be validated in a larger 
cohort to determine to what extent it can, for example, identify dogs likely to need 
transfusion during surgery. 
     Lastly, this thesis demonstrates that there are many gaps in our knowledge regarding 
IMHA. The triggers for development of apparently idiopathic IMHA remain unknown, 
and investigation of the role of specific environmental and genetic factors (e.g. skewed 
X-inactivation) deserve further study. There is a lack of understanding of the extent to 
which extra-vascular hemolysis is pro-thrombotic, and the mechanism by which it may 
act. Investigation of the effects of erythrocyte phagocytosis on macrophages, and 
subsequent influences on coagulation are clearly needed. The introduction provided 
evidence that survival of dogs with IMHA has not improved over time, despite increasing 
complexity and costs of care. There is an urgent need for evaluation of novel therapeutic 
strategies, and the growing body of literature linking hemolysis to thrombosis suggests 
therapies such as L-Arginine to increase nitric oxide availabilty should be included in 
these investigations (15). 
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APPENDIX A 
CONSENT FORM FOR IMHA CASES 
Consent to Assess Clinical Outcomes in the Course of  
New Veterinary Treatments 
 
This Form to be used in conjunction with ISU Veterinary Medical Center 
“Consent to Treatment and/or Operation” 
 
Title of Study:  Coated platelets in dogs at risk of thrombosis  
Investigators: Dana LeVine and Unity Jeffery  
 
What is the purpose of this research study? 
 
The purpose of this study is to determine if dogs with conditions known to be associated with 
increased risk of blood clots (thrombi) have higher levels of coated platelets than healthy dogs. 
Platelets are cell fragments that are important in clot formation. Coated platelets are a subtype 
of platelet which has increased potential to activate proteins important in blood clotting. If we 
find coated platelets are increased in dogs at risk of blood clots, they are a potential drug target 
to protect dogs against pathologic blood clot formation. 
 
What is involved in participation in the study? 
 
If you agree to have your animal participate in this study, the participation will involve collection 
of a single blood sample of up to 10ml by a licensed veterinarian or technician, which will take 
approximately 5 minutes.   
 
What are the possible risks to my animal from being in this study? 
 
The possible risks for your animal from participation are:  mild bruising at the site of blood 
collection and mild discomfort during blood sample collection.  Additionally, there may be 
unforeseen risks of participation in this study.  In the event of unforeseen risks, the investigator 
will use his or her judgment to guide the care of your animal and discuss options with you when 
possible under the circumstances.  The investigator may terminate your animal’s participation in 
the study if continuation is not in the best interest of your animal or as otherwise deemed 
prudent or necessary by the investigator.  In the unexpected event of your animal’s death during 
the study, a post-mortem examination may be required to determine the cause of death (i.e., 
the death may or may not be related to the research and may even be the result of a natural 
cause). The need for autopsy will be determined by the investigator and the ISU Attending 
Veterinarian and/or the Institutional Animal Care and Use Committee; the investigator will pay 
for any costs associated with the necropsy. 
 
Will I have any costs from this research or will I be compensated?  
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You will not have costs from your animal’s participation in this study.  You will be responsible for 
any costs associated with the normal course of treatment, the treatment of any complications 
that may arise, and unrelated medical conditions.  
 
You will not be compensated for your animal’s participation in this study.   
 
 
 
Can my animal receive treatment if I do not want them to be in the research study? 
 
Participation in this study is completely voluntary.  You may choose not to have your animal 
participate.  If you decide to have your animal participate, please realize that once the blood 
sample has been collected, this cannot be reversed.  However, you may change your mind and 
withdraw your animal from further participation in the study at any time.  If you decide not to 
have your animal participate in the study or if you withdraw your animal from the study early, it 
will not affect your right to receive treatment for your animal at the Iowa State University 
College of Veterinary Medicine.  We can discuss the usual treatment options noted above and 
any alternative diagnostics, procedures, or treatments that may be available if your animal is not 
enrolled in the study. 
 
What measures will be taken to protect my privacy? 
 
Government regulatory agencies and Iowa State University may inspect and/or copy the records 
for your animal for quality assurance and data analysis.  These records may contain private 
information.  Additionally, the investigators may use data generated from this study, including 
photographs and video images, in scientific journal articles or presentations and for educational 
purposes.  Neither you nor your animal will be identified individually in such articles, 
presentations, or educational programs.   
 
Whom can I call if I have questions or problems? 
 
You are encouraged to ask questions at any time during this study.  For further information 
about the study, contact Unity Locke (515 203 5916, ublocke@iastate.edu) or Dana LeVine (515 
291 5722, dnlevine@iastate.edu).   
 
****************************************************************************** 
 
246 
 
 
OWNER SIGNATURE 
 
Your signature indicates: (1) you voluntarily agree to your animal’s participation in this 
study; (2) you are the legal owner of the animal or are an agent of the owner with 
authority to consent to the animal’s participation in this study; and (3) you have read this 
Owner Consent Document and your questions have been satisfactorily answered.  You 
will receive a copy of this Owner Consent Document prior to your animal’s participation 
in the study. 
 
Printed Name of Owner or Agent:         
 
Owner or Agent’s Signature:          
 
Name of Animal:            
 
Date:      
     
 
INVESTIGATOR STATEMENT 
 
It is my opinion that the owner or owner’s agent understands the purpose, risks, benefits, 
and the procedures that will be followed in this study and has voluntarily agreed to 
participate.    
 
Investigator Signature:                                                                                               
  
 
Date:                                                  
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APPENDIX B 
SAMPLE COLLECTION AND PROCESSING SOP FOR IMHA CASES 
  SOP: Blood Collection for “Are canine NETs prognostic markers in Immune Mediated 
Hemolytic Anemia (IMHA)?”  
IACUC requirements: Up to 80 dogs enrolled. Up to 10ml of blood and 1 free catch voided urine 
sample/dog 
Criteria for blood collection:  
• Owner consent 
• Suspected IMHA 
• Not heparinized at time of collection 
Criteria for long term storage: 
• Anemia  
• Positive Coomb’s test OR positive saline dispersion test 
• No evidence of underlying cause 
Required samples 
1. Citrated platelet poor plasma 
2. EDTA plasma 
3. Serum 
4. Blood smears 
5. Urine 
6. Urine sediment 
Blood sampling 
Equipment 
1. LAVENDER top tube (EDTA)=3ml tube 
2. RED top tube (Plain)=2.5ml tube 
3. Citrated syringe=6ml syringe with 0.5ml 3.8% sodium citrate 
4. 2x 3ml syringe 
5. 21g butterfly needle 
6. 15ml polypropylene centrifuge tube labelled CITRATE 
Method 
Samples cannot be drawn from a heparinized catheter 
1. Add 0.5ml of sodium citrate to a 6ml syringe 
2. Insert a 21 g butterfly needle into the cephalic vein  
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3. Draw 2.5ml into a plain syringe and dispense into the RED top plain tube 
4. Draw 3ml into a plain syringe and dispense into the LAVENDER top EDTA tube. Invert the 
tube 8-10 times. 
5. Draw  4.5ml into the sodium citrate syringe, giving a total of 5ml 
6. Transfer contents of citrate syringe to plastic tube labelled citrate. Immediately invert 
the tube 6 times to mix blood and anticoagulant  
7. If the cephalic vein is not accessible (e.g. due to hematoma) use another suitable vein 
and record site on submission form. 
Processing: 
Plasma: CITRATE  
1. Centrifuge the 15ml centrifuge tube containing citrated blood tubes at 2500 g for 20 
min at room temperature with brake turned off. (Program 25 on CR422)  
2. Collect the platelet poor plasma (PPP)  with a micropipette (e.g. Gilson P1000) stopping 
1cm above the buffy layer while avoiding disturbing the buffy layer, as illustrated in 
figure 1.   
3. Aliquot 0.5ml to a cryovial and label with the dog’s ID number, date, citrate and volume. 
Store in the box for PT,PTT and D-Dimers at -80 C  
4. Aliquot 200 µl of the supernatant to cryovials labelled with the dog’s ID number, date, 
and citrate.  Repeat 5 times for the 1st and 2nd spin samples. Store in the citrate box. 
5. Store at -80 C. 
6. Fill in the freezer log sheet   
 
 
 
 
Lavender top tube: Blood smears 
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1. Mix blood by inverting tube 6 times 
2. Wipe 2 glass slides gently with a Kimwipe to remove any dust 
3. Label slides with the dog’s hospital ID number  
4. Transfer a drop of blood (approximately 50ul) from the EDTA tube to the 1st slide using a 
capillary tube or two wooden transfer sticks 
5. Immediately make a smear blood using a spreader slide 
6. Repeat using the 2nd clean slide and a new spreader slide 
7. Allow to air dry 
8. Store 1 slide at room temperature in a slide box, and the other slide at -80 C in a slide 
box. Do NOT fix smears 
 
Lavender top tube: Plasma  
 
1. Centrifuge at 2500g for 15minutes with brake off  at room temperature (Program 25  
on CR422) (can be done at same time as citrate) 
2. Transfer the plasma (i.e. supernatant) to a microcentrifuge tube. Do not disturb the 
buffy coat layer 
3. Aliquot 100ul of plasma into cryovials, labelled with the dog’s ID, EDTA, and date 
4. Store at -80 
5. Fill in freezer log 
 
Red top tube: Serum 
1. Allow to clot at room temperature (approximately 20-30 minutes) 
2. Take a wooden applicator stick and go around the outside of the clot to separate it from 
the tube wall 
3. Centrifuge at 1000g for 15minutes with brake on  at room temperature (Program 24 on 
CR422) 
4. Using a micropipette aliquot 90ul of serum into a cryovial. Do not disrupt clot.   
5. Repeat. To each 90ul sample add 10ul of 100mM pH 8 EDTA. Label as serum EDTA, with 
the dog’s id and date 
6. Aliquot 100 µl of serum to cryovials labelled with dog’s ID, serum and date  
7. Store at -80 C. 
 
Urine 
1. Collect a midstream voided urine sample into a clean kidney dish 
2. Use a 5ml syringe to transfer 1.5ml to a 1.5ml conical micro-centrifuge tube 
3. Repeat 
4. If urine sediment will not be examined within 30 minutes, store at 4C (i.e. refrigerate) 
5. Allow urine to return to room temperature before centrifugation at  400g for 5 minutes 
with brake off 
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6. From the supernatant of the first microcentrifuge tube, use a pipette to transfer 1ml to 
an Eppendorf  tube labelled with the dog’s ID number and UPC 
7. From the second microcentrifuge tube, aliquot 100ul of supernatant to an Eppendorf 
tube labelled with the dog’s ID number, date and urine. Repeat 4 times (to give a total 
of 5 tubes) 
8. Store all aliquoted supernatant at -80 C 
9. Discard the remaining supernatant except the last approximately 0.5ml 
10. Gently manually re-suspend the sediment  
11. Place 1 drop on a glass slide and cover slip (wet prep) 
12. Examine the wet prep immediately. Record the average number of casts/LPF; RBC/x40 
field; mean number of WBC/x40 field; presence of bacteria or crystals. 
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APPENDIX C 
SUPLEMENTARY DATA: CHAPTER 6 
Supplementary data table 1. Validation of PicoGreen for measurement of cell-free DNA. The 
PicoGreen assay kit had a low coefficient of variation and good linearity over the range of DNA 
concentrations recommended by the manufacturer. However, there was marked interference by 
hemoglobin, bilirubin and lipid. As hemoglobin and bilirubin at concentrations equal to or above those 
tested here are common in plasma from dogs with IMHA, the kit was unsuitable for use directly in plasma. 
DNA was therefore extracted prior to analysis in the current study. DNA extraction also has the added 
benefit that for dogs with plasma DNA concentration below the limit of detection of the assay; DNA can be 
eluted into a smaller volume to produce a concentrated sample for analysis and plasma concentrations can 
then be estimated by correction for elution volume. 
Validation test Method Result 
Intra-assay 
coefficient of 
variation 
10 replicates of 180ng/ml DNA standard diluted 
in Quant-iT PicoGreen assay kit dilution buffer 
and DNase free water. 
4.5% 
Linearity A standard curve was constructed from DNA 
standards of 2ng/ml-2000ng/ml diluted in dilution 
buffer and analyzed in duplicate. Linearity was 
determined by simple linear regression. 
R2 > 0.99 
Bias For 10 replicates of 180ng/ml DNA diluted in 
dilution buffer and DNase free water; average 
bias was calculated by [(measured concentration-
180)]/180]*100 
-1.67% 
Interference 
from hemolysis 
200ng/ml DNA standard spiked (10% by volume) 
with hemoglobin derived from washed, lysed dog 
erythrocytes to a final concentration of 0.08g/dl; 
0.18g/dl or 0.35g/dl and compared with an equal 
volume DNase-free water spike. Ten replicates of 
each condition were analyzed an interference 
calculated as [(DNAinterference spike-DNAwater 
spike)/DNAwater spike]*100 
0.09g/dl hemoglobin: -40% 
 
0.18g/dl hemoglobin: -56% 
 
0.09g/dl hemoglobin: -87% 
 
 
Interference 
from bilirubin 
Calculated as for hemoglobin, except interference 
test samples were spiked with a commercial 
bilirubin control (MAS Bilirubin, ThermoFisher) 
to a final concentration of 2.5mg/dl. 
71% 
Interference 
from lipid 
Calculated as for hemoglobin, except interference 
test samples were spiked 10% by volume with a 
commercial lipid control (Intralipid, 20% 
emulsion, Sigma Aldrich) 
196% 
 
Supplementary table 2:  Effect of removing samples stored for > 9 months. After removal of data from 
cases where plasma storage exceeded the recommended 9 months, difference in cell-free DNA remains 
significant between cases and controls.  
 Controls (n=20) Cases (n=26) p value 
Cell-free DNA, ng/ml 
(median; range) 
26 (1-151) 45 (10-2334) P=0.0127 
 
 
